var title_f5_0_5120="Essential features meiosis";
var content_f5_0_5120=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F79125&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F79125&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    Essential features of meiosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 308px; background-image: url(data:image/gif;base64,R0lGODlhEwI0AeYAAP///4CAgABmM/8AAAAAAP+AgICzmYiIiLu7u0RERH8AAAAzGcDAwN3d3SIiIhEREWZmZjMzM+7u7pmZmczMzFVVVf/AwMDZzXd3d2CggEBAQP9AQDCDWZC8pv9gYP8wMKqqqkCMZkBZTYBAQP+QkP9QUP8gIFCWcyB5Tf+goP/w8P9wcHCpjf/g4KDGs//Q0P+wsPD287DQwP8QENDj2eDs5hBwQH8zGSBGMiAgIGBgYH8gIIBgYL+ZjFBjWeDg4KCgoGBsZnBwcI+slvDw8NDQ0BAQELCwsBA8JpCQkFBQUHB2c2CPcMDJvDBySYAQEH9QUDAwMIAwML+QkICZjI8sFjBiOb+pnT9MJm85HF+AX78gIL9QUC9SKb8ZDMC5rTBQP+/Gw79ZTYBDKV8/H+8GA79wcA8sFj85LLC2s88TCb+AgI+cho88JoBwcN/Nxq8fD58mE8CwsFB8ZgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAATAjQBAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8vP09fb3+Pn62AQI+/8AAzIiQJDAAUf9EBBgpFDQgQQCI0pUR2ACABAEJDTq56jhxI8gyVUEcOCBoAoEI0hQGIGAAwoAEi5s0JJAhQYFVTog6OAhAAQPCDyweMDBTpUhkypdltPfAaQRDiiEWaFCTAQNK0AshBOER58PDk54IKFoAwlDl6pdK6wihQcg/wBAKEgAwlcHVxs6sCiIQoKCE74mwNlAEIEGPgHsZcu4ca6RIB5QeKpRkMcIEPIu1DoIQgQAEioq1Aj2YMmyWxc7Xs361UiSDhqgJBg4Z2GZAGgSrADUZUUJLXtC7J02serWyJPH8qi8uXNozJ9Ln069uvXr2LNPb5CW47gGDuJqH0+IAsGDiglgGPQXJjQI668qSgyJPqUE6FUBrfyKQs2eldinjX885aeId9REh4p5LpFE0HoYEeSeMzhVhuAhAjaSYST4tRIBX65wlxlJVs0jokMlLnKhNAqeYl5QRQUVHwAoTdjMBJ8ZVpNFABJW0Ig60vZTUEPhRBCQNBJk0v8BPMFEwI4TAIZfArHVtJ5COz0w25U7jTRllUcCMNZ5gmCQYitPFaKQQhMw+SQFEvwlFAAYFDQZRAnUlJluBPkzCHET4ATTaAh0aVFFDiApS5qFzKYSS0JRMBdBOE2QKKAAUEmQpg8U5uZLMVlql6F02jlInEr+RKqbBOD5EJh15VZTP0Y+KUGXeDnKXyjmRYBSWOoNUiM0BwBpEEkm9XhYhscWBUBYYpIloFl9SUanVc3i1WGmERRWFQBvYcWRAxBF+axFkXHr7Z6SJTCjIBNs5Uqxah5rHkwQJDDaIASIRxKewx1WQY4XQjtWnJlVkFla6dqEC72EUAZAVGtmmpn/dw4/KxZZCZQ77gFvwWRmTCUybFK/huwriMnmxeVTnuvmJtnAhvmZW79fQWUgKL2aBwGTMw77DMTyKQTeQYQx64+lhBmGmLyCQABklAXhxZGlmaK3rWoJ1CZIh0bTddjWdAXWUgLuxQuLs4R4hLWqpUJbVF2oZX0zeHwh2HRMDQBFWK2UrjgL253RZddCcl3sJ0d7j32QR/hRzZN8gC+7EwS71hlW5W+/jF6XtKnWj1+AeTRpmKP0OgjQwhJgIzM48usPBtpmxiRiORJyNV5yS5u7Q7FVa+Pumca37bfmifv14wulxR56Ch8S/bWwcFfiAbwhfi+N8ppX2Mptuno3//IFm0aWYuSCr7vNtViPosSWIS51TOJ513uczC8f8vrqG+J8eYf53/Y4czwkkQ8BngGNaDJCEqSYQnUOCVaEdvOMChmGJ/5QyJMO85ZYyU5MeMFUB5EkpyX9SD5Yo1q80MOnKyEObAsp1OS2xaexNUkQH1pOTSiGOAe9SYN0C4qtPHc3CuxkJ+zDlJi8I8MGCW4WCNjhQWazwKhlZlI48ROmYLg8H8aKibhCS0r4A8TMNBEvk0ofDWfVACP6BitB2ckEgNMgKoJIIvBJx36w4T3y0EhRiehjcrhzx++ExxpA3Jl15NStRSTSj5CMpCQnScmJMCAAmMykJjfJyU568v+ToAwlJxlQyVLaIwAaEKUqV8nKVqbyEZdspSxnSctaspKUsLSlLnfJy17e0hGx9KUwQ4lLAARzmMgcZSgwaQxmOgKVyYymNEP5ykdAc5rYzGYvq8mIa2rTl9z05jd5yU1POJMY5+xmANCRTnVGpJ2JgKcuzinPXNQzE/fsRT4Lsc9u9JMQ/5xHQAMqC3qu8xcElURCbUHQhV4joQ51x0AP6guDAiOiz6ToMBqqUXJAtKP7mOhFKYpRVpTUnZS4gAFWytILLMICBYipTC1gCY6yE6SKOKk6RIpQkuLUnj/FZ1AZYQABGPWoBlhEAQbA1KYWoKZD5WdU/TlVgFZVoFf/1WkqLNrTZV71EEU9qlGTqoilNpWpT62ETc/x0Xdm9aux4GpF4RqJkoZVrGRNhFnPmlZKrFUSKm0pKGA6U1S0NRKBXalLc0HYmNL0FDxFLEsNsNhSyFWfdIWEXcU6VqWeFa1QtWZmBdEBsWbAETJwASRIcFYPOAIGKcDEYSFR2qOelhGpXQVrm+raRsBWtm+dRG2Nelvcqja0gsBoYwvwWFJoNZ6jFcRdkerZz/Z1En9FrFg54IgTCAAFx2WEBc76AUeUYAAmiK1a4erQC4g1BI0IwXfDa4rxNnUDjtgAetXr1+ACdrvdne96B4HR3TK1t4v4LXI/sVnO5hURe3Xq/4JROgnOxqARHDgqCmTQiM+qoBEfaKoJYNBfzWY2BpxtBAo0zGFTqOCzjjCBiEmMXf9KwsIYZnGNCRxd+zIVv4zQb3oHDIoG47W6fJ3wIkoq36NWNhEoFmsHGqHfpjY3ES8+KwlKLNpJrPioNVhEDTg75VPIuKktYEQLPrvlHTcCo0026pMREeWjlrmuPqVElpvaiDOjl8Z49molptvZsn52ANdV6FdLyoIjL8K9Yp0zIlaQ5Jd+9somzrQkvOvkRbiAszRAxXmtzIgUfPYFXKZwJBpN3UdzVtJvzjMl/DyANCtizVp2M4OjCwBCC+DBh4gwaIkc60rIQKwnIGqKff971hIwQtjELrYkpgtsQ2RArDZIRYQTfQgPnHUG0c5pdI991GQvgtCpLumomYppQ5j6rKhWtKAp4etqF0LYiFayuCsxZg0zgtNG5W4jcM1UEzBi3QMob6qlHQlyG9XcifiyUeGLChg0mxG0BrKulxzdfhsVBf8GsK5Luu1FeLup4N54J4zcar0emtuaZriXxXphRUhcAMXF+Fk/rAhaI1jeXZaExwUgcEQM/depIHjCF6H0fC9835S4ec0jbtp089riTXV2z8+q8UAXmdf1RrKEww11SgBcALAeRJ2NeueDn7XdhNgzU9usco5TwgZiVcSnI62KGZx1Ee8m9dOhW4n/s6ddEGsXQNtjXlKlKxwRTYe5zFfe0TrdEQNQG0TYDW1dQ1i+L3oyRHbL9JoyZV66jkYEpDvtiJInwsfs9vxrCORBHsf884PAPCLiLIBQI4LVRy1ES76HQ0UWAve0B6QgqszUeE8axseffeilmtHoX/70vU79IVYv50KEBi+D4A77ACDX4cNLiIUkhN/5nIjAxz730kedVectCLR0jF+tAitnkc75Sp/qAfcnJuuxPfNXfYRgf/KyKdv3XoqAbo8Ae11nCNDmfQC4FRMwgK5TgAaIgPiHfQAAfALQYoeQYUdVdEMSFfFzLInAgQIILhloCJTWVIB2CCHWVI9XfxUI/y8Y+DqRBRo5eEHYx30UhwgOGDER8AB+4ibjx1VAgYJ0QhQmgQjMNwDOB4PQh4MBeIEuyIO8pmpjsTf/MgjBJAILUIZmKALFJIaZNAIK0IZuOAIBUExfeBgH+IK2Z4CDMIfERx/HZIYLgARxqIaZhAN+CIhpaAjH5IYK8ASBKIgBsAOKyIhpqId1aCOHRYkOsRXHFABkaIZUQAh96IdgUEwQUAFv00WJgIn1Z4eE4H6SBwByNwArUAiqqEBciIfRAoYbAgDYpgi8Z4KC0BPz80Ea6EyleIqCkC7PJ4OJUINMdYO1GBq3+HWE4C52k4mO2Il+iIaIuIaK2IZwWEzWuP8tX/MuybVoHTWO+cGHmkSIZhgExRSKZ9iIiHBMkOiGPJCGwfSN4ViN60GOxUN9QaeOq6OJm7QEfjgHoJhJPuCHCwCPOAgCaGEzAGkIBMke8bGJPKCIXLCQmbSRijgFhXCR5Sh6NhaQ5MiOmYQEfohJ8biSfogD9Ego51MzAkl+64QWEomE4XdIiOCKiBCLs4iR11iSN2lOFAU44BeGhrB5Ltd54UcX4AccypddSlmQvydWIlgIR7d4jBCDTDWDhNB0dCcIVwkamGGSmXaWTHkIYgVyhwCCAjB1klN7FUkIZ0mVjphJirgFHolJUvCNaZiXaamWDMeWKolJ2rgAPkD/j7EUBA7ZmKRYNsR4hzi5RCcELv9jTJsEkm3YkYJwTJ7ZhlCAS4RZlV1odw6RIzqJjU25f/ZGCPh2XYyik0CRfucYdKsZka5pCHtXaIbgcN0HCUB5CFgneKvDmnBxm4fQVrUJF71pCCRoVIgwnd/lj/FTGXeZnBHJnIrgjAPQjGdlcEbYnZupgarZQLzZloXwm/wXnK92gNCpnjZZjOtkjT+REUXxOpsYAH25l4GpiI34nF5xnpaJlIMAIFGDLQVBfKjnYGI3bMGYH6V4OrWXm7iooHLBoJRiCEM3hIVQhI+gdBE4CBNICBpaoYaDnu6UohxKh9bGd4WQeMUlKAkq/xVVgwguaqHKBwAn936FEIs/pxgUqjAryqKEN6Gd8aIOKggfSoTLlodReDOTkZkYipM2OqGgU3qGAJ6IAJ7kqaQLyqNHSXmDBpsR6nSDl6SWgHdGlW2H8IuTsH4DkHKGMIU3WHdlJwnDJQD0JQjc56etYGADwF+EAHuFegk9OAluKgBwaghySmw69aMD0G5Cqm+bwHLACWEvh6mIoFW853uF0Kg4NwlTWIWDQKcDMKRAh4va1XKaB2qtAHswJ2yo2qrpSQmhegikmnOtqlOEaqiCgKjC6nW7dqYQ2n9jt6afmprZd1R/CgA0QGaTEGHF+gJspqjsxWtrB6KCwHuPuv8KcleiADCFdkp2zXoJ0xWt0yplC6ZTtCqBp+apQoWs2hdsnYqu6XoJ3McCvhmfkgB7Q9mKl6atMTdzH2cInAVxrOBnYUoIn6V19Fqm/3VU/tqeAGt1lzCud/ptBkuN9IamyiqherqvltCthiCXesZ1Vvh3H+uqkXB2UwcAgeqVqYBwPDcIiFqWzGqYlYCyhaCy7+qsDmsIEfuyCBqyyfqU/leyzemsAGCdkCpyk+ClhYCnwHWw0yajD8p6rRBhmCZscGesuUoJUlsIkSqpzoqzh5qtE4u0keCUnAqVPeuzlnBtRyWqgsBZvgoJlIqqn8WquKpqkiCcbcd7AgALxzn/ADw7heGZtZM3CXhrVHrLi1U3tJgAtrJZsG/buYkgt/hKt05rt5XgnvTVrnZWCe5nqNiaa3BbtpEwdBe7twz4Cko3sILwWeQ6uGxaumJ1utSKuZewuGXpuJB7rEp7r/Iqurzbu5WAuqU6CO6JdpXQugdGsG93vJEbCY06hND7nq5Ap11nvSSrr6Q7CdCbc9N7eHioVbcLsSz7upkKdiLLtMs6uhRLCVQLAJNLnZZAXoRAqY8rv84rCXH2qH0agrHAfOdKqAMglnWLpBVWgoTQv4n7ss8lvoNAvmpqvtobt/U7t03bvCZ7CbxHCNYJjJIwhYQAnnkawfkLCSBYc2c3/5exAJYDkLMIl8P1ur0GnHeDkMLH+1wMPAgODMEk3MOAZZ2baggWAJ7lS7awm7zUS7u2dQmam7utpcQ+/AjuuVikqsKs4H7NpaovDMNXagnTVVl8O8RQi8M8t8M568EEfG7793D2e3F0LMGTIJyk6q6WsLiq6rp1/LSX8L13PLuvwMGHxlS467mXiQl+fMeK58aZQMaCYMZcbKaRkMDBWwgO7Lb4y8eSkHiUzL6NEIuNXKmbPMWRQMm/Owur/FnFisaRfAmmfMeozHDPxciH9si2PMpcCctgVghN18i2lsTnWwk3R8mZQGurrAmzVQlMvH9hJgtQjMzSfJKW0Mx3rP/EzwUAs9xUtazMhXwIFnzHvirAjSy4XbzMZkfMRJcJO3xoZyzMBxrPsAyXslDPn/Ww55zPhSfPYvyrUAsA2fxZyQzJ+DwIf3zH4QoAg9zI56q1e3oJ3sxZ/GwJ0HxoAL3HpPwIGe1vs9DR/zy/MBt18rzRaqsJ/ixi20x/jiDPwQe/48xUzFoE8DzB8pwJN43TrSwIOr3Tj0DTtPDTA/zBADDUMXxjRm3JzzzOHx3M5qywNH3Bg4DUSW3RhmEESpAEP5DGl3DV1/y/P73Q+koAXg3WAu3UxFzWsIDUaE12av3VYS3WlUDWUI0JPx3TIFvUV10IWs2sYpMDOlBOY/3/1JeA1H5tCIWtA0AgBM6q2LHA2I2NfwVh2JF90IG914t903Pd0FU9qjQd0RN9aBXdCBqgATmQA6v92q8tNnQRBVA70iR9CSY9npfw2q0N27At25mdmrZ9nSV901P9CL7d274N3ASRA7W90uB80H0d1JfdCOm8f+v80+6sCAzAADqgA90d3uEN3K59iPZKyd5KCfimu5cQ3t8t3uIN3KutA5ggl5yV3q6w3vFLCfD93vAt3xpA35nga/cd3ZqQ2wVX3ZywUEd3x3ANAMd8aKHtw5ktBEdABOEsCMPN0pWA4Oil4BdEADlg4URwy5Vw3bctCx5+3HVX4Rdu4hhNzBw+/3IHjcOHtrujTdWkRcw2G8qETMKQfdd4bQnVHKWXkNAuq9SCEORN/QhFDsSzgOTs18pMHtKR8OQ1jcEHzc66Td1e3oCUzLD3tsoS29AZbrnEXLmU8NO3KtpaRdNq7gpsDuKGrAlw7tmWIOVAreR0zggXUM2xOazZ/Irv3OSvCq1oPpyWQKzinL18XsKTEKghmLGwwOic++iG/giBqlqUrrE+fdNtnuOiHaIhHLojLMUXbQkJbMVshwkOrMVNxbNUrVOenOiVLAsO/GGiHNBDLlzL9sktjQmI+sCXztCi/ppLK8L3K+oZ3r8Cx3uB/giUqnBTSOi6WeiMYMHcBe2zQP+p5FntfZ7pjuDs36q8Bp0Jodzosf7lvA6lyW7qy47qBUzNl8t7+B0J4NlbU4jjXD3vkMDEp2XvUR6/+x7uVu7k9V67wnsJAlxe4I7p7a5/7768p97vdZ4JwTtdBQ0Jbhth9yzv/g7Y7qrxslxpHm/wbc3Trf6sAYfnlADFrlXwEG/spD7xY868IH/x/AqwIjoJiPpYJ2rsJyXpLtXzs/pZNBb0kPxcgbpYRn/ufJ2tJz/zxAZEKkgn2Ae6FH+/Vn8QyUfUR9n1ueeBg7DqgMpZDx4Jrz6sCn0IYv/1Bz9/Ym96ilDrNIv2hyAnT/I94ocIbz99ieDAtoaoof338pf/8j4791i/CGZ/92KV9l9jG2bJk5bJTKziAEuDfpZWsEqfgmQC93GfakaDLEAo8ea+uaI7+iXRggSI+Har+lGogIpA7mfPtZMw7Tpb7H9Ch6uvha0P43YH+6WfCNpe+15bjZmBFqbRJ37P+ybh+6xoCAKc+45eL57y/Dso7rcs/DGRf7NPtU2PCAmQ/HLD/JW/TmyTAFaBAVC4COkOAISfMs7P+tF/5jc5+iPTm2PokAsACCIMAISFDAGIIwqLjCMBgwAIBA0AGBWFABIEFJgAiJ2gmJ+FkpSWhQcJoZgcAq4CLJivri6rtp0fA7oDK5i7uimhpZWXhZqchaO3ogGR/5PEqKq2rbOxhLMCtaAJEAAND8gABAirw6fGm7e5uxu+v8Gg5sWEx53Ky8ry0cvUrtbXs7Rt6/Yt3DhmyZodcEAowgFMIB4s8/BrwAdCFipaiPfsHL10CJeJtJWPgEkCECQQSmUIUQARC2LKFATqUCJGjR4RknQyZaEEGEDdw9eM1EmUKgGw7GQTkcyYNA89XSACEaSRTXEqGDHokFZHVo32TAoAqL2iIz0142nSp1JpmJpOXUAFgNSnVcMSSnAywoRCB4UddVs2KFOXAbSasYvoq96dg8maPZu25NiVcOO6nFqVwd2ZLq+W7fuXUGBCyj4dOOngIaEGDkAsW7erF/+hivAwsUX603DItMBRox0mwYHhpZ0MYBNgYFmBigMK6H5WPKiECN2EohV5j7hxzDVdBpm6pGsAHE9xPBZpk4dWN+Z34NwR2iil6pmwaw/+yfvxzITYNN5UaTCGnkzqPcbNSgQkdVon/uWX3WGIuIfTFIwFIB8j9OlkXybfXTfhb0R9iN9boQhI3iOHHBhTgh7uld1qDpKT0I0LEUIBAbJR8EBpFDam1RqMORZjhCKGMlRw3A1HXWvggaIcNs3d8lxF0pnYGgI/rrIkSdt55xpyoXSATScnzBICk5iQUFEnJfzSDkf3bdnlfsD19+SYAGJi5pmFpPnKmgOt9ECN5ez/ySWQtrj5y0aFxMmOYHUesKiX291SUqVRrvLnK2iqucqCSh1qmo3C4cgQADsisFA4QVqIkxyMbbhIh1eJeamSmbKpqZMnVaDSUZRgMuUsVdpy5S9ZQhasBBAMRlllYR4lrDgnFQtKBqIaC6ivFE2KybK6CPZstD2R2KQzz2JrkraYcNstIce6EgpfJjnw12ptmWuSsOj2u0q4u3RC7gD+EgCwtOqCKda/w2a7iryuEFpIvQKMytq+6aaaKr8mPeTAUYx24ugvmEiqy5zTncvwjb6O9GVaGDPnHHTN+jozrzF30g8snXzqSgwx08aLyRWp0LPH1Pb8M9CFCC0A0UtX/w2A0Re1mbTVO0+79M//ECI11TGn1iuTBK887ptVd9322TQvl+wqB0e3tNsN+4qNQIRcgM0FMePWSUaPvs0f3CMtx7ffswBu9dIVlTC4Rlwj7nXPe3fC+CuOl40W3rNVZBshJ+ui9N2WGx5zzXOHUnfObILOdM+bu0JDJzRgI4OvhO/yQicvVASD6k37WrvtmOQ+y+6Px9y7LrAH/8vwxJe49PG3J6876jD3DF1uADw/AKQ9y65z6rewfjOW3Be/tNShUOlr6QiDwn777jMpdcadyN+8r1eoghd2Qb5C3A9/1usZ/EDhP891j3fQ+V0hpLcL6pUPfRfsmfqshDMEJv+wZxQTgMUwYYNZZABccgrFDH7hgeqty1chFCEoSviKE/6PTRTDQhbeAIoV7qKFLnTY0kI4wkLQ0BU2dODs2BTAARasEwdU4g0fyKQNKquDGcxfzMAWihDMKzhGGx0mNpBCD34wOE8LGyG8OKgpMulpNQAFGcVlRkxVjYugYGPF8Ge+UFCsC2QQQw9ZGMT/9TE5clsfs+pox6plDhSCcoUNfCU4UKhsADMopBDZpDhIvgILYyigG5exnFBcMpOaxBPmAhIKQXUhC23gIwangQ02yLGMWRzlIb3VQLphUYovpB02sofIWbBJfBI0GNtyKbNZam45xCxED+KghtqMciT/xysiIQ5WOS0yCXuh6AEcyvBEKe5SFtj4giV/gUpmTvGc9EokB6MYO2fCM2qzmGSZ/sak0rUTaYVz5xnTIjV9KhOX17SF1NRIOsoxUpW+EppBD7qLMOTynscTQDILwc2HdnN18rwiPZlkvnsSgoirOF7n0pI2lk0uoMAMZnBiqM3wVcSlCfUjNjoQCvGJsp7enOkXMSE+CwJ1icGRmhVCQb+fHi6h97SiL0f61KCiEVmrUN4rWicSo8FuglTNkzPV4quncdWmy8xpKJ62UrAu0qN5A87PzorWXXxVrFQU6iy00FOHxvSGUQ3pVN/6103GbHurwAZDlyE8W4gOrpcD/85ymGe/tKq1f9+qrDUhi9TgIDYUkbvoWH2GjSGEgoLQ42xh49ZL1/3yfHgV5iziuAoUDHUZ4muBLUyA0KNa9RYZpa1mCXhZUBwPBbvtrW8HCpzjCXe4A8BpVcl6WGw0YRWPFaghR8tLrM6TsLD97Ugkegs9CgC5wPHnLeaoCxOotrPLKKgt2KsLp6pVaieY7y/cq9p7kle/KDMnd/u2HN2Ggrd0DK8uBxzP1oLide81KUptEcPgtPQWaavfahup1zaugr52K268HFyIDKcysh2WIYB3YWDfwlOpKx4Afzf8UV9J1bVhFS+Kr7rV9A0TOF79ri42StKx7tKsIrWriP9Z8dkHV4TIRdbxLeYq5PEJOGYx5OvALBvla96DAhHIl2tAQIBQ3NjJ9ASzmCWArwiQBb48w4SaCQAlAJA5fsu7hQv4mZbG2iIFftVRmOl8ADabxM1xbeSc63xnzOZ5FfRz6QRGRoAIIGACDzBJyeQ8aEaXGc+z/XOgWdXpQrf5zdSV6aLH/GlHu4KyTK0ICTqxakNXmixmI8SkD20jDPSJEE8z7WCHzOk1n3rHzVPGN2Z0CXyZWbA4Bu+yV1KBBiRAAsVxTV4NO22lNNskxsXGc8M9C56OJLe3EN+sC9HtA1T72tlONM/a/e1WE1jcthAfy8hcGggcAAP7kkgo6D3/GnsXIqPpljUm6G1tbNd523H2xgOYXXByv2LcL93sayZO7YbHm2mf4Dch/I2tXwNgOdddBaBhynB4PxzONT5ABATzbBKvLYoyt4VDkB1xpcycI5rxwVQe05QADAg0ogkPFLRSnwC5RFaLcAQkcr6KnUPcjlSHUKsPIfShx6gpUFfAE3RSAd90IiKryPp0NBOAriPoKkUPQNi5goqfh8LqV/ea2o0SdK9//elaoc/U7Q4KvOe67KEg08ELnG+Fr4TwncA7zIl3gBHx3emIgAlnkp6hACjCMVO3fN0h+sHK07wlLlpAguCOmABMRT2c14ytFNChv7sk8B4yfeIh30fV/4jeGah/PdERoxUF6CQBm/ZGbNL+e0mwPfVUYX3rA38V3YNi76lOoPXXHnwENb3ziWF66NNO+FwjP/EA4vpUzmD7CoFeKb/3OekBi5YcAR3zL5kLTYL0eZxIfSWr0gkQgGg8B1H2p3WgQGXLYFuvwAFpEWTLgGC6kDUAGAoDiGq9pxAByH2FgGS34EO+QwgVIHo+knwVeH+kVW4R+AsUqBQbWAgXOH8cdoAc2IHe9YFpRYMwSIAg1wwjiH6HAX1o0H5CwiE6oYMjx4N5RzzfUAzuBhk1d4PDllrs9gBOWG360XMf1ITUBoWuJgCwtgrmxT8i4WfrlVZc6G0NkIUFuP8fafiEwIdOjxZjVmZnBOAa/vYqt/CGxeB8DMRndLhwVthxbNiG3cOHXiiHryYSIEY+fLiGopdrZIaHfLJWpbWCu0CBj1iI8lY9CDBoO4cvBFAyZ0ZRSqYboHgAE3AUL1hSmfKJh/YQoggkx0M2FIYNtrgK4nM6GLY1pJCKq8ganTgtsFhpsngSpZFRubhOv7BupWISCYAAlKZp5ZCKBTeKmKCME+GLOwGMrGiIs1OMoYiMizcLy8iMuwA+4qiK39iDhgKN5EAsXygAKReIvxiLwZgv4Ehjy1CKNwdey8Vc4zUL6NWPgNgo+zUSB2NfMtWQ8YUNBZlkVFhcUhORU8j/kA7JYUlFkAqZY7+yhKGQUby4Zb8wktPlRoFlcxz1WgH5kTA0C/klEnvGStu4C5IjEiuXjvy4jyeFDTF5CzmpCzdZXDSFk5WkYAK5DCH0k0AZWi7GXVLjBCKxkDupXawlhdF2ilU5ebTUYyJxPHSFCRCIWx7pklLGZFjZV8qVUB6YcAB5kmbJY64QlkRVES0YW9mXFjHEBEb5DluJlFUEbWj2lnAZl57VOCMRAz5ZhjB1CyrglC1pmKR0kKvQAhUxY5c1WSLxmL8wlJGphWlBmZUJHQp2ZJdIloTZTFDFYADgjytZlkkpg1+Ji6F5WxlnOn22lqqJl7NJm4wZYJeV/1HR5Fi6uZsZuQy1mJu/AGXBtEvL0VahwJk2+ZefORKuuU0s2WXGuZGvYJFTllmxtguYGTrAqZ3b+ZAcORISqAstllP784BcxpuSKRJC453J1Zjuc0giORI3RZ3mGZgqiZ2wOZ8aCRxLCRxjWJNCCRwgRp3mE0NMeYb4eU1FORINupW7dKBpAWJ3lUCHFJXwWZ6FuV0aJJimOJGASaD8kJa2wAKiKZapGQorMGpnCZI2yKKhkGHgw5bYkETLMKMTWqOm6ZUjkWFANF2HtJcbGp/nSX8lGqAAAGFWCZqJg5hXuYjESVxpcTBGJZ+xOY/QOYUdOkXLYW5TaYb/aVi1yf85wHEw0tWcoxVsaQGkWpqmJApSUCqlf7lLyZkWMqCSuwgcMDCgslmgtqCNIzGohKRWGRWmoaCoWmmnVApcvpmoFfFP+Tlaz7mlaOqld2pjJvqPkVqdhapQ6ZkWx+OjANVewSE+RzqiamqqpyoS+nZZ+3OOavlDGDpa9dmq0GGScBoc+2mpMaqiNcYm1xml2Qmrk3oLGpoWimmbhJA2nrmZ/UmqpTpiMAkc0jmBlxVD9rkK3Rpdu8okzzoS41qHeNlHIJoWrpqin4qsofqaxXqczdqVrmCmaypJtmA0zqicuoCpNcqVwLZTwUGaavU0NZWlAVuucikA+sqfjreuY6X/pGkxrm9qr8cKoDhKr6MqqfeaWFYqV+DpDnUaouXErCFbCJsKZNx4TfMaCkajYSDLkwDBpmBEqN3TR08TsYzFTvCabKyZrHoatCv7TMbEJGM4nBjBpBIagjWbrfeWtAxKozeUUWG4DCDGnBo7jNlYsox4rRR7mCM7EjNrtBsbHES7rJ5qqOjpCg7IJC5atoVQOnc5EnRaX9gKjlITt8CRtwPQpVO0P0x7C4CLkbHqtrIKt2wCuOMZrKhaSsGxtXs7pSKxtjp7tASbjSdAQ6qKTRnQD2dlASXgQ6/qrh5AG2OauKyrOaFbQ0xiAan7sVfbuVSLuqqLtl57cLYrAJ9L/6uzm7LGaT59yySHW7n+2V1EOoUhtqcMRgMd4KioGr238AIkgLi4db3Iu7kHR73Oo72XBb0nsFjuCr5Ra6OgAL3Se24rUADAapbmcwGvi0SxG7zN27aPg1EGsL/8u77hUwAAHMDYa6w2u2QG3Lqae8AKvGADu8CqdE4X4L28Y774m7YO7LwXnMFNSsAa3MH9xZoLnGse3MDnO8KKm8AmLGIZmMIsfGK7O8Ii3MInbMEyPMMFXMMMXME4vMPoa1IKHMM8zL3bK8OuGMQOvMJGnMS768MHDMRBzMQI/MT2BMJKrLs3XMUZLDtQvGROzMNbrCQa0HpiPMZkXMZmfMZojP8IYazDWOykbNzGMDxLX1xcXbzDcxwkaZzHerzHZxx7XhLGfBzIgjzIhEzGa5wngFzIirzIjNzIYnzI3JHIjjzJj/w5kkzJmBwAkAzHKRx3mfzJoNx6frwKnhzKpnzKgjzKeIzKjCx9rNzIqszJsjzLtFzLtnzLuJzLurzLvNzLvvzLwBzMwjzMxFzMxnzMyJzMyrzMzNzMzvzM0BzN0jzN1FzN1nzN2JzN2rzN3NzN3vzN4BzO4jzO5FzO5nzO6JzO6rzO7NzO7vzO8BzP8jzP9FzP9nzP+JzP+rzP/NzP/vzPAB3QAj3QBF3QBn3QCJ3QCg3NircMD4LPDa1WD73/0Aa8I3dICCMTFD4CjfAyRas2EhPtwCyRANp2eYCBKtSMAWPR0BGdFi29NH7ohyftwSTNJAeQaZVmgmkh09Ns0QzBL0FxAA9BZiZnNQQnEiG9wC8dCkntzBFBCWDW0fsQM0sdMzzdCU1twDUNHAvRa/G30wYXzTuSaQuRaWa3ipD3P9hXAYcmAZIQZuAQMA0wig4AAVxCAF2SAJSm13hNCfziAJxA13ZNaX+h0iYBKyCjCiSNaY/nfGt4EuTA1rcGzRGB0ixh2JvQE4+NEm+xGtoijSGzECPjZpIgCRPALxEQ2JSGLjM3121NaQ7g2IM2DnM2DwCAaSEDAJKNaJJ9/4elPYqgjY2JDQABMwH5OAHBXRoXjQl3ggmwrdptcWgi+Nr6uNsSgNvLfcw7EgFs/QCr4RsRkd1TtH0+pxIOUdpl0Q2BoTCE4N23fSgJoAqrSA6t4SOccArsDQBdgnY8AgqtgiIkLQFd8iPOVwHSMA4yZ94l3cwyh9cPwRL9HSU/WBBd3QnuDYANIODIfdE7wgkQoAoXDQEO0ABzjSpzDQIxXWYGfirYVxh1p+A3TQkkLQmusd/g0N9kMoBlUeN/gXbiUNIlrhQCg9FBEeIjXuIJDgDn/WlJ7hCToczbvSP+RgCGgS62Pd4vGDAo4YcQoN42chBzXSyTUNN+uNjfCP/mRzEJC8EburYqI/3gCQACDOF8+nIqWv7Vy+wjIMASa54SSzGNo6h4YT7V+uKHk7YTDHEQS0Hbs5jiAFDn4oAADcDWfoGKBJAAFHDnXb4XlvJpro2Mbq4KN62PNf3p77IKzd3l0JIuin7gCHDnXD4YsIjpybzdqEDlum0SZudGfJjkXrjpER4Y7n3TbPYQZX4A9o0Jwp58zd3huq3YDzHXUFLgl9Aqvh7NlacSPuIqmfEjVPeDU83c2vbnG64j6bDirW7nM6cJG64S1M4qp4GEuu1vPLgQDtfphdDs554AJ14JDDEZzW0aC44BdzKCq2jeXo4ikX7tkqAS114I4K7/3ZV260HR24d9TeuY65rG5d2ALkEeCZmW18b+aTUNMgkfCbAt4G2NCawN7SNnKs5HAaN9EL2t08dcjBedCip/axsNAZut5n1y13dI7jKN2oFNDouOAHc9MhNwHXQW8zPvKuT4E/nCCTXv9IQm08HNEOjiAIqdLwwRjMgN2wJ/fTjtF5td15Gu8DSPjE7PEDWPL4BN0XSfzsVh85gQ8XW/93zfMydR1FRfaVLd94Rf+IZ/+Iif+DVcyq+MybEcHo3Pyo/fPIwv+cFR+ZYPHJh/ypPfEpEvyrisyZ//yZssM5c8+pRc+lB1+qys+prC+q1vZLB/yq5PErNP+1Scwnd8/8GHtPsa7Pso7MYkLPwbTMdGlvuWi8XA/8OjtfxHjPzFf1lIHMLH//wqq1bO38TQ38G9v/1xrMLef/1XLLTi72XVb/23nP1c3Pzhz/3tb8OrWf7mL/8oef7UH/qseQH827+oCggGgoMXAIaHiImKhgEBi4+MjpCTiBYFl5gWlIeWmJeam5ONoaSUo6WUF4OEkKekrpCqqwaFqI+wm7i2hp2eoKKSr8GKvZm7wMfJyqW6pQYC0NEGpM/R0NPLzcjLAAUD3+AFpN7g3+LZw9ym6cvV1tiL2rfsiu7S6gDy8fS25OXn24RB8hcO3yF9BhPm4hfK3jVq1h6is4UwFEFz4//KYZyosBXDXQ4FwFNUEVHFkCOVlTz4MaNGgB5Rybs4AKa6lR1zRlKGEmLElLtw7uRG0+ZAjTW5CeWIr+c8mS0BOFUa1WRVSkUXQj36UuFSnQm/HppKieyxpWITZbWI1CjFqzfhbjJrdWvZiCLxCU2LaG3AUDPbepULNixhRHQfJbbL7LAiv1gFMy08tCleoCwZQ1r8VnMyyE8bc/03mLJpko4NcU60GjBhvodAjy44mTJs1pdjir77U6/c290k/9X6SHbt07ZTS83dkLnK18pjC4/c9ThY4GOdo/a8qLXA3cuMJ9rLUHwy7Mhd89Q+yfu6zkSnTzL//TT65b1D19//zP787+iG0FeZesXJR1V6yPHlHn7vHMjdLgJKV91z6d3HGXlz9XfWf+pEiGGBE/qGoH3KLbigbuApE2GABsJHYkIXcshbg3E92E+L48m4yIopjqiTghp2F2SPxIWH42NH7pccjEN+2N6QNuqnYpIDFolkiDX6WBgsGBAwASIYJKAYlIj11+WXh4QpJYFgemkIBREQQAAEIJLGFpaGxNnAm3HOuV2CH50JpphC5rdPlNkZ+oieg+bInaAAwCknnTtSmY+OV9oJCaOR9kmpo1peF4wEDyRAKABynoqbok+ySqqph6S6ppUAvEroBBhESgAFleJZJ22IIPBABAcYgquu/7zWBSgktsZKgKplsqqskoXS+IiwxDoLrZOGNAvAsRTs2qumKLKZKbCLYFvst7mGm+y0oXbkygQPNEDAnoYcAG2i1s54DyL02osvAPrO+h7A9d6LiATinrvRJrJBUMEEDiTC8LtVbslQwArnu69qTWI6prSISEwxIgXDSyvHA9fasFqWcguzr4eYXPHCL2cWb06uJJBrAusSrCoDjQQgwgJIJy0CA5AQ3cjRSSMtQgBMG+IzAEAfkvKfPV6d9SFXH+J0ACMoYPbZI1S9yNhln232CFQfQioIpCKASNgqawyJ10FvDcDYUEc9tdp5Dyd20YErHbcic9et9bYi8313rv+HN9K223ATzrW5fxd9OdqLW/wA3Q/YDTbloO5cGgD2yknAzUIjAnjUUmsuO+K0LzC4Ia3LCbvfhf/V++vdRvCpIWy7/bbtlZOtvAKZHzKB637Wavyhyy4y/O9D40777pvT2nziUocOMPWfAs/t9sUf37nlz0dfLq3JKy9/ItO7TqkE12OvumH5ikC3RuexkfWrVf06gABrRcDY+W8/ChwgCISFpl89jDrkwhrlEEAACVDQYD/iRwQZCIICVutfDxRfPYYUNg5KwIQ6g+AC5/bB2VwQhDg0Tws7WMMU/s9BDgiaxFDlupaBjGQnlIghglizChBRTka8lIsAwERDSAz/AugbF7rmMx17vSuIWNRf6kyjjSoCYIjUi2KMEHXEAx7Ci4dgYhpjaC4zXjGLDkvKwagloQy+8WVgxGPwfrih9SBxhYfko+EgZCkW0YxIomLSIWWWxLxkSZGo8JDI+tJISBKykMkwEZlUuMgbPXJmfpzikgyyRk9Gy42gxGQpNBklHsnyk67MUCJfiUL/qPIYPLIlDuUFIF4qMXx75M8ubznGz8Rsk33cooNwaR2fwLKSmGEjMhl5Sk52k5Q8Kya/etnMZBqQnL7MpUtSWc5SBueb2qSmOVEhymXO856mZGce3RJPEbEyZNo8kTt9yE190hGcwgSnPDlHz1G2EZ2//8RnJjuZ0G2GUJLXlKI6GQTRoEAzn9K0aA47ycyFzq+h9uToMWNZUgyGVIs39GiFxPnQlQ6SoKvKaD8zVtCX3lSkFR2oSYWKwI4iUqcMlegsKUrSYa7OMpP8qDEtOc2kgjSmIsXpOw0q06F29Rj1RKpCtbpUeG7Vpy29pDpayUyBnpSoEHtmLZs6Vq+S1V82PWded8rTq+oxrmZ960X/GdWAOrSuP70TVzWKyaAK1q6P1aVYa0rVdG4UsIt1ZGbh6k+oZpSSRzUqX4FDS1c61qmQbac1RTvVbF42sZhFqzc3G9mnrhWgG3UramHrUqyqdqSBtWpq7wqJGoTgsCzAC/8LqipcUljgA51cAVJWwFy9GSS5EVnubg+6COxaQ7vV5SwknitXT7ZgA3RV6nB5m4gO4CUaHdhEBt4rgAxUs7aU8ABSvlGCUOh3vx64LzENMt/32pe4Py0wXg4s4Kxu4r9I6a9620mC/X6DBABcL2JzSl/XAkDBBqYQXxMBYQDn18LfCLBlyShOEC8YwdxFhIsjwuAVb3gRJUaKivGbN5oEV7ypXcoF6BuRWihiyESGhpEjCuRKoBgcvyDGk78R5RGLeBlITvKS+4rDLBN5y0zerpSnXOXfptACU6ZyZzXMY0ScIMnROMEj3gxnObO0uZMoQZolvAg9T5nPYR4wN+j/nGQ7s5exiiA0kQ195wk/ws9PBrSDmwnpSK+ZzTA+BJyt8YhNQ8PGN05Emr8BiVEPANSR5IanBTDpQa66wWaehKmBjAtTn1qtmG41IlbN6kWsugaNdvQiTN2CRxA72INdxq9j/dtlo7rNiji2mBENAFsXO7y55nKnX+1rTz8b2qIedanFjexwqoPbh5YHusud6XCnmdbpsPWlsx3jSfB625v+9rQRMWtjk/urLD63t5nt6oHrW9fR/ne7a91vbGd7KYpe9Jw3zegRp6XSFpY0IjC+X42n1eGliPh7K05tiYocLyQfbWo4HmF4J4LlLcc1vbW9CC9/+RE2fy+YP15y/+emucyc+PnBM4zlTYMZtIbIOV52/lqaj1fo4MYFmqEOckx/JSSJnLE1ahzodpP4yTt+RI41EvauE30ZWo8G151+07RDY+1mP/TXUVx2hJfcx7QV9nDF4l76xpcSaYd709kOibHz178WrruVh06KwE8bIY6vOsELn/FQN6PCFsawQe7zw7QYF7nKlfzkxwtds0pXI9SF9eZpCgDvRgO8dq+I66EB+yvjeRPk/SbSz5veJtsVSCnV7egJz0Wznpb4higC41e7157jV/ixL2ZpG9t7cEMW+JNVaWXZ7XWY/rW33+e+IghgBCUk4QeL1+v20x0V6A+ftOWl/o/1HuQSHf/W/ch3/kSNX/16Q4J6BJADOgAERBBqeLV+/kdc+JeAdmdB4bdw5dF/3edV2Mda49R8PAd//Dd/OaIBHviBIBiCHgiA1BMFH2EhuNVWh0V/GrhYSHdWvrV8e2d/wbeC+9aCshVNMSgMDNCDPviDQNiDJEgAGmA+E6h+rvWCF4iAAGeA3sdP7GdDD6h663UKHOQ6QaMm2MR8lXWFcpKFH6N/UuKFBFAsklI9+7ROW0SGZugpDeg6OSAER1CAVsWGaRKGbHV7nGGHhqCFDDhGdniG7qODU/h+EfhIgeiGDfh7ksBBe3IAD2AIsrKFzaEojkgwkUhEYYgWw3CJkMguyPL/hGp4Q54YieCSM2K4CAOIfkxWipL4LEgYde03JK6oiYYYLArziaeIMYQIhX84SObhiru4iBTYiAqDAU4EQxyGga2Fi3uCjI9zg514jMnYLaioWTmIjaRIjTjDi5xXSpcIjcrYjI83i4cUjtWoPpiCjt0oiix4iPrEjnJzjd+oOlaIPi/kQMjjPYLDPPv4NLkDPmQIAfkIPL8ILwOZjxp0O/BjP/74Ps5jP6GTkKdDjMhGkfoIkeSjO0aIfNowO9/TkQCAkeqoGRi5kM3zOW8jkgdZJfWDOSJ5kngjd4xoCJcoAQ5AOX4Dkv3YNPyoOFVzkzk5ji05IEKZK/zjPi+J/zYPuZQrqTZHaT2DmIpn54y1MpQZyZNACYGPoJXlwzxRmZFUiZAKg5NI2T8pGT8s6ZHp4JTQE5NlOZRJuW81OZJxuS4GSVkeRo42eZdEmX+wIJQH0EPuGFvbuCc4OZgPUEHDV02C+Zfal4RStYSu9ZhiyS2CSZhp+I5SCIWZuZjWV5dkWAEvNEfLyIShdUyjWZpF1ICBST2kGUaTUpjgZxOrKZtomH+2h4uuQ5pP1DF8GX2SZVSr+ZsDg5mwKQG4OZXTJ1zBmJzLaZEmVYHMSJmiR5ObaZiFOHhUWImfNZl6OW++l52y2Jm2NXO6aZ3eaYH0N5a1OYrbyXO72Q4pqP+HNlie8aF7UnV80rlQ1Imap7mXBoiDOzhb2Tie4ucM9VlXC8iWHRJ/zimB/SlP/ymg4dmd6YlKB8qf9UiXyvSdhpVSnJmfLrifEtqYdQlWh9UDN9CiLtoD11mUj8CiLtqiMKpYBxqaMjiczaeEhkCjNXqjMeqekwCkL2p58Jijt6dhFQqfvrik2BmgTjqkGHqAkqlN/Omg3OAdL5ilUTqdNJh9HAodt5VSYzpTGGVUPgqD8Tl4wMGlJsqBOjpUTYqjBTqgxbQgZ5o9nqWm4MmmT/pxbzpKXXqiX+qfYcqegEqlg2qmEtqhR0iJXPmeMoegwVmO5lmV6Fmn2hmo7dn/qGL6qKzXnkXVo3/qpWvKowCqpbRZqfTGqZQ6n6Samqvai1Qqq6G0oBOGqn+qqgJaqHLqoXSaqNWpjW2Kp2UaqsGaoU1In4W1Ubyafpc6qa16q8VoSMqad14Hqoq6py9CWCAKrYaaqlaKpJm6euiJourZqYyap4flrQEHrn6KpePaq+U6otVapSkKEu8qqnF3r+yqrzsKsMIZqxjKrdUJrNo6q8OKrd3qr9K6rgaboOKZq8/KTNHKnZKKn/mKqw8XDGdYRSBAALFop+EXsgcgAQkgJxGgkDKKCyhrCCP7oQ/rKwfQmw3QJa/jjaPqTjELADO7sbc4sYpws3JSATnr/zvvIjM/G7RCS63kuQhGSwBIq7MOwItEWn+88wCUcgBOtLIk+7QOCBMNwLX5grQJIAGJ6ZrDULZd+7VyQrPFuqiJgAFXyzoJgAAVwCsVUI3MymRue7ZYE7diy6rnugh2yysNkLd7CwB9W5SwELgEA7dhW7hROLaTkLh4q7d867d/S6GSMEKJwEElG7ABtClB87LDILq4KLe1aqxG0UCKII4yiqusewika7lrSh+yW7fVyC2325eu+6txalC9Cyaem7XXF7pTmbv/aDQB2ZSeo5ZVcwBTSTAL1JiwYL3pUrnPu5FL45MNCZOEA5zBUi/qimzcqwjOq5EBKZJI55b3k/8I5ou76Gu46zu63uu+IfmQWYsL8suS9WuT93uooJsvsNO64xO94huR5IvAiwABLbutq5vAuLu/Xqk70ju+oEM4oIk/d5u+zQrB7Ou9GQw+Q6sIAeyPHwwwIYy/Fiy8DAm9/etyM6ySb8nCjGksL2zA1HQKZZuMXivDtGqhdLu1Qoy0aMm2iBDEgmuXwzuldesAdrO4CJAAEzyhnuTEk0vEUoqpRAsmVLy5WOyy/9u2D5DEXvzFNtyxfTjGVlzGwgqmuNsn2QK2bsLGE4sAdnwA+eM7TBwsfTy4crLDF2q6JaM/w2O+kCpSfMyyxYLHhpyHdSUgsgkBi4wvMvPIBHD/x65jyJFprpg7CZecySKMqA47t/AKpaX6ukc8sB7Lrxd7exkrn0Usym5MsTOYyq68yk54yybrqZb6r+tpqvS6rJDrrsuksEr6yw1rsdnazIHsrNF8pww7wtA8r+KKzIabzQlbvNI8zAfszb0MsRoLzIisy9ZaugVbfAsLteRMvHPFzT6MS7DqzuEsdwhbzsjcyKesxyl8uLGsxXA6z+88p3Qcz1I80ATdr/3cswiNzu0s0Du6z/JsWoZau9eq0MHcrslaswet0epMsAE9ykNq0bgcteuc0CrqqA9NzFHc0QI70q18pdsc0pdLzRbIzNZ8zs/c0tV8rJ+qzEEtzBEd/7EAndMUrc4oja8qPdMsLctF7dFb6tA4rbwMraCzXMn1itSh7NQa2tO2/NNSDdL5rLofrcrmHK99asw3fdZKzdFt/NRZXYXEys9XzYlpjddwjdWwHNPwnMtuStQ7Dc5izcpaK9dhbHGErdYvzad7bdMY29U+Pa0THdZCXdmorNj4fNgUHNkL/dc0DdiXLdiC2ti1ytOZPdZRbQt6utaIzc6dvdpzDNMkHdemjdhNPdeYbdSxva+ubdV9rddV7dJ5DdG1ndTJnM4VjdoXLX9X/c8/fNdG7MvXLLGz7duRats1zbFLjc3J/dW8baCefd3jDNRmXd7a69yhPdrurbunSv/ZrI3dgW2rmjpzfCELq8B0xOAJn0DVWDYLtOBc/l0AQOfV850I+s0KYDwJxfDfrhreCy4I/L3cj/DgBn6em4rcoULc6VrPv42umn3SHJ7SPuLPJ17iKc7dy4umHW6vyRbiFRvedb3LH668KK4lOf65Ne7XIp7gPb7jNP5JQv6tI77ZRr7iRx7kKj7eCFLkSb7hLA7c1qXjMG5uS87UTS7O033jOL7lSh7lT37lggbkzb0zUM7W6erhXi7kaW7hL47gWo7mYF4hRVg0eJ7ner7nfN7nfv7nfl6EFHHngF7ohn7oiJ7ngp4ghJ7ojq7ni/4Kjf7olN4IkQ4Yk17pjn6H6bmQ6Zqe6JyOnmPz6aRe6mvZlaae6qbuvwox6qpu6KyeCK7+6oUe6zNM67WOCrOO635u617+68Ae7MI+7MRe7MZ+7Mie7Mq+7Mze7M7+7NAe7dI+7dRe7dZ+7die7dq+7dze7d7+7eAe7uI+7uRe7uZ+7uie7uq+7uze7u7+7vAe7/L+SYEAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The first meiotic division is summarized in the top panels and the second meiotic division is summarized in the bottom panels. Crossing-over occurs at the 4-strand stage between pairs of non-sister chromatids. The first meiotic division precedes centromere replication, and leads to segregation of non-sister chromatids. The centromeres replicate prior to the second meiotic division, resulting in sister chromatid segregation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_0_5120=[""].join("\n");
var outline_f5_0_5120=null;
var title_f5_0_5121="Olecranon bursitis";
var content_f5_0_5121=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F64359&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F64359&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Olecranon bursitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 265px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Swelling of both olecranon bursa is readily visible in this patient with olecranon bursitis secondary to gout.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Sheon, RP, Moskowitz, RW, Goldberg, VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_0_5121=[""].join("\n");
var outline_f5_0_5121=null;
var title_f5_0_5122="Vaginal tubal sterilization D";
var content_f5_0_5122=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59942&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59942&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vaginal tubal sterilization",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 321px; height: 373px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_0_5122=[""].join("\n");
var outline_f5_0_5122=null;
var title_f5_0_5123="Linear porokeratosis";
var content_f5_0_5123=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F73545&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F73545&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Linear porokeratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Linear erythematous plaques with prominent keratotic rims are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_0_5123=[""].join("\n");
var outline_f5_0_5123=null;
var title_f5_0_5124="Cross wall PM";
var content_f5_0_5124=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F71699&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F71699&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cross wall PM",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 309px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gomori methenamine silver staining of bone marrow aspirate (original magnification, x1000).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Hung, Y, and Yang, S. Photo Quiz: Pancytopenia in a Southeast Asian Woman with HIV Infection. Clin Infect Dis 2009; 49:122. Copyright &copy; 2009 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_0_5124=[""].join("\n");
var outline_f5_0_5124=null;
var title_f5_0_5125="Oxytocin: Drug information";
var content_f5_0_5125=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Oxytocin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?18/30/18915?source=see_link\">",
"    see \"Oxytocin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F205493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pitocin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F205494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Oxytocin for injection",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F205529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Oxytocic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F205497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     I.V. administration requires the use of an infusion pump.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Induction of labor:",
"     </b>",
"     <i>",
"      Manufacturer's labeling:",
"     </i>",
"     I.V.: 0.5-1 milliunits/minute; gradually increase dose in 30-60 minute intervals by increments of 1-2 milliunits/minute until desired contraction pattern is established; dose may be decreased after desired frequency of contractions is reached and labor has progressed to 5-6 cm dilation. Infusion rates of 6 milliunits/minute provide oxytocin levels similar to those at spontaneous labor; rates  &gt;9-10 milliunits/minute are rarely required. Higher dose regimens (example, initial dose 2-6 milliunits/minute) with larger incremental dose increases (example, 1-6 milliunits/minute) have also been proposed; decrease or discontinue dose for abnormal or excessive uterine contractions (ACOG, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Postpartum bleeding:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: Total dose of 10 units after delivery of the placenta",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 10-40 units by I.V. infusion in 1000 mL of intravenous fluid at a rate sufficient to control uterine atony",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Adjunctive treatment of abortion:",
"     </b>",
"     I.V.: 10-20 milliunits/minute; maximum total dose: 30 units/12 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F205472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 10 units/mL (1 mL, 10 mL, 30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pitocin&reg;: 10 units/mL (1 mL, 10 mL) [contains chlorobutanol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F205457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F205474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: An infusion pump is required for administration",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F205534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amikacin, ampicillin, cefazolin, cefotaxime, cefoxitin, clindamycin, doxycycline, erythromycin lactobionate, gentamicin, heparin, hydrocortisone sodium succinate, insulin (regular), meperidine, metronidazole, minocycline, morphine, nafcillin, oxacillin, piperacillin, potassium chloride, tobramycin, trimethoprim/sulfamethoxazole, vancomycin, vitamin B complex with C, warfarin, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Pantoprazole.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Dimenhydrinate, hydrocortisone sodium succinate, pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F205473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Induction of labor in patients with a medical indication; stimulation or reinforcement of labor; adjunctive therapy in management of abortion; to produce uterine contractions during the third stage of labor; control of postpartum bleeding",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F205536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F205527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Fetus or neonate:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias (including premature ventricular contractions), bradycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Brain or CNS damage (permanent), neonatal seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Neonatal jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Neonatal retinal hemorrhage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Fetal death, low Apgar score (5 minute)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Mother:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias (including premature ventricular contractions), hypertensive episodes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Pelvic hematoma, postpartum hemorrhage, uterine hypertonicity, tetanic contraction of the uterus, uterine rupture, uterine spasm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Afibrinogenemia (fatal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Anaphylactic reaction, subarachnoid hemorrhage; severe water intoxication with convulsions, coma, and death is associated with a slow oxytocin infusion over 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F205477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to oxytocin or any component of the formulation; significant cephalopelvic disproportion; unfavorable fetal positions; fetal distress when delivery is not imminent; hypertonic or hyperactive uterus; contraindicated vaginal delivery (invasive cervical cancer, active genital herpes, prolapse of the cord, cord presentation, total placenta previa, or vasa previa); obstetrical emergencies where surgical intervention is favored; where adequate uterine activity fails to achieve satisfactory progress",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F205461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antidiuretic effect: May produce antidiuretic effect (ie, water intoxication). Severe water intoxication with convulsions, coma, and death is associated with a slow oxytocin infusion over 24 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Uterine effects: High doses or hypersensitivity to oxytocin may cause uterine hypertonicity, spasm, tetanic contraction, or rupture of the uterus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use:",
"     <b>",
"      [U.S. Boxed Warning]: To be used for medical rather than elective induction of labor.",
"     </b>",
"     Medical indications for labor induction may include Rh problems, maternal diabetes, preeclampsia at or near term, when delivery is in the best interest of mother or fetus, or premature rupture of membranes when delivery is indicated.  Use is generally not recommended in the following conditions: Fetal distress, hydramnios, partial placenta previa, prematurity, borderline cephalopelvic disproportion, or conditions where there is a predisposition for uterine rupture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Trained personnel: Intravenous preparations should be administered by adequately trained individuals familiar with its use and able to identify complications.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F205466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dinoprostone: May enhance the therapeutic effect of Oxytocin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Misoprostol: May enhance the therapeutic effect of Oxytocin. Management: The manufacturer of misoprostol recommends avoiding concomitant use with oxytocin.  Misoprostol may augment effects of oxytocin, particularly when given within 4 hours of oxytocin initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F205468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (manufacturer specific) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F205479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: To be used for medical rather than elective induction of labor.",
"     </b>",
"     Animal reproduction studies have not been conducted. When used as indicated, teratogenic effects would not be expected. Nonteratogenic adverse reactions are reported in the neonate as well as the mother.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F205500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F205480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Endogenous levels of oxytocin naturally increase during breast-feeding.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Oxytocin Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 units/mL (10 mL): $12.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Pitocin Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 units/mL (10 mL): $7.19",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F205470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fluid intake and output during administration, uterine activity, blood pressure; fetal monitoring",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F205481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ao Sai Juo Xing (CL);",
"     </li>",
"     <li>",
"      Evatocin (PH);",
"     </li>",
"     <li>",
"      Induxin (ID);",
"     </li>",
"     <li>",
"      Litocin (TW);",
"     </li>",
"     <li>",
"      Matosin (ID);",
"     </li>",
"     <li>",
"      NeOxyn (PH);",
"     </li>",
"     <li>",
"      Octocin (TH);",
"     </li>",
"     <li>",
"      Oksitocins (EE);",
"     </li>",
"     <li>",
"      Oxitone (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, PH, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Partocon INJ (FI);",
"     </li>",
"     <li>",
"      Pitocin (EC);",
"     </li>",
"     <li>",
"      Pitocin INJ (IN);",
"     </li>",
"     <li>",
"      Pitogin (ID);",
"     </li>",
"     <li>",
"      Piton S INJ (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, NL, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Santocyn (ID);",
"     </li>",
"     <li>",
"      Synthetic Oxytocin INJ (IN);",
"     </li>",
"     <li>",
"      Syntocinon (DK, HR, LU, PT);",
"     </li>",
"     <li>",
"      Syntocinon INJ (AR, AT, AU, BE, BF, BJ, BR, CH, CI, CN, DE, ES, ET, FI, FR, GB, GH, GM, GN, HK, IE, IT, KE, LR, MA, ML, MR, MU, MW, MX, MY, NE, NG, NL, NZ, PE, PH, PK, PL, PY, SC, SD, SE, SG, SL, SN, TN, TZ, UG, UY, VE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Syntocinon Spray (AT, CH, NO, PL, SE);",
"     </li>",
"     <li>",
"      Udoxan (MY);",
"     </li>",
"     <li>",
"      Xitocin (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F205460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oxytocin stimulates uterine contraction by activating G-protein-coupled receptors that trigger increases in intracellular calcium levels in uterine myofibrils. Oxytocin also increases local prostaglandin production, further stimulating uterine contraction.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F205476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Uterine contractions: I.M.: 3-5 minutes; I.V.: ~1 minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: I.M.: 2-3 hour; I.V.: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Rapidly hepatic and via plasma (by oxytocinase) and to a smaller degree the mammary gland",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 1-6 minutes; decreased in late pregnancy and during lactation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACOG Committee on Practice Bulletins - Obstetrics, \"ACOG Practice Bulletin No.107: Induction of Labor,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2009, 114(2 Pt 1):386-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/0/5125/abstract-text/19623003/pubmed\" id=\"19623003\" target=\"_blank\">",
"        19623003",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rajan PV and Wing DA, \"Postpartum Hemorrhage: Evidence-Based Medical Interventions for Prevention and Treatment,\"",
"      <i>",
"       Clin Obstet Gynecol",
"      </i>",
"      , 2010 53(1):165-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/0/5125/abstract-text/20142654/pubmed\" id=\"20142654\" target=\"_blank\">",
"        20142654",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wei SQ, Luo ZC, Qi HP, et al, \"High-Dose vs Low-Dose Oxytocin for Labor Augmentation: A Systematic Review,\"",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 2010, 203(4):296-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/0/5125/abstract-text/20451894/pubmed\" id=\"20451894\" target=\"_blank\">",
"        20451894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9734 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-31C67D9254-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_0_5125=[""].join("\n");
var outline_f5_0_5125=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709190\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205493\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205494\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205529\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205497\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205472\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205457\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205474\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205534\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205473\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205536\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205527\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205477\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205461\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299808\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205466\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205468\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205479\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205500\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205480\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323589\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205470\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205481\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205460\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205476\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9734\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9734|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/30/18915?source=related_link\">",
"      Oxytocin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_0_5126="Chylopericardium and cholesterol pericarditis";
var content_f5_0_5126=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chylopericardium and cholesterol pericarditis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/0/5126/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/0/5126/contributors\">",
"     Brian D Hoit, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/0/5126/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/0/5126/contributors\">",
"     Martin M LeWinter, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/0/5126/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/0/5126/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/0/5126/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chylopericardium is a pericardial effusion comprised of chyle, the normal content of the lacteals (lymphatics of the small intestine) and thoracic duct. Chylopericardium may be primary (idiopathic) or, much more often, secondary. The pericardial effusion appears milky and opaque, with a triglyceride level greater than 500",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    and a",
"    <span class=\"nowrap\">",
"     cholesterol/triglyceride",
"    </span>",
"    ratio is less than 1.",
"   </p>",
"   <p>",
"    Although the cholesterol content is high, chylopericardium should not be confused with cholesterol pericarditis in which the fluid contains cholesterol crystals, foam cells, macrophages and giant cells. The fluid in cholesterol pericarditis is clear, and classically is said to have a glittering \"gold paint\" appearance, although many other colors have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5126/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chylopericardium and cholesterol pericarditis will be reviewed here. Other causes of pericardial effusion and pericarditis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30392?source=see_link\">",
"     \"Etiology of pericardial disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4025?source=see_link&amp;anchor=H2#H2\">",
"     \"Diagnosis and treatment of pericardial effusion\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY OF THE THORACIC DUCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thoracic duct carries chyle from the intestinal tract to the blood stream (",
"    <a class=\"graphic graphic_figure graphicRef57280 \" href=\"UTD.htm?9/19/9525\">",
"     figure 1",
"    </a>",
"    ). Although wide anatomic variation exists, in up to 50 percent of the population the thoracic duct ascends from the cisterna chyli (into which the lacteals discharge their chyle), which lies just anterior to the first or second lumbar vertebra, and passes through the aortic hiatus of the diaphragm [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5126/abstract/2\">",
"     2",
"    </a>",
"    ]. The thoracic duct continues cephalad in a rightward position between the aorta and the azygos vein until it is close to the fifth thoracic vertebra where it crosses over the vertebral column behind the esophagus and continues its course in the left posterior mediastinum. At this point, the thoracic duct passes behind the aortic arch, along the left border of the esophagus and behind the left subclavian artery over which it arches in the anterolateral aspect of the superior mediastinum. It then descends to empty into the junction of the left internal jugular and left subclavian veins (",
"    <a class=\"graphic graphic_figure graphicRef65131 \" href=\"UTD.htm?5/14/5353\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In some individuals, two thoracic ducts exist within the mediastinum, or occasionally, a single thoracic duct drains into a right sided great vein [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5126/abstract/2\">",
"     2",
"    </a>",
"    ]. The relatively high incidence (39 percent) of duplication or multiplication of the mediastinal portion of the thoracic duct has important implications for successful duct ligation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5126/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CHYLOPERICARDIUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chylopericardium is a rare disorder that may be primary (ie, idiopathic) or, more often, secondary to injury to the thoracic duct. The pericardial effusion appears milky and opaque with a triglyceride level greater than 500",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (",
"    <a class=\"graphic graphic_picture graphicRef77602 \" href=\"UTD.htm?28/24/29071\">",
"     picture 1",
"    </a>",
"    ). Significant leakage of chyle causes serious nutritional, metabolic, and immunologic abnormalities. In addition, cardiac complications can occur including cardiac tamponade and, since chyle appears to be a pericardial irritant, acute pericarditis or chronic constriction [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5126/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. Without treatment, chylopericardium is associated with a high mortality rate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Secondary chylopericardium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary chylopericardium usually results from injury or damage to the thoracic duct. The most common causes of secondary chylopericardium are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Trauma (blunt or penetrating)",
"     </li>",
"     <li>",
"      Thoracic or cardiac surgery (especially for congenital heart disease)",
"     </li>",
"     <li>",
"      Congenital lymphangiomatosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other documented causes of secondary chylopericardium include radiotherapy, subclavian vein thrombosis, infection (eg, tuberculosis), mediastinal neoplasms (eg, lymphoma, signet ring carcinoma), cystic hygroma, acute pancreatitis, and Gorham&rsquo;s disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5126/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42150?source=see_link&amp;anchor=H2#H2\">",
"     \"Antineoplastic therapy for miscellaneous benign diseases affecting soft tissue and bone\", section on 'Gorham's disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chylopericardium is a rare complication of thoracic surgery, primarily represented in the literature as case reports following aortic valvotomy, repair of tetralogy of Fallot, coronary artery bypass graft surgery, the Blalock-Taussig anastomosis, orthotopic cardiac transplantation, and esophagectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5126/abstract/2,9-14\">",
"     2,9-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Congenital mediastinal lymphangiomatosis can produce chylopericardium either by direct pericardial extension or by obstruction of mediastinal lymphatics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Chylothorax",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chylothorax, with or without chylopericardium, is much more common than isolated chylopericardium. Most cases are nontraumatic, with the major cause being malignancy, particularly lymphoma. Surgical procedures account for most of the traumatic cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37192?source=see_link\">",
"     \"Etiology, clinical presentation, and diagnosis of chylothorax\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Primary chylopericardium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary or idiopathic chylopericardium is much less common than secondary chylopericardium and is a diagnosis by exclusion [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5126/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. Potential causes in isolated cases have included aplasia of the cisterna chyli and the distal portion of the thoracic duct, acquired ectasia of septal and perivascular lymphatics in a drug user in whom talc granulomata was the presumed etiology of lymphatic obstruction, and inflammation due to allergic alveolitis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5126/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of chylopericardium is suggested by the discovery of a milky opalescent pericardial effusion (",
"    <a class=\"graphic graphic_picture graphicRef77602 \" href=\"UTD.htm?28/24/29071\">",
"     picture 1",
"    </a>",
"    ). The diagnosis is confirmed by analysis of the fluid, which reveals a triglyceride level greater than 500",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    <span class=\"nowrap\">",
"     cholesterol/triglyceride",
"    </span>",
"    ratio of less than 1, negative cultures, lymphocyte predominance on cytologic examination, and fat globules by Sudan 111 staining [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5126/abstract/20\">",
"     20",
"    </a>",
"    ]. The major cellular component of chyle is the lymphocyte, primarily T lymphocytes. The lymphocyte count ranges between a few hundred to several thousand per milliliter. The electrolyte concentration mirrors that of the plasma and the protein content exceeds 3",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    The protein content and specific gravity are characteristically high. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4025?source=see_link&amp;anchor=H10#H10\">",
"     \"Diagnosis and treatment of pericardial effusion\", section on 'Establish the cause of the effusion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Contrast-enhanced computerized tomography together with",
"    <span class=\"nowrap\">",
"     lymphangiography/lymphangioscintigraphy",
"    </span>",
"    can be used to help identify an injury or blockage of the thoracic duct (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69482 \" href=\"UTD.htm?11/34/11808\">",
"     image 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5126/abstract/21\">",
"     21",
"    </a>",
"    ]. Scintigraphy after the oral administration of I-131 triolein has been used to establish the diagnosis in primary chylopericardium [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5126/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The milky opalescence may disappear or decrease with fasting or dietary modification, but returns after resuming fat intake. In asymptomatic patients, the effusion may be controlled by adherence to a diet that is low in fat and high in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/51/19250?source=see_link\">",
"     medium chain triglycerides",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5126/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. In favorable cases, the chylous effusion does not recur after a few weeks of dietary treatment, presumably because the initiating cause has resolved.",
"   </p>",
"   <p>",
"    A symptomatic effusion (acute pericarditis, tamponade, or constrictive pericarditis) or a large uncontrolled effusion (an average daily loss of chyle of 500",
"    <span class=\"nowrap\">",
"     mL/d",
"    </span>",
"    for 5 days) usually necessitates more aggressive therapy. Conservative treatment consists of pericardial drainage (pericardiocentesis or tube pericardiostomy), fluid and electrolyte replacement, and intravenous hyperalimentation. This approach is effective in approximately 55 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5126/abstract/25\">",
"     25",
"    </a>",
"    ]. Nonoperative therapy is usually unsuccessful when chylopericardium is secondary to congenital lymphangiomatosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4025?source=see_link&amp;anchor=H15#H15\">",
"     \"Diagnosis and treatment of pericardial effusion\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/36/25159?source=see_link\">",
"     \"Technique of pericardiocentesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgical therapy consists of ligation of the thoracic duct and tributary lymphatics, and pericardiotomy or pericardiectomy. It is usually considered if conservative therapy does not reduce pericardial drainage after 7 to 14 days or if the effusion recurs [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5126/abstract/3,20\">",
"     3,20",
"    </a>",
"    ]. There is no widely accepted daily drainage volume of chyle that indicates the need for surgical treatment, although significant nutritional loss is one criterion.",
"   </p>",
"   <p>",
"    Video-assisted thoracic surgery with port access and precise ligation and division of the thoracic duct just above the diaphragm appears to be a safe and effective method in a small number of patients with chylothorax and chylopericardium [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5126/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients in whom aggressive therapy is considered inappropriate, a tube can be placed in the pericardium at one end and in the peritoneum at the other to drain the chyle away from the pericardium and into the peritoneal cavity where it can be absorbed [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5126/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CHOLESTEROL PERICARDITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distinction between chylopericardium and cholesterol pericarditis is analogous to that between chylothorax and chyliform pleural effusion (pseudochylothorax). Cholesterol pericarditis is a complication of chronic pericardial effusion or chronic scarring of the pericardium and is exacerbated by cholesterol crystals [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5126/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37192?source=see_link\">",
"     \"Etiology, clinical presentation, and diagnosis of chylothorax\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Common underlying causes include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tuberculous pericarditis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2633?source=see_link\">",
"       \"Tuberculous pericarditis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Rheumatoid pericarditis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=see_link&amp;anchor=H23#H23\">",
"       \"Overview of the systemic and nonarticular manifestations of rheumatoid arthritis\", section on 'Pericarditis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pericardial trauma, which is a less common cause (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20968?source=see_link&amp;anchor=H7#H7\">",
"       \"Post-cardiac injury syndromes\", section on 'Pericardial trauma'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cholesterol crystals are characteristic of this relatively rare disease. When a pericardial effusion is relatively acute, its cholesterol content remains in solution. However, when the pericardial effusion is chronic, the normal ability to dissolve cholesterol is impaired and cholesterol crystals are deposited in the pericardium and effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5126/abstract/1\">",
"     1",
"    </a>",
"    ]. The fluid is clear, in contrast to chylopericardium, and classically is said to have a glittering \"gold paint\" appearance, although many other colors have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5126/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effusions tend to be large. The concentration of cholesterol equals or exceeds that of the blood, often attaining values above 500",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (13",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    The pericardial effusion associated with myxedema also has a high cholesterol concentration, but crystals are usually absent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=see_link\">",
"     \"Clinical manifestations of hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Blood associated with inflammation is thought to be the source of cholesterol in the pericardial fluid, and evidence of current or previous hemorrhage is usually evident. The pericardium is thicker than normal and its inner surface is lined with plaques and cholesterol deposits. The histologic findings include fibrosis, inflammatory cells, cholesterol clefts and crystals of variable geometry, and giant cell granulomata.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pericardiocentesis is seldom effective over the long-term because the cholesterol effusions tend to recur and can cause tamponade at any time. This procedure also fails to address the thick, scarred pericardium and does not prevent the late development of constrictive pericarditis. Thus, optimal therapy is radical pericardiectomy plus treatment of the underlying cause of chronic recurrent pericarditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"     \"Cardiac tamponade\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=see_link\">",
"     \"Constrictive pericarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/58/11177?source=see_link&amp;anchor=H6#H6\">",
"     \"Recurrent pericarditis\", section on 'Therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234278\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The thoracic duct carries chyle from the intestinal tract to the blood stream (",
"      <a class=\"graphic graphic_figure graphicRef57280 \" href=\"UTD.htm?9/19/9525\">",
"       figure 1",
"      </a>",
"      ). Wide anatomic variation exists, though in about 50 percent of persons the thoracic duct ascends from the cisterna chyli (anterior to the first or second lumbar vertebra), passes through the diaphragm, continues cephalad in the mediastinum, and eventually empties into the junction of the left internal jugular and left subclavian veins (",
"      <a class=\"graphic graphic_figure graphicRef65131 \" href=\"UTD.htm?5/14/5353\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomy of the thoracic duct'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chylopericardium is a pericardial effusion comprised of chyle, the normal content of the lacteals (lymphatics of the small intestine) and thoracic duct. Chylopericardium may be primary (idiopathic) or, much more often, secondary to injury to the thoracic duct (eg, trauma, iatrogenic, malignancy). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Chylopericardium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of chylopericardium is made by sampling pericardial fluid during pericardiocentesis or pericardiotomy. The pericardial effusion in chylopericardium appears milky and opaque, with a triglyceride level greater than 500",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      <span class=\"nowrap\">",
"       cholesterol/triglyceride",
"      </span>",
"      ratio of less than 1, negative cultures, lymphocyte predominance on cytologic examination, and fat globules by Sudan 111 staining. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapy for chylopericardium varies depending on the level of severity. For asymptomatic patients, dietary reduction in fat intake may lead to resolution, while more aggressive therapy is indicated for persons with symptomatic pericarditis or pericardial effusion with cardiac tamponade or constrictive pericarditis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cholesterol pericarditis is a distinct clinical entity from chylopericardium in which the pericardial fluid contains cholesterol crystals, foam cells, macrophages and giant cells. The fluid in cholesterol pericarditis is clear, and classically is said to have a glittering \"gold paint\" appearance. Because of the tendency for effusions to recur, with the associated risk of cardiac tamponade and constrictive pericarditis, optimal therapy is radical pericardiectomy along with treatment of the underlying cause of chronic pericarditis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Cholesterol pericarditis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Spodick DH. The Pericardium. A comprehensive textbook, Marcel Dekker, New York 1997. p.84.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5126/abstract/2\">",
"      Valentine VG, Raffin TA. The management of chylothorax. Chest 1992; 102:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5126/abstract/3\">",
"      Wurnig PN, Hollaus PH, Ohtsuka T, et al. Thoracoscopic direct clipping of the thoracic duct for chylopericardium and chylothorax. Ann Thorac Surg 2000; 70:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5126/abstract/4\">",
"      Brawley RK, Vasko JS, Morrow AG. Cholesterol pericarditis. Considerations of its pathogenesis and treatment. Am J Med 1966; 41:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5126/abstract/5\">",
"      Mogulkoc N, Onal B, Okyay N, et al. Chylothorax, chylopericardium and lymphoedema--the presenting features of signet-ring cell carcinoma. Eur Respir J 1999; 13:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5126/abstract/6\">",
"      Andrade Santiago J, Robles L, Casimiro C, et al. Chylopericardium of neoplastic aetiology. Ann Oncol 1998; 9:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5126/abstract/7\">",
"      Arendt T, Bastian A, Lins M, et al. Chylous cardiac tamponade in acute pancreatitis. Dig Dis Sci 1996; 41:1972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5126/abstract/8\">",
"      Swelstad MR, Frumiento C, Garry-McCoy A, et al. Chylotamponade: an unusual presentation of Gorham's syndrome. Ann Thorac Surg 2003; 75:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5126/abstract/9\">",
"      Tchervenkov CI, Dobell AR. Chylopericardium following cardiac surgery. Can J Surg 1985; 28:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5126/abstract/10\">",
"      Papaioannou Y, Vomvoyannis A, Andritsakis G. Combined chylopericardium and chylothorax after total correction of Fallot's tetralogy. Thorac Cardiovasc Surg 1984; 32:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5126/abstract/11\">",
"      Lee Y, Lee WK, Doromal N, et al. Cardiac tamponade resulting from massive chylopericardium after an aorta-coronary bypass operation. J Thorac Cardiovasc Surg 1987; 94:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5126/abstract/12\">",
"      Feteih W, Rao PS, Whisennand HH, et al. Chylopericardium: new complication of blalock-taussig anastomosis. J Thorac Cardiovasc Surg 1983; 85:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5126/abstract/13\">",
"      Mailander L, Van Meter C, Ventura H, et al. Chylopericardium after orthotopic heart transplantation. J Heart Lung Transplant 1992; 11:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5126/abstract/14\">",
"      Nakamura S, Ohwada S, Morishita Y. Isolated chylopericardium following radical esophagectomy: report of a case. Surg Today 1996; 26:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5126/abstract/15\">",
"      Y&uuml;ksel M, Yildizeli B, Zon&uuml;zi F, Batirel HF. Isolated primary chylopericardium. Eur J Cardiothorac Surg 1997; 12:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5126/abstract/16\">",
"      Svedjeholm R, Jansson K, Olin C. Primary idiopathic chylopericardium--a case report and review of the literature. Eur J Cardiothorac Surg 1997; 11:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5126/abstract/17\">",
"      Mewis C, K&uuml;hlkamp V, Sokiranski R, Karsch KR. Primary chylopericardium due to partial aplasia of the thoracic duct. Eur Heart J 1997; 18:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5126/abstract/18\">",
"      Chan RM, Dodek A. Chylopericardium in a drug addict. Arch Intern Med 1984; 144:1857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5126/abstract/19\">",
"      Bewick DJ, Johnstone DE, Landrigan PL. Primary chylopericardium associated with allergic alveolitis. Can Med Assoc J 1984; 130:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5126/abstract/20\">",
"      Dib C, Tajik AJ, Park S, et al. Chylopericardium in adults: a literature review over the past decade (1996-2006). J Thorac Cardiovasc Surg 2008; 136:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5126/abstract/21\">",
"      Akamatsu H, Amano J, Sakamoto T, Suzuki A. Primary chylopericardium. Ann Thorac Surg 1994; 58:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5126/abstract/22\">",
"      Hamanaka D, Suzuki T, Kawanishi K, et al. Two cases of primary isolated chylopericardium diagnosed by oral administration of 131I-triolein. Radiat Med 1983; 1:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5126/abstract/23\">",
"      Jensen GL, Mascioli EA, Meyer LP, et al. Dietary modification of chyle composition in chylothorax. Gastroenterology 1989; 97:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5126/abstract/24\">",
"      Nguyen DM, Shum-Tim D, Dobell AR, Tchervenkov CI. The management of chylothorax/chylopericardium following pediatric cardiac surgery: a 10-year experience. J Card Surg 1995; 10:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5126/abstract/25\">",
"      Chan BB, Murphy MC, Rodgers BM. Management of chylopericardium. J Pediatr Surg 1990; 25:1185.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4917 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-C80C007BE0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_0_5126=[""].join("\n");
var outline_f5_0_5126=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H234278\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY OF THE THORACIC DUCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CHYLOPERICARDIUM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Secondary chylopericardium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Chylothorax",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Primary chylopericardium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CHOLESTEROL PERICARDITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H234278\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/4917\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4917|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?11/34/11808\" title=\"diagnostic image 1\">",
"      Primary chylopericardium CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4917|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/19/9525\" title=\"figure 1\">",
"      Anatomy of thoracic duct",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/14/5353\" title=\"figure 2\">",
"      Anterior neck anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4917|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/24/29071\" title=\"picture 1\">",
"      Chylous pericardial fluid",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42150?source=related_link\">",
"      Antineoplastic therapy for miscellaneous benign diseases affecting soft tissue and bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=related_link\">",
"      Cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=related_link\">",
"      Clinical manifestations of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=related_link\">",
"      Constrictive pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4025?source=related_link\">",
"      Diagnosis and treatment of pericardial effusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30392?source=related_link\">",
"      Etiology of pericardial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37192?source=related_link\">",
"      Etiology, clinical presentation, and diagnosis of chylothorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=related_link\">",
"      Overview of the systemic and nonarticular manifestations of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20968?source=related_link\">",
"      Post-cardiac injury syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/58/11177?source=related_link\">",
"      Recurrent pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/36/25159?source=related_link\">",
"      Technique of pericardiocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2633?source=related_link\">",
"      Tuberculous pericarditis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_0_5127="Cervical hypoplasia";
var content_f5_0_5127=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F80051%7EOBGYN%2F67197&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F80051%7EOBGYN%2F67197&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cervical hypoplasia with the presence of a vagina",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 406px; height: 338px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from:&nbsp;Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012.&nbsp;Copyright &copy; 2012 Lippincott Williams&nbsp;&amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Congenital cervical dysgenesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 547px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The cervical body is intact (A) with obstruction of the cervical os. The cervical body (B) consists of a fibrous band of variable diameter that may contain endocervical glands. Fragmented portions of the cervix are noted (C) with no connection to the uterine body. Hypoplasia of the uterine cavity may be associated with cervical cords or fragmentation. The midportion of the cervix (D) is hypoplastic with a bulbous tip. No cervical lumen is identified.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn with permission from: Rock, JA, Carpenter, SE, Wheeless, CR, Jones, Jr., HW. The clinical management of maldevelopment of the uterine cervix. Journal of Pelvic Surgery 1995; 1:129.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_0_5127=[""].join("\n");
var outline_f5_0_5127=null;
var title_f5_0_5128="Ovarian tumors of low malignant potential";
var content_f5_0_5128=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ovarian tumors of low malignant potential",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/0/5128/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/0/5128/contributors\">",
"     Lee-may Chen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/0/5128/contributors\">",
"     Jonathan S Berek, MD, MMS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/0/5128/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/0/5128/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/0/5128/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/0/5128/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/0/5128/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/0/5128/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumors of low malignant potential (also called borderline tumors) are a heterogeneous group of lesions defined histologically by atypical epithelial proliferation without stromal invasion [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE AND EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Borderline tumors account for 10 to 20 percent of ovarian epithelial tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Approximately 4000 cases of borderline or low malignant potential ovarian tumors are diagnosed annually in the United States. The average age at diagnosis is 40 to 60 years old, but the highest frequency relative to invasive ovarian cancer of these tumors occurs in the 15 to 29 year-old age group. Thus, the disease frequently affects women with a desire to preserve childbearing potential.",
"   </p>",
"   <p>",
"    Although BRCA gene mutations are associated with an increased risk of developing invasive ovarian cancer, these mutations do not appear to confer an increased risk for tumors of low malignant potential [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Oral contraceptive use does not appear to be protective; however, increasing parity and lactation appear to reduce the risk of borderline ovarian tumors in women aged 50 to 74 years [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=see_link\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Use of fertility drugs was a risk factor for development of borderline ovarian tumors in some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]; however, other studies have not shown this association.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HISTOLOGIC TYPES",
"    </span>",
"    &nbsp;&mdash;&nbsp;These tumors probably represent a variety of histologies with different molecular biology, prognosis, and response to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/11\">",
"     11",
"    </a>",
"    ]. There is no consensus on how to best categorize them. Common nomenclature is described below:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Serous borderline tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of borderline tumors are serous. Approximately 75 percent of patients are diagnosed with stage I disease; 25 to 50 percent of tumors are bilateral [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/2,12\">",
"     2,12",
"    </a>",
"    ]. These tumors tend to remain confined to the ovary. However, complete surgical staging is important for both diagnostic and therapeutic purposes as 25 to 30 percent of women with serous tumors will have extraovarian disease, and 6 to 27 percent of those with a frozen section diagnosis of borderline tumor will be upgraded to invasive cancer on final histologic examination [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Higher stage disease is the major risk factor associated with recurrence; it is less clear whether the presence of invasive peritoneal implants, histologic subtype (eg, serous borderline with micropapillary pattern, mucinous peritoneal), DNA aneuploidy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    microinvasion affect overall prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/14-18\">",
"     14-18",
"    </a>",
"    ]. Micropapillary features are present in 10 to 15 percent of serous borderline tumors, as well as in other types of benign and malignant serous ovarian tumors. The presence of micropapillary features increases the probability of both invasive peritoneal implants (from 6 to 49 percent) and of recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Mucinous borderline tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucinous tumors are the other common cellular type; 90 percent are stage I and fewer than 10 percent are bilateral. One exception is the \"endocervical\" subtype of mucinous tumor, which is bilateral in up to 40 percent of patients. Of note, mucinous tumors involving the ovary that are associated with pseudomyxoma peritonei are potentially of appendiceal origin, and therefore not a borderline ovarian tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36074?source=see_link&amp;anchor=H11#H11\">",
"     \"Cancer of the appendix and pseudomyxoma peritonei\", section on 'Pseudomyxoma peritonei'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometrioid, clear-cell, and transitional cell (Brenner) borderline tumors are rare. They are usually unilateral and confined to the ovary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients present with an asymptomatic adnexal mass noted either on bimanual examination or as an incidental finding on sonography; however, symptoms (eg,",
"    <span class=\"nowrap\">",
"     abdominal/pelvic",
"    </span>",
"    pain or dyspareunia) may occur, as with any adnexal mass.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Imaging and laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no sonographic features strongly suggestive of borderline histology. Sonographic appearance ranges from unilocular cysts to masses with both solid and fluid components; papilla are common [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34440?source=see_link\">",
"     \"Sonographic differentiation of benign versus malignant adnexal masses\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A retrospective series of 1069 patients with borderline tumors reported 49 percent had normal serum levels of CA 125, and fewer than 25 percent had levels above 100",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of these neoplasms is based on histopathological examination. Frozen section is commonly performed intraoperatively and the information is used to help determine the extent of the surgical procedure. A meta-analysis of 18 studies on the diagnostic accuracy of frozen section results of ovarian pathology found generally good sensitivity (65 to 100 percent) and excellent specificity (&gt;99 percent) when compared to the final histopathological diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/26\">",
"     26",
"    </a>",
"    ]. Factors that lower the sensitivity of frozen section diagnosis of malignancy include large neoplasms, mucinous tumors (which have more histologic variation), and borderline tumors, since all require a large number of sections to exclude the presence of a focal area of invasive disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The staging system for borderline tumors is the same as for other ovarian tumors (",
"    <a class=\"graphic graphic_table graphicRef51205 \" href=\"UTD.htm?14/43/15038\">",
"     table 1",
"    </a>",
"    ). In one review including 948 cases, 70 percent presented as stage I, 10 percent presented as stage II, 19 percent presented as stage III, and less than 1 percent presented as stage IV [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The need for complete surgical staging of borderline tumors is controversial. Upstaging when a comprehensive staging procedure is performed is not uncommon (12 to 47 percent) with presumed stage I serous, but not mucinous, tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Staging is useful in the event that final pathologic analysis finds invasive disease missed on frozen section. The low prognostic utility of lymph node sampling was illustrated in a meta-analysis of 97 studies including over 4000 patients with ovarian tumors of low malignant potential that reported 98 percent survival at 6.5 years in women with lymph node involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our practice, for apparent stage I disease, we perform pelvic washings, removal of the affected ovary, an omental biopsy, and a biopsy of any peritoneal lesions; appendectomy is performed for mucinous tumors. Removal of the unaffected ovary is not required, but is an option for women who have completed childbearing. Some surgeons do not perform complete staging since survival is high regardless of stage [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/13,32-34\">",
"     13,32-34",
"    </a>",
"    ] and the role of postoperative therapy is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/35-37\">",
"     35-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The advantages of staging are to provide better information for prognostic counseling, to discover areas of occult invasion, and to obtain information about the biologic behavior of these tumors. For these reasons, we recommend a comprehensive staging procedure for all patients (",
"    <a class=\"graphic graphic_table graphicRef75194 \" href=\"UTD.htm?40/8/41099\">",
"     table 2",
"    </a>",
"    ), although other gynecologic oncologists would disagree. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=see_link\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Fertility preserving surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Borderline tumors generally have an excellent prognosis and can be treated conservatively in women who wish to preserve their fertility or are pregnant at the time of diagnosis. Unilateral salpingo-oophorectomy, or, in some instances, ovarian cystectomy may be performed. All macroscopic disease should be resected. A laparoscopic approach has not been evaluated in randomized trials. In general, retrospective series have reported that cyst rupture was more likely and complete staging was less likely with laparoscopic surgery than laparotomy, but there was no difference in recurrence rate [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. Abdominal exploration and appendectomy should be performed in women with mucinous tumors.",
"   </p>",
"   <p>",
"    The overall risk of recurrence after conservative surgery ranges from 7 to 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/41\">",
"     41",
"    </a>",
"    ], and recurrences typically show borderline histology, not invasive cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/42\">",
"     42",
"    </a>",
"    ]. In one review including 1066 patients treated with conservative surgery, there were 142 recurrences (13 percent), 134 were borderline tumors and eight were malignant [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/43\">",
"     43",
"    </a>",
"    ]. Ovarian cystectomy appears to be associated with a greater risk of recurrence than salpingo-oophorectomy (23 versus 7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/43\">",
"     43",
"    </a>",
"    ]), especially if the margins are positive [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/41,44,45\">",
"     41,44,45",
"    </a>",
"    ], but these data are limited. The risk of relapse in the contralateral ovary is highest in women with advanced stage disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Hysterectomy and bilateral salpingo-oophorectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total abdominal hysterectomy plus bilateral salpingo-oophorectomy (TAH-BSO) is recommended for women who are not planning pregnancy or have advanced stage disease. The advantage of TAH-BSO was illustrated in a study of patients with stage I-III disease that showed that tumor recurrence rates after TAH-BSO, adnexectomy, and cystectomy were 6, 15, and 36 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/42\">",
"     42",
"    </a>",
"    ]. However, in another series the rate of recurrence following both conservative and radical surgical procedures in low-stage, low-grade tumors was low, 9 and 11.6 percent, respectively; and disease-free and overall survival rates for the two approaches did not differ significantly [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic chemotherapy is a standard component of primary treatment for all women with invasive epithelial ovarian cancer other than those with grade 1 stage IA or IB disease. In this setting, platinum-based chemotherapy significantly improves survival over surgery alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26231?source=see_link&amp;anchor=H2#H2\">",
"     \"Adjuvant therapy of early stage (stage I and II) epithelial ovarian, fallopian tubal, or peritoneal cancer\", section on 'Choice of adjuvant treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    As noted above, the prognosis of borderline tumors is more favorable than that of invasive ovarian cancer. While most clinicians would agree that there is no advantage for chemotherapy in women with early stage, completely resected disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/47\">",
"     47",
"    </a>",
"    ], its use for women with more advanced stage disease is controversial.",
"   </p>",
"   <p>",
"    There are no randomized trials. Some retrospective studies suggest benefit for adjuvant chemotherapy following optimal debulking of stage III or IV disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/48,49\">",
"     48,49",
"    </a>",
"    ], while others do not [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/37,50\">",
"     37,50",
"    </a>",
"    ]. The largest of these reports consisted of 80 patients with stage II to IV serous borderline tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/50\">",
"     50",
"    </a>",
"    ]. At a median follow-up of 4.8 years, 17 (21 percent) developed recurrent disease, all of whom had metastasis to the omentum or to multiple sites at original presentation. The sites of recurrent disease included pelvis in 15, omentum in 29, isolated lymph nodes in two, axilla in one, and multiple sites in 32.",
"   </p>",
"   <p>",
"    No patient with stage II disease received adjuvant chemotherapy, while of the 65 patients with stage III or IV disease, 17 received adjuvant chemotherapy (with a variety of both intravenous and intraperitoneal regimens) and the remainder did not. None of the patients with residual disease after initial surgery received chemotherapy. For the entire cohort, three-year progression-free survival was 71 versus 90 percent for those who did versus did not receive chemotherapy. Thus, the use of chemotherapy did not appear to impact the risk of recurrence.",
"   </p>",
"   <p>",
"    Given the apparently favorable outcome of advanced stage serous borderline tumors, and the fact that a survival benefit from administration of adjuvant chemotherapy has not been clearly demonstrated, most physicians recommend chemotherapy after aggressive surgical debulking only if invasive implants are identified [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Posttreatment surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who undergo fertility-preserving surgery are at risk for persistent or progressive disease. Recurrences are most often in an ovary left in situ after cystectomy, and may be microscopic or macroscopic (22 cm), but are usually not bulky [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many investigators believe that the presence of invasive peritoneal implants is associated with a poorer prognosis and should preclude categorization as a tumor of low malignant potential. These patients are at higher risk of",
"    <span class=\"nowrap\">",
"     persistent/recurrent",
"    </span>",
"    disease, may be considered for chemotherapy, and should be followed closely. Other potential risk factors for recurrence include increasing age at diagnosis, elevated preoperative CA 125, and micropapillary histology.",
"   </p>",
"   <p>",
"    There is no high quality evidence to support one posttreatment surveillance strategy over another. The Society of Gynecologic Oncologists (SGO) and National Comprehensive Cancer Network (NCCN) have each published guidelines for posttreatment surveillance [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Review of systems and physical examination &ndash; for the first five years, every three to six months; then annually.",
"     </li>",
"     <li>",
"      For women treated with fertility-preserving surgery, transvaginal ultrasound &ndash; every six months. In our practice, we follow with a pelvic ultrasound every six months for five years, and then annually indefinitely.",
"     </li>",
"     <li>",
"      CA 125 or other tumor markers if initially elevated (according to SGO, measurement of tumor markers is optional if recurrence is not suspected) &ndash; every three to six months. Other tumor markers are not included in this guideline, but serial testing of serum human epididymis protein 4 or carcinoembryonic antigen is reasonable if either of these was elevated at time of diagnosis.",
"     </li>",
"     <li>",
"      NCCN advises complete blood count or chemistry profile as indicated.",
"     </li>",
"     <li>",
"      If a recurrence is suspected, computed tomography (CT) of the pelvis and a serum CA 125 should be performed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some experts advise a baseline chest radiograph, particularly in women with bulky disease.",
"   </p>",
"   <p>",
"    NCCN advises consideration of completion surgery upon completion of childbearing for women with a remaining ovary. We do not routinely perform completion surgery in these women when childbearing is complete, but this is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/12,27\">",
"     12,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Future pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence that women who undergo fertility-sparing surgery and become pregnant are at increased risk of mortality from disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/42,54-61\">",
"     42,54-61",
"    </a>",
"    ]. Fertility treatments, such as ovulation induction, also appear to be safe, if indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/59,62,63\">",
"     59,62,63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Hormone therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence that estrogens stimulate the growth of borderline serous or mucinous tumors of the ovary, or that their use in any way adversely affects the likelihood of relapse or survival.",
"   </p>",
"   <p>",
"    The rare endometrioid tumor of low malignant potential, just like endometriosis, could theoretically (and anecdotally) be stimulated to grow by estrogens; one could test ER receptors and if they are highly positive, one might avoid estrogens in these tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis depends upon the stage and histologic features of the tumor, but is generally good (",
"    <a class=\"graphic graphic_table graphicRef72025 \" href=\"UTD.htm?38/4/38987\">",
"     table 3",
"    </a>",
"    ). A series of 2818 women with ovarian tumors of low malignant potential from the Surveillance, Epidemiology and End Results (SEER) database from the National Cancer Institute reported the following 5 and 10 year relative survival rates [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage I &mdash; 99 and 97 percent, respectively",
"     </li>",
"     <li>",
"      Stage II &mdash; 98 and 90 percent, respectively",
"     </li>",
"     <li>",
"      Stage III &mdash; 96 and 88 percent, respectively",
"     </li>",
"     <li>",
"      Stage IV &mdash; 77 and 69 percent, respectively",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of malignant transformation is unclear. For example, a serous ovarian tumor of low malignant potential may recur with similar histology or as a peritoneal grade 1 serous carcinoma, or both histologies may be present. In one series of 339 women with borderline tumors, only 2 percent went on to develop invasive carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/12\">",
"     12",
"    </a>",
"    ]. Progression to invasive cancer may represent true transformation, de novo development of an ovarian cancer, or a peritoneal cancer.",
"   </p>",
"   <p>",
"    There is increasing evidence that the pathogenesis of low-grade serous carcinomas and of serous tumors of low malignant potential (ie, noninvasive borderline tumors, see below) involves similar genes and pathways, and is distinct from that of high-grade serous carcinomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17224?source=see_link&amp;anchor=H4#H4\">",
"     \"Epithelial ovarian cancer: Pathology\", section on 'Histopathology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF RECURRENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal approach to management of recurrent disease has not been determined, but appears to be surgical cytoreduction, which is associated with improved survival in observational series [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/64-68\">",
"     64-68",
"    </a>",
"    ]. As an example, one retrospective series of 21 patients with recurrent serous borderline tumors (micropapillary pattern) reported median overall survival of 61 months with optimal resection versus 26 months with suboptimal resection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5128/abstract/67\">",
"     67",
"    </a>",
"    ]. Five patients did not undergo secondary surgery and were treated with chemotherapy alone; their median survival was 30 months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8871446\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ovarian tumors of low malignant potential (also called borderline tumors) are a heterogeneous group of lesions defined histologically by atypical epithelial proliferation without stromal invasion. These tumors account for 10 to 20 percent of ovarian epithelial tumors. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Incidence and epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of borderline tumors are serous. Approximately 75 percent of patients are diagnosed with stage I disease; 25 to 50 percent of tumors are bilateral. Mucinous tumors are the other common cellular type; 90 percent are stage I and fewer than 10 percent are bilateral. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Histologic types'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients present with an asymptomatic adnexal mass noted either on bimanual examination or as an incidental finding on sonography; however, symptoms (eg,",
"      <span class=\"nowrap\">",
"       abdominal/pelvic",
"      </span>",
"      pain or dyspareunia) may occur, as with any adnexal mass. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no sonographic features strongly suggestive of borderline histology. Sonographic appearance ranges from unilocular cysts to masses with both solid and fluid components; papilla are common. Measurement of CA 125 does not reliably predict borderline histology. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Imaging and laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of these neoplasms is based on histopathological examination. Frozen section is commonly performed intraoperatively and the information is used to help determine the extent of the surgical procedure. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Borderline tumors are staged using the same criteria as other ovarian tumors (",
"      <a class=\"graphic graphic_table graphicRef51205 \" href=\"UTD.htm?14/43/15038\">",
"       table 1",
"      </a>",
"      ). Most women present with stage I disease (approximately 70 percent); stage II and III disease are relatively infrequent. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Staging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Borderline tumors generally have an excellent prognosis and can be treated conservatively in women who wish to preserve their fertility or are pregnant at the time of diagnosis. Unilateral salpingo-oophorectomy, or, in some instances, ovarian cystectomy may be performed. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Fertility preserving surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of adjuvant chemotherapy is controversial; there is no advantage to treatment of women with early stage disease. While patients with more advanced disease may be rendered disease-free, survival benefit related to the administration of neoadjuvant chemotherapy has not been clearly demonstrated. We recommend chemotherapy after aggressive surgical debulking only if invasive implants are identified (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no evidence that estrogens stimulate the growth of borderline serous or mucinous tumors of the ovary, or that their use in any way adversely affects the likelihood of relapse or survival. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Hormone therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of malignant transformation is unclear. Progression to invasive cancer may represent true transformation, de novo development of an ovarian cancer, or a peritoneal cancer. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Progression'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Seidman JD, Russell P, Kurman RJ. Surface epithelial tumors of the ovary. In: Blaustein's pathology of the female genital tract, 5th, Kurman RJ (Ed), Springer Verlag, New York 2002. p.791.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/2\">",
"      Pecorelli S, Odicino F, Maisonneuve P, et al. FIGO annual report of the results of treatment in gynaecological cancer. Carcinoma of the ovary. J Epidemiol Biostat 1998; 3:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/3\">",
"      Sk&iacute;rnisd&oacute;ttir I, Garmo H, Wilander E, Holmberg L. Borderline ovarian tumors in Sweden 1960-2005: trends in incidence and age at diagnosis compared to ovarian cancer. Int J Cancer 2008; 123:1897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/4\">",
"      Gotlieb WH, Friedman E, Bar-Sade RB, et al. Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors. J Natl Cancer Inst 1998; 90:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/5\">",
"      Gotlieb WH, Chetrit A, Menczer J, et al. Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer. Gynecol Oncol 2005; 97:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/6\">",
"      Lu KH, Cramer DW, Muto MG, et al. A population-based study of BRCA1 and BRCA2 mutations in Jewish women with epithelial ovarian cancer. Obstet Gynecol 1999; 93:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/7\">",
"      Riman T, Dickman PW, Nilsson S, et al. Risk factors for epithelial borderline ovarian tumors: results of a Swedish case-control study. Gynecol Oncol 2001; 83:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/8\">",
"      Ness RB, Cramer DW, Goodman MT, et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol 2002; 155:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/9\">",
"      Shushan A, Paltiel O, Iscovich J, et al. Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertil Steril 1996; 65:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/10\">",
"      Parazzini F, Negri E, La Vecchia C, et al. Treatment for fertility and risk of ovarian tumors of borderline malignancy. Gynecol Oncol 1998; 68:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/11\">",
"      Trimble CL, Trimble EL. Ovarian tumors of low malignant potential. Oncology (Williston Park) 2003; 17:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/12\">",
"      Zanetta G, Rota S, Chiari S, et al. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol 2001; 19:2658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/13\">",
"      Winter WE 3rd, Kucera PR, Rodgers W, et al. Surgical staging in patients with ovarian tumors of low malignant potential. Obstet Gynecol 2002; 100:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/14\">",
"      Morice P, Camatte S, Rey A, et al. Prognostic factors for patients with advanced stage serous borderline tumours of the ovary. Ann Oncol 2003; 14:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/15\">",
"      Gershenson DM. Is micropapillary serous carcinoma for real? Cancer 2002; 95:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/16\">",
"      Kaern J, Trop&eacute; CG, Kristensen GB, et al. DNA ploidy; the most important prognostic factor in patients with borderline tumors of the ovary. Int J Gynecol Cancer 1993; 3:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/17\">",
"      Buttin BM, Herzog TJ, Powell MA, et al. Epithelial ovarian tumors of low malignant potential: the role of microinvasion. Obstet Gynecol 2002; 99:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/18\">",
"      Longacre TA, McKenney JK, Tazelaar HD, et al. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (&gt; or =5-year) follow-up. Am J Surg Pathol 2005; 29:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/19\">",
"      Sood AK, Abu-Rustum NR, Barakat RR, et al. Fifth International Conference on Ovarian Cancer: challenges and opportunities. Gynecol Oncol 2005; 97:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/20\">",
"      Seidman JD, Ronnett BM, Kurman RJ. Pathology of borderline (low malignant potential) ovarian tumours. Best Pract Res Clin Obstet Gynaecol 2002; 16:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/21\">",
"      Exacoustos C, Romanini ME, Rinaldo D, et al. Preoperative sonographic features of borderline ovarian tumors. Ultrasound Obstet Gynecol 2005; 25:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/22\">",
"      Valentin L. Use of morphology to characterize and manage common adnexal masses. Best Pract Res Clin Obstet Gynaecol 2004; 18:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/23\">",
"      Valentin L, Ameye L, Testa A, et al. Ultrasound characteristics of different types of adnexal malignancies. Gynecol Oncol 2006; 102:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/24\">",
"      Yazbek J, Raju KS, Ben-Nagi J, et al. Accuracy of ultrasound subjective 'pattern recognition' for the diagnosis of borderline ovarian tumors. Ultrasound Obstet Gynecol 2007; 29:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/25\">",
"      Ochiai K, Shinozaki H, Takada A, et al. A retrospective study of 1069 epithelial borderline malignancies of the ovary treated in Japan. Proceedings of the Annual Meeting of the American Society of Clinical Oncology 1998; 17:A1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/26\">",
"      Geomini P, Bremer G, Kruitwagen R, Mol BW. Diagnostic accuracy of frozen section diagnosis of the adnexal mass: a metaanalysis. Gynecol Oncol 2005; 96:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/27\">",
"      Tinelli R, Tinelli A, Tinelli FG, et al. Conservative surgery for borderline ovarian tumors: a review. Gynecol Oncol 2006; 100:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/28\">",
"      Gershenson DM. Clinical management potential tumours of low malignancy. Best Pract Res Clin Obstet Gynaecol 2002; 16:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/29\">",
"      Fauvet R, Boccara J, Dufournet C, et al. Restaging surgery for women with borderline ovarian tumors: results of a French multicenter study. Cancer 2004; 100:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/30\">",
"      Seidman JD, Kurman RJ. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol 2000; 31:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/31\">",
"      Lesieur B, Kane A, Duvillard P, et al. Prognostic value of lymph node involvement in ovarian serous borderline tumors. Am J Obstet Gynecol 2011; 204:438.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/32\">",
"      Rao GG, Skinner E, Gehrig PA, et al. Surgical staging of ovarian low malignant potential tumors. Obstet Gynecol 2004; 104:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/33\">",
"      Lin PS, Gershenson DM, Bevers MW, et al. The current status of surgical staging of ovarian serous borderline tumors. Cancer 1999; 85:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/34\">",
"      Camatte S, Morice P, Thoury A, et al. Impact of surgical staging in patients with macroscopic \"stage I\" ovarian borderline tumours: analysis of a continuous series of 101 cases. Eur J Cancer 2004; 40:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/35\">",
"      Trimble CL, Kosary C, Trimble EL. Long-term survival and patterns of care in women with ovarian tumors of low malignant potential. Gynecol Oncol 2002; 86:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/36\">",
"      Barnhill DR, Kurman RJ, Brady MF, et al. Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential: a Gynecologic Oncology Group study. J Clin Oncol 1995; 13:2752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/37\">",
"      Sutton GP, Bundy BN, Omura GA, et al. Stage III ovarian tumors of low malignant potential treated with cisplatin combination therapy (a Gynecologic Oncology Group study). Gynecol Oncol 1991; 41:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/38\">",
"      Desfeux P, Camatte S, Chatellier G, et al. Impact of surgical approach on the management of macroscopic early ovarian borderline tumors. Gynecol Oncol 2005; 98:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/39\">",
"      Fauvet R, Boccara J, Dufournet C, et al. Laparoscopic management of borderline ovarian tumors: results of a French multicenter study. Ann Oncol 2005; 16:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/40\">",
"      Maneo A, Vignali M, Chiari S, et al. Are borderline tumors of the ovary safely treated by laparoscopy? Gynecol Oncol 2004; 94:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/41\">",
"      Boran N, Cil AP, Tulunay G, et al. Fertility and recurrence results of conservative surgery for borderline ovarian tumors. Gynecol Oncol 2005; 97:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/42\">",
"      Morice P, Camatte S, El Hassan J, et al. Clinical outcomes and fertility after conservative treatment of ovarian borderline tumors. Fertil Steril 2001; 75:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/43\">",
"      Suh-Burgmann E. Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population-based study. Gynecol Oncol 2006; 103:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/44\">",
"      Lim-Tan SK, Cajigas HE, Scully RE. Ovarian cystectomy for serous borderline tumors: a follow-up study of 35 cases. Obstet Gynecol 1988; 72:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/45\">",
"      Yokoyama Y, Moriya T, Takano T, et al. Clinical outcome and risk factors for recurrence in borderline ovarian tumours. Br J Cancer 2006; 94:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/46\">",
"      Ayhan A, Celik H, Taskiran C, et al. Oncologic and reproductive outcome after fertility-saving surgery in ovarian cancer. Eur J Gynaecol Oncol 2003; 24:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/47\">",
"      Trop&eacute; C, Kaern J, Vergote IB, et al. Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors. Gynecol Oncol 1993; 51:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/48\">",
"      Fort MG, Pierce VK, Saigo PE, et al. Evidence for the efficacy of adjuvant therapy in epithelial ovarian tumors of low malignant potential. Gynecol Oncol 1989; 32:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/49\">",
"      Barakat RR, Benjamin I, Lewis JL Jr, et al. Platinum-based chemotherapy for advanced-stage serous ovarian carcinoma of low malignant potential. Gynecol Oncol 1995; 59:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/50\">",
"      Shih KK, Zhou QC, Aghajanian C, et al. Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors. Gynecol Oncol 2010; 119:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/51\">",
"      NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA 1995; 273:491.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/53\">",
"      Salani R, Backes FJ, Fung MF, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol 2011; 204:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/54\">",
"      Fauvet R, Poncelet C, Boccara J, et al. Fertility after conservative treatment for borderline ovarian tumors: a French multicenter study. Fertil Steril 2005; 83:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/55\">",
"      Chan JK, Lin YG, Loizzi V, et al. Borderline ovarian tumors in reproductive-age women. Fertility-sparing surgery and outcome. J Reprod Med 2003; 48:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/56\">",
"      Beiner ME, Gotlieb WH, Davidson B, et al. Infertility treatment after conservative management of borderline ovarian tumors. Cancer 2001; 92:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/57\">",
"      Seracchioli R, Venturoli S, Colombo FM, et al. Fertility and tumor recurrence rate after conservative laparoscopic management of young women with early-stage borderline ovarian tumors. Fertil Steril 2001; 76:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/58\">",
"      Camatte S, Morice P, Pautier P, et al. Fertility results after conservative treatment of advanced stage serous borderline tumour of the ovary. BJOG 2002; 109:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/59\">",
"      Donnez J, Munschke A, Berliere M, et al. Safety of conservative management and fertility outcome in women with borderline tumors of the ovary. Fertil Steril 2003; 79:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/60\">",
"      Tinelli FG, Tinelli R, La Grotta F, et al. Pregnancy outcome and recurrence after conservative laparoscopic surgery for borderline ovarian tumors. Acta Obstet Gynecol Scand 2007; 86:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/61\">",
"      Marcickiewicz J, Br&auml;nnstr&ouml;m M. Fertility preserving surgical treatment of borderline ovarian tumour: long-term consequence for fertility and recurrence. Acta Obstet Gynecol Scand 2006; 85:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/62\">",
"      Fasouliotis SJ, Davis O, Schattman G, et al. Safety and efficacy of infertility treatment after conservative management of borderline ovarian tumors: a preliminary report. Fertil Steril 2004; 82:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/63\">",
"      Fortin A, Morice P, Thoury A, et al. Impact of infertility drugs after treatment of borderline ovarian tumors: results of a retrospective multicenter study. Fertil Steril 2007; 87:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/64\">",
"      Crispens MA, Bodurka D, Deavers M, et al. Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet Gynecol 2002; 99:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/65\">",
"      Leake JF, Currie JL, Rosenshein NB, Woodruff JD. Long-term follow-up of serous ovarian tumors of low malignant potential. Gynecol Oncol 1992; 47:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/66\">",
"      Bostwick DG, Tazelaar HD, Ballon SC, et al. Ovarian epithelial tumors of borderline malignancy. A clinical and pathologic study of 109 cases. Cancer 1986; 58:2052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/67\">",
"      Bristow RE, Gossett DR, Shook DR, et al. Recurrent micropapillary serous ovarian carcinoma. Cancer 2002; 95:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5128/abstract/68\">",
"      Zang RY, Yang WT, Shi DR, et al. Recurrent ovarian carcinoma of low malignant potential: the role of secondary surgical cytoreduction and the prognosis in Chinese patients. J Surg Oncol 2005; 91:67.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3181 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-83C710A96E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_0_5128=[""].join("\n");
var outline_f5_0_5128=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8871446\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE AND EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HISTOLOGIC TYPES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Serous borderline tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Mucinous borderline tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Imaging and laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Fertility preserving surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Hysterectomy and bilateral salpingo-oophorectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Posttreatment surveillance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Future pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Progression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      MANAGEMENT OF RECURRENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8871446\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3181\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3181|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/43/15038\" title=\"table 1\">",
"      Staging ovarian peritoneal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/8/41099\" title=\"table 2\">",
"      Steps in staging ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/4/38987\" title=\"table 3\">",
"      Borderline ovarian CA survival",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26231?source=related_link\">",
"      Adjuvant therapy of early stage (stage I and II) epithelial ovarian, fallopian tubal, or peritoneal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36074?source=related_link\">",
"      Cancer of the appendix and pseudomyxoma peritonei",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17224?source=related_link\">",
"      Epithelial ovarian cancer: Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=related_link\">",
"      First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34440?source=related_link\">",
"      Sonographic differentiation of benign versus malignant adnexal masses",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_0_5129="Serotonin modulators: Pharmacology, administration, and side effects";
var content_f5_0_5129=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Serotonin modulators: Pharmacology, administration, and side effects",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/0/5129/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/0/5129/contributors\">",
"     Michael Hirsch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/0/5129/contributors\">",
"     Robert J Birnbaum, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/0/5129/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/0/5129/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/0/5129/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/0/5129/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/0/5129/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H665875\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advances in understanding brain neurophysiology have led to the development of serotonin modulators, including [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/0/2057?source=see_link\">",
"       Nefazodone",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"       Trazodone",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39175?source=see_link\">",
"       Vilazodone",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The serotonin modulators are distinct from other classes of antidepressants that include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), atypical antidepressants, tricyclics, and monoamine oxidase inhibitors (MAOIs). Serotonin modulators antagonize postsynaptic serotonin receptors and inhibit reuptake of postsynaptic serotonin to varying degrees; effects upon norepinephrine reuptake are minimal.",
"   </p>",
"   <p>",
"    The pharmacology, administration, and side effects of serotonin modulators are reviewed here. Choosing a regimen for the initial treatment of depression and treatment of resistant depression is discussed separately, as are other antidepressant drug classes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"       \"Initial treatment of depression in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link\">",
"       \"Treatment of resistant depression in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=see_link\">",
"       \"Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=see_link\">",
"       \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/18/5417?source=see_link\">",
"       \"Atypical antidepressants: Pharmacology, administration, and side effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36169?source=see_link\">",
"       \"Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7574?source=see_link\">",
"       \"Monoamine oxidase inhibitors (MAOIs) for treating depressed adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H666429\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28673015\">",
"    <span class=\"h2\">",
"     Drug-drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serotonin modulators may inhibit hepatic cytochrome P450 enzymes that metabolize other medications and thereby interact with other drugs. The specific cytochrome enzyme that each serotonin modulator and their metabolites potently or moderately inhibit is as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/0/2057?source=see_link\">",
"       Nefazodone",
"      </a>",
"      &ndash; CYP3A4",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"       Trazodone",
"      </a>",
"      &ndash; None",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39175?source=see_link\">",
"       Vilazodone",
"      </a>",
"      &ndash; None",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"     Trazodone",
"    </a>",
"    may thus be beneficial for depressed patients who are receiving other medications for general medical conditions.",
"   </p>",
"   <p>",
"    Serotonin modulators should not be combined with MAOIs and should be used cautiously with other serotonergic medications (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , selective serotonin reuptake inhibitors, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/20/43336?source=see_link\">",
"     clomipramine",
"    </a>",
"    ) (",
"    <a class=\"graphic graphic_table graphicRef64604 \" href=\"UTD.htm?42/19/43324\">",
"     table 1",
"    </a>",
"    ), because of the potential drug-drug interactions that can cause the serotonin syndrome (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=see_link\">",
"     \"Serotonin syndrome\"",
"    </a>",
"    ). Specific interactions of serotonin modulators with other medications may be determined using the drug interactions tool (Lexi-Interact Online) included in UpToDate. This tool can be accessed from the UpToDate online search page or through the individual drug information topics in the section on Drug interactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H666436\">",
"    <span class=\"h2\">",
"     Guidelines to review with patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to prescribing serotonin modulators, clinicians should discuss:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Drug interactions",
"     </li>",
"     <li>",
"      Side effects",
"     </li>",
"     <li>",
"      Time to response",
"     </li>",
"     <li>",
"      Stopping the medication",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Common and serious side effects and the need to take the medication as prescribed rather than on an as needed basis should be reviewed. Patients should also be informed that although some response may occur within the first two weeks of treatment, it may take many weeks (eg, 8 to 14) for a full response (severity of illness and co-morbid disease may affect how quickly depressed patients respond to treatment) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H666443\">",
"    <span class=\"h2\">",
"     Medical tests and plasma levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;No specific medical tests are required before starting serotonin modulators, and drug serum concentrations are not routinely monitored because they have not been shown to correlate with clinical response. However, levels can assess adherence and whether unresponsive patients are rapid metabolizers. Levels can also establish that it is safe to begin another serotonergic drug (eg, a monoamine oxidase inhibitor) after discontinuing a serotonin modulator, in order to avoid the serotonin syndrome (",
"    <a class=\"graphic graphic_table graphicRef64604 \" href=\"UTD.htm?42/19/43324\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=see_link\">",
"     \"Serotonin syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H666450\">",
"    <span class=\"h2\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest starting with the lowest minimal effective dose in order to avoid side effects and slowly increasing the dose as needed. Starting doses and target dose ranges of each serotonin modulator are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef88067 \" href=\"UTD.htm?18/29/18908\">",
"     table 2",
"    </a>",
"    ). Depressed patients with comorbid anxiety disorders may tolerate the medication better by starting with half of the suggested dose. Doses are adjusted according to patient response, tolerability, and clinical urgency.",
"   </p>",
"   <p>",
"    Finding the effective dose of an antidepressant involves trial and error. After starting the drug and titrating up to the minimum effective dose, response should be monitored over the following two to four weeks. For patients who tolerate the antidepressant but do not respond, we continue titrating up the dose slowly (to avoid side effects) every two to four weeks. For unresponsive patients who do not tolerate the drug, we suggest switching to a different antidepressant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26135?source=see_link\">",
"     \"Antidepressant medication in adults: Switching and discontinuing medication\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link\">",
"     \"Treatment of resistant depression in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who recover from an episode of major depression should generally receive maintenance treatment with the full dose that successfully resolved the episode, rather than a lower dose. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/39/9850?source=see_link&amp;anchor=H8038660#H8038660\">",
"     \"Unipolar depression in adults: Continuation and maintenance treatment\", section on 'Dose'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H666457\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of pregnant women with antidepressants is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=see_link\">",
"     \"Depression in pregnant women: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H667313\">",
"    <span class=\"h2\">",
"     Serotonin syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serotonin modulators increase serotonergic neurotransmission and can cause the serotonin syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=see_link\">",
"     \"Serotonin syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3491829\">",
"    <span class=\"h2\">",
"     Suicide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential effect of serotonin modulators on suicidal ideation and behavior in adults is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43783?source=see_link\">",
"     \"Effect of antidepressants on suicide risk in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H664422\">",
"    <span class=\"h1\">",
"     NEFAZODONE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/0/2057?source=see_link\">",
"     Nefazodone",
"    </a>",
"    is used to treat major depression and premenstrual syndrome. The drug is contraindicated in patients with elevated serum transaminases, active liver disease, or liver injury due to previous nefazodone treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H664429\">",
"    <span class=\"h2\">",
"     Pharmacology",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/0/2057?source=see_link\">",
"     Nefazodone",
"    </a>",
"    is a phenylpiperazine whose structure resembles that of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. Nefazodone antagonizes and down regulates postsynaptic serotonin 5-HT2A receptors, and weakly inhibits presynaptic serotonin and norepinephrine reuptake; these actions increase activity at the serotonin 5-HT1A receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/1,5,6\">",
"     1,5,6",
"    </a>",
"    ]. The drug has little to no affinity for alpha-adrenergic receptors, cholinergic, dopamine D2, and histamine H1 receptors. The pharmacokinetic parameters of nefazodone are displayed in the table (",
"    <a class=\"graphic graphic_table graphicRef88062 \" href=\"UTD.htm?41/43/42684\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H664436\">",
"    <span class=\"h2\">",
"     Administration, dose, and discontinuation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual starting dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/0/2057?source=see_link\">",
"     nefazodone",
"    </a>",
"    for major depression is 100 mg twice daily (",
"    <a class=\"graphic graphic_table graphicRef88067 \" href=\"UTD.htm?18/29/18908\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/5\">",
"     5",
"    </a>",
"    ]. For patients who do not respond after two to four weeks, the dose is increased to 150 to 200 mg twice daily. The dose is increased further by increments of 100 to 200 mg per day every two to four weeks until the desired clinical response is achieved; the maximum dose is 300 mg twice daily. In clinically urgent situations, dose increases can occur once a week as tolerated. The effectiveness and tolerability of once daily and twice daily dosing may be comparable [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abrupt discontinuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/0/2057?source=see_link\">",
"     nefazodone",
"    </a>",
"    does not cause a withdrawal syndrome. In two randomized trials, patients with major depression (N = 259 and 131) who received nefazodone for 16 weeks were randomly assigned to either continue the drug or abruptly stop it and start placebo (as part of relapse prevention studies); the incidence of discontinuation symptoms was comparable for the two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Nevertheless, we taper the drug over one week before stopping it, which is consistent with the preferred method of discontinuing any psychotropic medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H664443\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/0/2057?source=see_link\">",
"     Nefazodone",
"    </a>",
"    can injure the liver; the estimated incidence of hepatotoxicity based upon a national registry in Spain is 29 cases per 100,000 patients per year [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/10\">",
"     10",
"    </a>",
"    ]. Adverse hepatic reactions can occur with doses as low as 100 mg per day and generally occur within six months of starting the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/11\">",
"     11",
"    </a>",
"    ]. These reactions include acute liver failure; the estimated incidence is 1 case per 200,000 to 300,000 patient years, which is three to four times greater than expected [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/12\">",
"     12",
"    </a>",
"    ]. A 2010 study of the World Health Organization (WHO) Programme for International Drug Monitoring database found 94 cases of acute liver failure attributed to nefazodone, including patients who received a liver transplant or died [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/13\">",
"     13",
"    </a>",
"    ]. Thus, nefazodone is not commonly used in United States; generic versions are available, but the brand-name version is no longer manufactured. In addition, the drug has been withdrawn from the market in Europe, Canada, and other countries. Patients receiving the drug should be monitored for signs and symptoms of liver failure (nausea, abdominal pain, jaundice, impaired synthetic function, coagulopathy, and delirium). Although periodic liver function tests (eg, every two to six months) may possibly be useful, there is no evidence that testing prevents hepatic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/0/2057?source=see_link\">",
"     Nefazodone",
"    </a>",
"    can cause several other side effects (",
"    <a class=\"graphic graphic_table graphicRef62488 \" href=\"UTD.htm?37/46/38639\">",
"     table 4",
"    </a>",
"    ). A pooled analysis of randomized trials (N = 2185 patients, most with unipolar major depression) found that the incidence of discontinuing nefazodone because of side effects was 12 percent and for placebo was 7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/14\">",
"     14",
"    </a>",
"    ]. Adverse effects that occurred more frequently with nefazodone included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nausea &ndash; 21 percent of patients who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/0/2057?source=see_link\">",
"       nefazodone",
"      </a>",
"     </li>",
"     <li>",
"      Somnolence &ndash; 19 percent",
"     </li>",
"     <li>",
"      Dry mouth &ndash; 19 percent",
"     </li>",
"     <li>",
"      Dizziness &ndash; 12 percent",
"     </li>",
"     <li>",
"      Constipation &ndash; 11 percent",
"     </li>",
"     <li>",
"      Weakness &ndash; 11 percent",
"     </li>",
"     <li>",
"      Blurred vision &ndash; 6 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Each of these adverse effects, except dry mouth and weakness, appear to be dose related and less likely to occur at doses &le;300 mg per day [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reduced systolic blood pressure (&le;90 mmHg and &ge;20 mmHg reduction from baseline) occurred in more patients who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/0/2057?source=see_link\">",
"     nefazodone",
"    </a>",
"    than placebo (5 versus 3 percent), but the incidence of syncope was comparable (0.02 and 0.03 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/14\">",
"     14",
"    </a>",
"    ]. In addition, asymptomatic sinus bradycardia was detected by electrocardiogram (ECG) in more patients who received nefazodone than placebo (1.3 versus 0.4 percent).",
"   </p>",
"   <p>",
"    Sexual dysfunction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/0/2057?source=see_link\">",
"     nefazodone",
"    </a>",
"    and placebo appear to be comparable, based upon a meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/15\">",
"     15",
"    </a>",
"    ] as well as a pooled analysis of randomized trials (N = 2185 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/14\">",
"     14",
"    </a>",
"    ]. In addition, weight gain during treatment lasting between 3 to 13 months is comparable for nefazodone and placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compared with selective serotonin reuptake inhibitors (SSRIs),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/0/2057?source=see_link\">",
"     nefazodone",
"    </a>",
"    is less activating and causes less gastrointestinal distress (eg, nausea, diarrhea, and anorexia), sexual dysfunction, and weight gain during long-term treatment (eg, 16 to 46 weeks), but causes more dry mouth, dizziness, constipation, visual disturbances, and confusion [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/5,16\">",
"     5,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H664450\">",
"    <span class=\"h2\">",
"     Overdose",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/0/2057?source=see_link\">",
"     Nefazodone",
"    </a>",
"    appears to have a wide therapeutic index [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/1,14\">",
"     1,14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study (primarily retrospective) examined 1338 cases of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/0/2057?source=see_link\">",
"       nefazodone",
"      </a>",
"      poisoning collected from 67 poison control centers in the United States; exposures involving concomitant drugs were excluded [",
"      <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/17\">",
"       17",
"      </a>",
"      ]. No deaths occurred; the most common clinical effects were drowsiness (17 percent), nausea (10 percent), dizziness (9 percent), and vomiting (8 percent); the most common, potentially serious clinical effects were hypotension (2 percent) and bradycardia (1 percent). Clinical effects generally began within 1 to 4 hours of ingestion and resolved within 8 to 24 hours. None of the patients required intubation, mechanical ventilation, or vasopressors. Suicide attempt was suspected in 35 percent, including one patient who ingested 13,500 mg.",
"     </li>",
"     <li>",
"      In a two year retrospective study of 12 patients who deliberately or accidentally overdosed on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/0/2057?source=see_link\">",
"       nefazodone",
"      </a>",
"      (mean dose 4594 mg, maximum 12,500 mg), none of the patients suffered seizures, prolonged corrected QT &ge;450 milliseconds, or arrhythmias, and none required airway management or ventilatory support [",
"      <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/18\">",
"       18",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H664457\">",
"    <span class=\"h1\">",
"     TRAZODONE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"     Trazodone",
"    </a>",
"    is used to treat major depression as well as functional dyspepsia. In addition, it is often used as a hypnotic to treat insomnia in the context of depression, as well as insomnia associated with antidepressants (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/19\">",
"     19",
"    </a>",
"    ]. However, the efficacy of trazodone for insomnia in the absence of depression appears to be short-lived. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of insomnia\", section on 'Antidepressants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H664464\">",
"    <span class=\"h2\">",
"     Pharmacology",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"     Trazodone",
"    </a>",
"    is a triazolopyridine whose structure resembles that of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/0/2057?source=see_link\">",
"     nefazodone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/4\">",
"     4",
"    </a>",
"    ]. Trazodone acts upon postsynaptic serotonin 5-HT2A and 5-HT2C receptors and weakly inhibits presynaptic serotonin reuptake. The effects appear to be dose dependent such that at low doses the drug acts as a serotonin antagonist and at high doses as a serotonin agonist [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/4,20\">",
"     4,20",
"    </a>",
"    ]. Effects on norepinephrine and dopamine reuptake are minimal. In addition, the drug blocks postsynaptic alpha-adrenergic receptors (which may account for the side effects of orthostatic hypotension and priapism) and histamine H1 receptors (which may explain its sedative effect) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/4,20,21\">",
"     4,20,21",
"    </a>",
"    ]. The drug does not affect cholinergic receptors.",
"   </p>",
"   <p>",
"    The pharmacokinetic parameters of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    are displayed in the table (",
"    <a class=\"graphic graphic_table graphicRef88062 \" href=\"UTD.htm?41/43/42684\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H664471\">",
"    <span class=\"h2\">",
"     Administration, dose, and discontinuation",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"     Trazodone",
"    </a>",
"    is available as two formulations that are dosed as follows for major depression (",
"    <a class=\"graphic graphic_table graphicRef88067 \" href=\"UTD.htm?18/29/18908\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Immediate release",
"      </strong>",
"      &ndash; This formulation is typically started at 50 mg twice daily, which is then increased by increments of 50 mg per day every three to seven days to a dose of 75 to 150 mg twice daily. The dose is subsequently increased by 50 to 100 mg per day every two to four weeks until the desired clinical response is achieved, to a maximum dose of 600 mg per day. The drug&rsquo;s sedative effects may be better tolerated if patients are given a smaller daytime dose and larger bedtime dose (eg, 100 mg in the morning and 200 mg at bedtime); some patients receive the entire dose at bedtime.",
"     </li>",
"     <li>",
"      <strong>",
"       Extended release",
"      </strong>",
"      &ndash; This formulation is started at 150 mg at bedtime. For patients who do not respond after two to four weeks, the dose is increased to 225 mg at bedtime. The dose is subsequently increased by 75 mg per day every two to four weeks until the desired clinical response is achieved, to a maximum dose of 375 mg per day. In clinically urgent situations (eg, during inpatient treatment), dose increases can occur every three days as tolerated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No studies have directly compared the efficacy and tolerability of the two formulations. &nbsp;",
"   </p>",
"   <p>",
"    Patients with insomnia associated with antidepressants (eg, selective serotonin reuptake inhibitors) may benefit from immediate release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    50 to 100 mg at bedtime [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/19\">",
"     19",
"    </a>",
"    ]. When prescribed as a hypnotic for insomnia in the context of depression, doses typically range from 50 to 300 mg at bedtime, but doses up to 600 mg have been used [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rapid or abrupt discontinuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    may be followed by withdrawal symptoms, including gastrointestinal distress, anxiety, and sleep disturbances [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/23\">",
"     23",
"    </a>",
"    ]. Thus, we suggest tapering the drug over one to two weeks prior to discontinuation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H664478\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"     Trazodone",
"    </a>",
"    can cause several side effects (",
"    <a class=\"graphic graphic_table graphicRef62488 \" href=\"UTD.htm?37/46/38639\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. A randomized trial that compared trazodone immediate release with placebo in 153 patients with major depression found that discontinuation of treatment due to side effects was greater in patients who received trazodone than placebo (23 versus 4 percent); trazodone caused a higher incidence of [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sedation &ndash; 61 percent of patients who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"       trazodone",
"      </a>",
"     </li>",
"     <li>",
"      Dizziness &ndash; 36 percent",
"     </li>",
"     <li>",
"      Dry mouth &ndash; 27 percent",
"     </li>",
"     <li>",
"      Nausea &ndash; 19 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Orthostatic hypotension and headache are also common with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    extended release were examined in an eight week randomized trial that compared trazodone with placebo in 406 patients with major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/21\">",
"     21",
"    </a>",
"    ]. Discontinuation of treatment due to side effects was four-fold greater in patients who received active drug than placebo (12 versus 3 percent). Adverse effects that occurred approximately twice as often or more with trazodone than placebo included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Somnolence &ndash; 31 percent of patients who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"       trazodone",
"      </a>",
"     </li>",
"     <li>",
"      Dry mouth &ndash; 25 percent",
"     </li>",
"     <li>",
"      Dizziness &ndash; 25 percent",
"     </li>",
"     <li>",
"      Fatigue &ndash; 15 percent",
"     </li>",
"     <li>",
"      Constipation &ndash; 8 percent",
"     </li>",
"     <li>",
"      Vision blurred &ndash; 5 percent",
"     </li>",
"     <li>",
"      Sexual dysfunction &ndash; 5 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rare but serious side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Priapism &ndash; Penile priapism secondary to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"       trazodone",
"      </a>",
"      is an emergency that should be evaluated immediately by a urologist (rare cases of clitoral priapism have also been reported) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/26\">",
"       26",
"      </a>",
"      ]. Trazodone induced priapism is estimated to occur 1 in 1000 to 1 in 10,000 patients, and has been reported at doses ranging from 50 to 400 mg per day. Although most cases occur within the first month of treatment, priapism may occur up to 18 months after onset of treatment. A prolonged erection during treatment may be a risk factor for subsequent priapism. Additional information about priapism is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/61/7127?source=see_link\">",
"       \"Priapism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiac arrhythmias &ndash; A review identified case reports of atrial and ventricular arrhythmias in patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"       trazodone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/23\">",
"       23",
"      </a>",
"      ]. Thus, the drug should be used with caution is patients with cardiac disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"     Trazodone",
"    </a>",
"    appears to be weight neutral during treatment lasting 4 to 12 weeks, based upon a meta-analysis of three heterogeneous randomized trials (N = 155 patients treated with trazodone for with major depression) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H664485\">",
"    <span class=\"h2\">",
"     Overdose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overdose with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    alone is typically not lethal; a study of 35 cases with doses up to 6400 mg and a second study of 22 cases with doses up to 3500 mg both found that no deaths occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. However, at least one fatal case of suicide with trazodone alone has been reported, in which the patient developed torsades de pointes, complete atrioventricular block, and multiple organ failure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/30\">",
"     30",
"    </a>",
"    ]; the serum concentration was 25",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    (steady state concentrations with recommended doses are approximately 1 to 3",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/28\">",
"     28",
"    </a>",
"    ]). Although most patients recover uneventfully, overdose can cause arrhythmias, respiratory arrest, coma, and priapism [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, overdoses with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    plus alcohol",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other drugs are often lethal. A study of 49 patients found that 9 (18 percent) died [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H664492\">",
"    <span class=\"h1\">",
"     VILAZODONE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39175?source=see_link\">",
"     Vilazodone",
"    </a>",
"    is used to treat major depression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H664499\">",
"    <span class=\"h2\">",
"     Pharmacology",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39175?source=see_link\">",
"     Vilazodone",
"    </a>",
"    is an indolalkylamine that inhibits presynaptic reuptake of serotonin and also acts as a partial agonist at postsynaptic serotonin 5-HT1A receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/31\">",
"     31",
"    </a>",
"    ]. Inhibition of norepinephrine and dopamine reuptake is minimal. The pharmacokinetic parameters of vilazodone are displayed in the table (",
"    <a class=\"graphic graphic_table graphicRef88062 \" href=\"UTD.htm?41/43/42684\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H664506\">",
"    <span class=\"h2\">",
"     Administration, dose, and discontinuation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual starting dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39175?source=see_link\">",
"     vilazodone",
"    </a>",
"    for major depression is 10 mg per day at bedtime, for one week (",
"    <a class=\"graphic graphic_table graphicRef88067 \" href=\"UTD.htm?18/29/18908\">",
"     table 2",
"    </a>",
"    ). The dose is then increased to 20 mg per day for week two, and then to the target dose of 40 mg per day [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/32\">",
"     32",
"    </a>",
"    ]. This two week titration schedule is intended to reduce gastrointestinal toxicity. Although doses of 20 or 30 mg per day may be better tolerated than 40 mg per day, it is not clear if doses &lt;40 mg per day are effective [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/33\">",
"     33",
"    </a>",
"    ]. The drug should be taken with food to increase bioavailability. Dose adjustments are not required for patients with severe renal impairment; use of the drug in patients with severe hepatic impairment has not been studied [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Withdrawal symptoms due to abrupt discontinuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39175?source=see_link\">",
"     vilazodone",
"    </a>",
"    have not been described. Nevertheless, for patients who take 20 to 40 mg per day, we suggest tapering the dose over one to two weeks prior to discontinuation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H664513\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39175?source=see_link\">",
"     Vilazodone",
"    </a>",
"    can cause several side effects (",
"    <a class=\"graphic graphic_table graphicRef62488 \" href=\"UTD.htm?37/46/38639\">",
"     table 4",
"    </a>",
"    ). A pooled analysis examined adverse effects in two randomized trials that compared vilazodone 40 mg per day with placebo for eight weeks in 891 patients with unipolar major depression; vilazodone caused a higher incidence of [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/34\">",
"     34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diarrhea &ndash; 28 percent of patients who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39175?source=see_link\">",
"       vilazodone",
"      </a>",
"     </li>",
"     <li>",
"      Nausea &ndash; 23 percent",
"     </li>",
"     <li>",
"      Sexual dysfunction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      16 percent of males",
"     </li>",
"     <li>",
"      5 percent of females",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dizziness &ndash; 8 percent of patients who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39175?source=see_link\">",
"       vilazodone",
"      </a>",
"     </li>",
"     <li>",
"      Insomnia &ndash; 6 percent",
"     </li>",
"     <li>",
"      Vomiting &ndash; 5 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, discontinuation of treatment due to side effects was greater in patients who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39175?source=see_link\">",
"     vilazodone",
"    </a>",
"    than placebo (7 versus 3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Concerns have been raised about the possibility that maternal use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39175?source=see_link\">",
"     vilazodone",
"    </a>",
"    during pregnancy may cause persistent pulmonary hypertension of the newborn. However, the United States Food and Drug Administration issued a Drug Safety Communication, which stated that it is not clear that there is a causal relationship due to conflicting results from different studies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/35\">",
"     35",
"    </a>",
"    ]. Persistent pulmonary hypertension in newborns with antenatal exposure to selective serotonin reuptake inhibitors (SSRIs) is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/29/11736?source=see_link\">",
"     \"Infants with antenatal exposure to serotonin reuptake inhibitors\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Based upon placebo controlled trials,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39175?source=see_link\">",
"     vilazodone",
"    </a>",
"    appears to have little or no effect upon [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/31,34\">",
"     31,34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vital signs",
"     </li>",
"     <li>",
"      Electrocardiogram parameters (including cardiac repolarization [corrected QT interval])",
"     </li>",
"     <li>",
"      Laboratory tests (including liver function tests)",
"     </li>",
"     <li>",
"      Body weight",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H664520\">",
"    <span class=\"h2\">",
"     Overdose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overdose with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39175?source=see_link\">",
"     vilazodone",
"    </a>",
"    has been described in five cases, at doses ranging from 200 to 280 mg; all patients recovered [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5129/abstract/34\">",
"     34",
"    </a>",
"    ]. Adverse effects included lethargy, restlessness, hallucinations, disorientation, and the serotonin syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=see_link\">",
"     \"Serotonin syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=see_link\">",
"       \"Patient information: Depression treatment options for adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/41/20116?source=see_link\">",
"       \"Patient information: Depression in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The National Institute of Mental Health also has educational material on the use of antidepressants, including SSRIs, entitled, \"What medications are used to treat depression?\" that is available online at the website",
"    <a class=\"external\" href=\"file://www.nimh.nih.gov/health/publications/mental-health-medications/what-medications-are-used-to-treat-depression.shtml\">",
"     file://www.nimh.nih.gov/health/publications/mental-health-medications/what-medications-are-used-to-treat-depression.shtml",
"    </a>",
"    . Material explaining the symptoms, causes, and treatment for depression is also available in a booklet entitled \"Depression\" that is available online at the website",
"    <a class=\"external\" href=\"file://www.nimh.nih.gov/health/publications/depression/index.shtml\">",
"     file://www.nimh.nih.gov/health/publications/depression/index.shtml",
"    </a>",
"    . Both publications can also be obtained through a toll-free number, 866-615-6464. The web site also provides references, summaries of study results in language intended for the lay public, and information about clinical trials currently recruiting patients.",
"   </p>",
"   <p>",
"    The Depression and Bipolar Support Alliance (",
"    <a class=\"external\" href=\"file://www.dbsalliance.org/\">",
"     file://www.dbsalliance.org",
"    </a>",
"    &nbsp;or 800-826-3632) is a national organization whose mission is to educate members about depression and how to cope with it. Other functions include increasing public awareness of the illness and advocating for more research and services. The organization is administered and maintained by patients and family members, and has local chapters.",
"   </p>",
"   <p>",
"    The National Alliance on Mental Illness (",
"    <a class=\"external\" href=\"file://www.nami.org/\">",
"     file://www.nami.org",
"    </a>",
"    &nbsp;or 800-950-6264) is a similarly structured organization devoted to providing education, support, and advocacy for patients with any mental illness. Depression is one of their priorities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H664534\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serotonin modulators include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/0/2057?source=see_link\">",
"       nefazodone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"       trazodone",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39175?source=see_link\">",
"       vilazodone",
"      </a>",
"      . These drugs can be used for the initial treatment of major depression, as well as treatment resistant depression. (See",
"      <a class=\"local\" href=\"#H665875\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"       \"Initial treatment of depression in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link\">",
"       \"Treatment of resistant depression in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The pharmacokinetic parameters of serotonin modulators are presented in the table (",
"      <a class=\"graphic graphic_table graphicRef88062 \" href=\"UTD.htm?41/43/42684\">",
"       table 3",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/0/2057?source=see_link\">",
"       Nefazodone",
"      </a>",
"      may inhibit the hepatic enzyme CYP3A4 and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39175?source=see_link\">",
"       vilazodone",
"      </a>",
"      may inhibit CYP2C8. (See",
"      <a class=\"local\" href=\"#H28673015\">",
"       'Drug-drug interactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to prescribing serotonin modulators, clinicians should discuss drug interactions, side effects (",
"      <a class=\"graphic graphic_table graphicRef62488 \" href=\"UTD.htm?37/46/38639\">",
"       table 4",
"      </a>",
"      ), time to response, and stopping the medication. No specific medical tests are required before starting serotonin modulators, and drug plasma levels are not routinely performed. (See",
"      <a class=\"local\" href=\"#H666429\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest starting with the lowest minimal effective dose in order to avoid side effects and slowly increasing the dose in unresponsive patients. Starting doses and target dose ranges of each serotonin modulator are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef88067 \" href=\"UTD.htm?18/29/18908\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H666450\">",
"       'Dosing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serotonin modulators can cause the serotonin syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=see_link\">",
"       \"Serotonin syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/0/2057?source=see_link\">",
"       Nefazodone",
"      </a>",
"      can injure the liver and is contraindicated in patients with elevated serum transaminases, active liver disease, or liver injury due to previous nefazodone treatment. Other adverse effects include nausea, somnolence, dry mouth, dizziness, constipation, weakness, and blurred vision. (See",
"      <a class=\"local\" href=\"#H664422\">",
"       'Nefazodone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Common adverse effects of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"       trazodone",
"      </a>",
"      include somnolence, dry mouth, dizziness, fatigue, constipation, vision blurred, sexual dysfunction, orthostatic hypotension, and headache. Rare but serious side effects include priapism and cardiac arrhythmias. (See",
"      <a class=\"local\" href=\"#H664457\">",
"       'Trazodone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adverse effects of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39175?source=see_link\">",
"       vilazodone",
"      </a>",
"      include diarrhea, nausea, sexual dysfunction, dizziness, insomnia, and vomiting. (See",
"      <a class=\"local\" href=\"#H664492\">",
"       'Vilazodone'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5129/abstract/1\">",
"      Horst WD, Preskorn SH. Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J Affect Disord 1998; 51:237.",
"     </a>",
"    </li>",
"    <li>",
"     Wynn GH, Sandson N, Muniz J. Psychiatry. In: Clinical Manual of Drug Interaction Principles for Medical Practice, Wynn GH, Oesterheld JR, Cozza KL, Armstrong SC.  (Eds), American Psychiatric Publishing, Inc., Washington, DC 2009. p.423.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5129/abstract/3\">",
"      Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006; 163:1519.",
"     </a>",
"    </li>",
"    <li>",
"     Golden RN, Dawkins K, Nicholas L. Trazodone and nefazodone. In: The American Psychiatric Publishing Textbook of Psychopharmacology, Fourth Edition, Schatzberg AF, Nemeroff CB.  (Eds), American Psychiatric Publishing, Inc., Washington, D.C. 2009. p.403.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5129/abstract/5\">",
"      Davis R, Whittington R, Bryson HM. Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs 1997; 53:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5129/abstract/6\">",
"      DeVane CL, Grothe DR, Smith SL. Pharmacology of antidepressants: focus on nefazodone. J Clin Psychiatry 2002; 63 Suppl 1:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5129/abstract/7\">",
"      Zajecka J, McEnany GW, Lusk KM. Antidepressant dosing and switching guidelines: focus on nefazodone. J Clin Psychiatry 2002; 63 Suppl 1:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5129/abstract/8\">",
"      Dunner DL, Laird LK, Zajecka J, et al. Six-year perspectives on the safety and tolerability of nefazodone. J Clin Psychiatry 2002; 63 Suppl 1:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5129/abstract/9\">",
"      Feiger AD, Bielski RJ, Bremner J, et al. Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression. Int Clin Psychopharmacol 1999; 14:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5129/abstract/10\">",
"      Carvajal Garc&iacute;a-Pando A, Garc&iacute;a del Pozo J, S&aacute;nchez AS, et al. Hepatotoxicity associated with the new antidepressants. J Clin Psychiatry 2002; 63:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5129/abstract/11\">",
"      Stewart DE. Hepatic adverse reactions associated with nefazodone. Can J Psychiatry 2002; 47:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5129/abstract/12\">",
"      Spigset O, H&auml;gg S, Bate A. Hepatic injury and pancreatitis during treatment with serotonin reuptake inhibitors: data from the World Health Organization (WHO) database of adverse drug reactions. Int Clin Psychopharmacol 2003; 18:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5129/abstract/13\">",
"      Suzuki A, Andrade RJ, Bjornsson E, et al. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. Drug Saf 2010; 33:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5129/abstract/14\">",
"      Robinson DS, Roberts DL, Smith JM, et al. The safety profile of nefazodone. J Clin Psychiatry 1996; 57 Suppl 2:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5129/abstract/15\">",
"      Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol 2009; 29:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5129/abstract/16\">",
"      Sussman N, Ginsberg DL, Bikoff J. Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials. J Clin Psychiatry 2001; 62:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5129/abstract/17\">",
"      Benson BE, Mathiason M, Dahl B, et al. Toxicities and outcomes associated with nefazodone poisoning: an analysis of 1,338 exposures. Am J Emerg Med 2000; 18:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5129/abstract/18\">",
"      Kelly CA, Dhaun N, Laing WJ, et al. Comparative toxicity of citalopram and the newer antidepressants after overdose. J Toxicol Clin Toxicol 2004; 42:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5129/abstract/19\">",
"      Nierenberg AA, Adler LA, Peselow E, et al. Trazodone for antidepressant-associated insomnia. Am J Psychiatry 1994; 151:1069.",
"     </a>",
"    </li>",
"    <li>",
"     DrugBank file://www.drugbank.ca/ (Accessed on July 29, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5129/abstract/21\">",
"      Sheehan DV, Croft HA, Gossen ER, et al. Extended-release Trazodone in Major Depressive Disorder: A Randomized, Double-blind, Placebo-controlled Study. Psychiatry (Edgmont) 2009; 6:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5129/abstract/22\">",
"      Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry 2005; 66:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5129/abstract/23\">",
"      Haria M, Fitton A, McTavish D. Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging 1994; 4:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5129/abstract/24\">",
"      Cunningham LA, Borison RL, Carman JS, et al. A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol 1994; 14:99.",
"     </a>",
"    </li>",
"    <li>",
"     Labbate LA, Fava M, Rosenbaum JF, Arana GW. Drugs for the treatment of depression. In: Handbook of Psychiatric Drug Therapy, Sixth Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2010. p.54.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5129/abstract/26\">",
"      Thompson JW Jr, Ware MR, Blashfield RK. Psychotropic medication and priapism: a comprehensive review. J Clin Psychiatry 1990; 51:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5129/abstract/27\">",
"      Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010; 71:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5129/abstract/28\">",
"      Gamble DE, Peterson LG. Trazodone overdose: four years of experience from voluntary reports. J Clin Psychiatry 1986; 47:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5129/abstract/29\">",
"      Henry JA, Ali CJ, Caldwell R, Flanagan RJ. Acute trazodone poisoning: clinical signs and plasma concentrations. Psychopathology 1984; 17 Suppl 2:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5129/abstract/30\">",
"      de Meester A, Carbutti G, Gabriel L, Jacques JM. Fatal overdose with trazodone: case report and literature review. Acta Clin Belg 2001; 56:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5129/abstract/31\">",
"      Frampton JE. Vilazodone: in major depressive disorder. CNS Drugs 2011; 25:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5129/abstract/32\">",
"      Rickels K, Athanasiou M, Robinson DS, et al. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009; 70:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5129/abstract/33\">",
"      Laughren TP, Gobburu J, Temple RJ, et al. Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant. J Clin Psychiatry 2011; 72:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5129/abstract/34\">",
"      Citrome L. Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 2012; 66:356.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Drug Safety Communication: Selective serotonin reuptake inhibitor (SSRI) antidepressant use during pregnancy and reports of a rare heart and lung condition in newborn babies. file://www.fda.gov/Drugs/DrugSafety/ucm283375.htm#data (Accessed on December 15, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86265 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.97.94.19-A044F949FA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_0_5129=[""].join("\n");
var outline_f5_0_5129=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H664534\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H665875\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H666429\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28673015\">",
"      Drug-drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H666436\">",
"      Guidelines to review with patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H666443\">",
"      Medical tests and plasma levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H666450\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H666457\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H667313\">",
"      Serotonin syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3491829\">",
"      Suicide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H664422\">",
"      NEFAZODONE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H664429\">",
"      Pharmacology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H664436\">",
"      Administration, dose, and discontinuation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H664443\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H664450\">",
"      Overdose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H664457\">",
"      TRAZODONE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H664464\">",
"      Pharmacology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H664471\">",
"      Administration, dose, and discontinuation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H664478\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H664485\">",
"      Overdose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H664492\">",
"      VILAZODONE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H664499\">",
"      Pharmacology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H664506\">",
"      Administration, dose, and discontinuation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H664513\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H664520\">",
"      Overdose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H664534\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/86265\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/86265|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/19/43324\" title=\"table 1\">",
"      Serotonin syndrome drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/29/18908\" title=\"table 2\">",
"      Serotonin modulators - Doses for treating depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/43/42684\" title=\"table 3\">",
"      Serotonin modulator antidepressants - Pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/46/38639\" title=\"table 4\">",
"      Side effects antidepressants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26135?source=related_link\">",
"      Antidepressant medication in adults: Switching and discontinuing medication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/18/5417?source=related_link\">",
"      Atypical antidepressants: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=related_link\">",
"      Depression in pregnant women: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43783?source=related_link\">",
"      Effect of antidepressants on suicide risk in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/29/11736?source=related_link\">",
"      Infants with antenatal exposure to serotonin reuptake inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7574?source=related_link\">",
"      Monoamine oxidase inhibitors (MAOIs) for treating depressed adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/41/20116?source=related_link\">",
"      Patient information: Depression in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=related_link\">",
"      Patient information: Depression treatment options for adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/61/7127?source=related_link\">",
"      Priapism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=related_link\">",
"      Serotonin syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=related_link\">",
"      Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=related_link\">",
"      Treatment of insomnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=related_link\">",
"      Treatment of resistant depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=related_link\">",
"      Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36169?source=related_link\">",
"      Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/39/9850?source=related_link\">",
"      Unipolar depression in adults: Continuation and maintenance treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_0_5130="Diagnosis and treatment of vitamin B12 and folate deficiency";
var content_f5_0_5130=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and treatment of vitamin B12 and folate deficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/0/5130/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/0/5130/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/0/5130/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/0/5130/contributors\">",
"     William C Mentzer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/0/5130/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/0/5130/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/0/5130/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic evaluation and treatment of the patient with suspected vitamin B12 (cobalamin, Cbl) or folate deficiency will be reviewed here. The causes of these deficiencies, their symptoms, and the mechanisms by which these vitamin deficiencies produce clinical abnormalities are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=see_link\">",
"     \"Etiology and clinical manifestations of vitamin B12 and folate deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23782?source=see_link\">",
"     \"Physiology of vitamin B12 and folate deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The terms &ldquo;folate&rdquo; and &ldquo;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    &rdquo; are sometimes used interchangeably; however, the vitamin is found in nature as a folate while folic acid (FA) is the synthetic, therapeutic form of the vitamin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INITIAL DIAGNOSTIC STRATEGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Classical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the \"classic\"",
"    <strong>",
"     advanced",
"    </strong>",
"    case of vitamin B12 or folate deficiency, the patient presents with severe anemia and macrocytic red cells (mean corpuscular volume (MCV) &gt;100 fL) with or without varying neurologic disturbances.",
"   </p>",
"   <p>",
"    However, many patients with B12 (Cbl) deficiency exist who have no or only mild anemia, and macrocytosis may be masked by a concurrent disorder (eg, iron deficiency, thalassemia). In one series, for example, the diagnosis of Cbl deficiency was confirmed in patients in whom only 29 percent had anemia, and only 36 percent had an MCV &gt;100 fL [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypersegmentation of neutrophils, if present, should suggest the diagnosis of B12 or folate deficiency, particularly in patients who also have neurologic symptoms, even in the absence of anemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=see_link\">",
"     \"Etiology and clinical manifestations of vitamin B12 and folate deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin B12",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    folate deficiency should be suspected in patients with one or more of the following clinical or laboratory findings (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=see_link&amp;anchor=H2126391#H2126391\">",
"     \"Etiology and clinical manifestations of vitamin B12 and folate deficiency\", section on 'Clinical manifestations'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oval macrocytic red blood cells (ie, mean corpuscular volume &gt;100 fL) on the peripheral blood smear, with or without anemia (",
"      <a class=\"graphic graphic_picture graphicRef74901 \" href=\"UTD.htm?9/45/9942\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The presence of hypersegmented neutrophils on the peripheral blood smear (ie, &gt;5 percent of neutrophils with &ge;5 lobes or &ge;1 percent of neutrophils with &ge;6 lobes) (",
"      <a class=\"graphic graphic_picture graphicRef58820 \" href=\"UTD.htm?4/47/4854\">",
"       picture 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pancytopenia (ie, the combination of anemia, thrombocytopenia, and neutropenia) of uncertain cause",
"     </li>",
"     <li>",
"      Unexplained neurologic signs and symptoms, especially dementia or weakness, sensory ataxia, and paresthesias (eg, suspected subacute combined degeneration) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=see_link&amp;anchor=H20#H20\">",
"       \"Disorders affecting the spinal cord\", section on 'Subacute combined degeneration'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Special populations, such as older adults, alcoholics, and patients with malnutrition are at high risk for the development of folate",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      Cbl deficiency. Strict vegans are at risk of Cbl deficiency. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/4/8266?source=see_link&amp;anchor=H19#H19\">",
"       \"Vegetarian diets for children\", section on 'Vitamin B12'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who have undergone bariatric surgery are also at risk of developing folate and Cbl deficiency. In an Australian study of 232 patients analyzed pre-operatively and 149 analyzed post-operatively, the vitamin B12 level was low in 11 percent and RBC folate was low in 12 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/2\">",
"       2",
"      </a>",
"      ]. However, the kind of bariatric surgery performed makes a difference and most bariatric surgery programs now provide vitamin supplements post-operatively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cbl and folate deficiency often coexist and are not easily differentiated on a clinical basis. Accordingly, such patients should be evaluated for",
"    <strong>",
"     both",
"    </strong>",
"    deficiencies. The first step should entail obtaining serum for determination of Cbl and folate concentrations. For hospitalized patients, blood samples should be obtained immediately on admission, before any meals have been taken and before any blood transfusions have been given, as even a single meal or transfusion may normalize serum concentrations of these vitamins.",
"   </p>",
"   <p>",
"    If a diagnosis of Cbl",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    folate deficiency has been established, it is reasonable to determine, if possible, the cause for the deficiency in order to not overlook a potentially treatable underlying condition (eg, sprue, inflammatory bowel disease, pancreatic insufficiency, medication). A listing of the various causes of folate (",
"    <a class=\"graphic graphic_table graphicRef55010 \" href=\"UTD.htm?26/43/27323\">",
"     table 1",
"    </a>",
"    ) and Cbl deficiency (",
"    <a class=\"graphic graphic_table graphicRef77437 \" href=\"UTD.htm?30/51/31547\">",
"     table 2",
"    </a>",
"    ) indicates the avenues that should be explored in this regard. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=see_link\">",
"     \"Etiology and clinical manifestations of vitamin B12 and folate deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     LABORATORY EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Overall approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of Cbl or folate deficiency can most often be established by a combination of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measurement of the serum Cbl and the red blood cell (or serum) folate concentrations",
"     </li>",
"     <li>",
"      Evaluation of specific metabolic intermediates (eg, methylmalonate and homocysteine) which can accumulate in these deficiencies (",
"      <a class=\"graphic graphic_figure graphicRef58245 \" href=\"UTD.htm?13/53/14175\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For the diagnosis of pernicious anemia, the presence of antibodies to intrinsic factor is a helpful finding. Malabsorption of Cbl, and its correction by the addition of intrinsic factor, can be established through use of the Schilling test, when this test is available (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Schilling test'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Therapeutic trials of Cbl are warranted when the above testing results are in conflict with the clinical diagnosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bone marrow examination to demonstrate megaloblastic erythropoiesis is usually unnecessary (",
"    <a class=\"graphic graphic_picture graphicRef68005 \" href=\"UTD.htm?23/25/23955\">",
"     picture 3",
"    </a>",
"    ). Even if performed, this examination will not distinguish Cbl deficiency from folate deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Red blood cell MCV",
"    </span>",
"    &nbsp;&mdash;&nbsp;An elevation of the red blood cell mean corpuscular volume (MCV) is one of the hallmarks of Cbl and folate deficiency, although other causes are possible (",
"    <a class=\"graphic graphic_table graphicRef66772 \" href=\"UTD.htm?9/47/9980\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23782?source=see_link&amp;anchor=H7#H7\">",
"     \"Physiology of vitamin B12 and folate deficiency\", section on 'Pathophysiology of megaloblastosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21767?source=see_link\">",
"     \"Macrocytosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/45/35543?source=see_link\">",
"     \"Mean corpuscular volume\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The degree of elevation of the MCV is often a clue as to whether a vitamin deficiency is present. Thus, the probability of a deficiency of folate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    Cbl being present when the MCV is normal (ie, 80 to 100 fL) has been estimated at &lt;25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/3\">",
"     3",
"    </a>",
"    ]. Unless a combined deficiency (eg, iron deficiency plus a deficiency of Cbl or folate) is suspected, routine testing for Cbl or folate deficiency in an anemic patient in the presence of an MCV &lt;80 fL is not likely to be productive.",
"   </p>",
"   <p>",
"    While an MCV &gt;110 is often seen in the megaloblastic anemias, other conditions are commonly associated with such high values. As an example, in a study of 100 consecutive inpatients in a large urban metropolitan hospital who had an MCV &gt;110 fL, 44 percent had been treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    (AZT), 19 percent were alcoholics, 12 percent had malignant neoplasms, 4 percent had vitamin B12 deficiency, and 3 percent had folate deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21767?source=see_link&amp;anchor=H12#H12\">",
"     \"Macrocytosis\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Folate levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <strong>",
"     serum",
"    </strong>",
"    folate concentration, although typically low in patients with folate-deficient megaloblastic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/5\">",
"     5",
"    </a>",
"    ], is primarily a reflection of short-term folate balance, as can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One hospital meal can normalize the serum folate in patients who are folate deficient",
"     </li>",
"     <li>",
"      Pregnancy, alcohol intake, certain anticonvulsants, or a few days of decreased dietary intake can lower the serum folate concentration, despite the presence of adequate tissue stores.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The",
"    <strong>",
"     red blood cell",
"    </strong>",
"    folate concentration is theoretically a more reliable indicator of tissue folate adequacy, since it reflects a time-averaged value of folate availability, and is therefore not subject to the short-term fluctuations noted above. The lower limit of normal for this test has been reported to be in the range of 283 to 340",
"    <span class=\"nowrap\">",
"     nmoles/L.",
"    </span>",
"    However, this test is not entirely without its own problems of interpretation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result, it has been suggested that the less expensive serum folate concentration should be obtained as an initial screening test [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/6\">",
"     6",
"    </a>",
"    ], and that there is no basis for the routine testing of all samples for both serum folate and red cell folate [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/7\">",
"     7",
"    </a>",
"    ]. Thus:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the serum folate concentration is &gt;4",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (9.1",
"      <span class=\"nowrap\">",
"       nanomol/L),",
"      </span>",
"      folate deficiency is effectively ruled out.",
"     </li>",
"     <li>",
"      In the absence of recent anorexia or fasting, a serum concentration &lt;2",
"      <span class=\"nowrap\">",
"       nanog/mL",
"      </span>",
"      (4.5",
"      <span class=\"nowrap\">",
"       nanomoles/L)",
"      </span>",
"      is diagnostic of folate deficiency.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Red cell folate levels and the more expensive metabolite testing should be reserved for patients with borderline values (folate concentration 2 to 4",
"    <span class=\"nowrap\">",
"     ng/mL),",
"    </span>",
"    in those suspected of having a combined deficiency of both Cbl and folate, and for patients in whom the serum folate level may not be easily interpreted (eg, recent hospital meal or recent anorexia) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Methylmalonic acid and homocysteine'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cobalamin levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several commercial laboratories use different methods (chemiluminescence or radioassay) for measuring Cbl. As a result, there are different normal ranges and no \"gold standard\" [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]. Accordingly, therapeutic trials of Cbl are warranted when testing results are in conflict with the clinical diagnosis.",
"   </p>",
"   <p>",
"    There are, in addition, important limitations in the ability of a single measurement of serum Cbl to detect B12 sufficiency or deficiency. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum Cbl concentrations commonly fall during pregnancy, but these patients do not necessarily exhibit hematologic evidence of deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Test results are highly variable. In one report, the median intraindividual variation in measured serum Cbl concentrations was 23 percent (range: 0 to 119 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/10\">",
"       10",
"      </a>",
"      ]. Absolute differences &gt;100",
"      <span class=\"nowrap\">",
"       pmol/L",
"      </span>",
"      on repeat testing were seen in 21 percent of patients.",
"     </li>",
"     <li>",
"      The serum Cbl concentration may be normal in up to 5 percent of patients with documented Cbl deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/11,12\">",
"       11,12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one study of 84 patients with low cobalamin values (&lt;180",
"      <span class=\"nowrap\">",
"       pg/mL),",
"      </span>",
"      only 16 were confirmed to be B12 deficient (positive predictive value of 22 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Spuriously high values for Cbl on competitive-binding luminescence assay (CBLA) testing can be seen when high serum levels of intrinsic factor-blocking antibodies are present [",
"      <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/14-16\">",
"       14-16",
"      </a>",
"      ]. Testing for the presence of IF-blocking antibodies is therefore suggested if CBLA test results are in conflict with the clinical diagnosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, however, serum Cbl levels can be interpreted, as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      &gt;300",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      (&gt;221",
"      <span class=\"nowrap\">",
"       pmol/L)",
"      </span>",
"      &mdash; normal result; Cbl deficiency is unlikely (ie, probability of 1 to 5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      200 to 300",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      (148 to 221",
"      <span class=\"nowrap\">",
"       pmol/L)",
"      </span>",
"      &mdash; borderline result; Cbl deficiency possible.",
"     </li>",
"     <li>",
"      &lt;200",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      (&lt;148",
"      <span class=\"nowrap\">",
"       pmol/L)",
"      </span>",
"      &mdash; low; consistent with Cbl deficiency (specificity of 95 to 100 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1276753\">",
"    <span class=\"h2\">",
"     Need for metabolite testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metabolite testing (see below) should be reserved for those patients in whom a high degree of suspicion of Cbl or folate deficiency is present, especially those with borderline serum Cbl or folate levels, in the patient with otherwise unexplained neurologic complaints or unexplained macrocytosis, and when it is important to uncover a treatable cause of dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=see_link&amp;anchor=H14#H14\">",
"     \"Evaluation of cognitive impairment and dementia\", section on 'Laboratory testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Methylmalonic acid and homocysteine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with low-normal or even normal serum Cbl values may be truly Cbl deficient and respond to replacement therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/5,6,12,18,19\">",
"     5,6,12,18,19",
"    </a>",
"    ]. Measurement of the serum concentrations of the metabolic intermediaries homocysteine and methylmalonic acid appears to be more sensitive for the diagnosis of these deficiencies than serum vitamin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/11\">",
"     11",
"    </a>",
"    ], and is helpful in clarifying the diagnosis when serum Cbl or folate concentrations are equivocal [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/12,17,20-22\">",
"     12,17,20-22",
"    </a>",
"    ], or are low in the pregnant subject [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/9,23-25\">",
"     9,23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum concentrations of homocysteine (HC) as well as serum and urinary concentrations of methylmalonic acid (MMA) are elevated in Cbl deficiency, due to a decreased rate of metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. In comparison, only HC is elevated in folate deficiency, since folate does not participate in MMA metabolism (",
"    <a class=\"graphic graphic_figure graphicRef58245 \" href=\"UTD.htm?13/53/14175\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This metabolic pattern was illustrated in a study of 434 episodes of documented cobalamin deficiency and 123 episodes of documented folate deficiency, in which the following results were obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum MMA and HC levels were elevated in 98 and 96 percent, respectively, of the episodes of documented cobalamin deficiency.",
"     </li>",
"     <li>",
"      In the episodes of documented folate deficiency, serum MMA and HC levels were elevated in 12 and 91 percent, respectively. Elevated MMA in all but one of the folate deficient subjects was attributable to renal insufficiency.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As with measurement of serum Cbl concentrations, there are a number of situations which may affect levels of MMA and HC:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hereditary homocysteinemia can raise serum HC levels [",
"      <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=see_link\">",
"       \"Overview of homocysteine\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serum and urinary levels of MMA are elevated in subjects with methylmalonic aciduria. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7914?source=see_link&amp;anchor=H9#H9\">",
"       \"Organic acidemias\", section on 'Methylmalonic aciduria'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Elevated levels of MMA can be found in patients with renal insufficiency.",
"     </li>",
"     <li>",
"      In one report, antibiotic treatment lowered the serum MMA but not the total HC level in two cobalamin-deficient patients, suggesting that propionic acid generated by anaerobic gut flora may be a precursor of methylmalonic acid in cobalamin-deficient patients [",
"      <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is considerable variability in repeat measurements of MMA and HC [",
"      <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/8,10,22\">",
"       8,10,22",
"      </a>",
"      ]. Suspect levels should be repeated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Elevated values of MMA and homocysteine return to normal with vitamin replacement, providing further evidence of vitamin deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/12\">",
"     12",
"    </a>",
"    ]. In addition, in a series of patients with documented pernicious anemia receiving inadequate treatment, MMA and total homocysteine concentrations rose sooner than did decreases in serum Cbl, establishing the superior sensitivity of these metabolites in detecting early Cbl deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Diagnosing pernicious anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several clinical and laboratory studies can suggest the diagnosis of pernicious anemia (PA). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=see_link&amp;anchor=H2126391#H2126391\">",
"     \"Etiology and clinical manifestations of vitamin B12 and folate deficiency\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While patients with PA are achlorhydric, confirming this by measurement of gastric acid secretion is highly invasive and rarely needed. Bone marrow examination helps to confirm the diagnosis of megaloblastic anemia, but there are no bone marrow findings which are specific for PA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Antibodies to IF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of anti-intrinsic factor (IF) antibodies is highly confirmatory for the diagnosis of PA, with a sensitivity of 50 to 70 percent and a specificity approaching 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/8,29\">",
"     8,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anti-parietal cell antibodies are perhaps more sensitive but less specific for the diagnosis of PA; as a result, the utility of anti-parietal cell antibodies in diagnosing PA has been called into question [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/8,29,30\">",
"     8,29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Elevated serum gastrin levels, low pepsinogen I levels, and a low ratio of pepsinogen I to pepsinogen II are highly sensitive for the diagnosis of PA (90 to 92 percent), although these tests lack specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Addition of these tests may help to make the diagnosis of PA in those patients who do not have anti-IF antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25751?source=see_link&amp;anchor=H7#H7\">",
"     \"Physiology of gastrin\", section on 'Causes of hypergastrinemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31205?source=see_link&amp;anchor=H7#H7\">",
"     \"Classification and diagnosis of gastritis and gastropathy\", section on 'Serum pepsinogen isoenzymes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Schilling test",
"    </span>",
"    &nbsp;&mdash;&nbsp;A classic procedure for diagnosing pernicious anemia is the two-stage Schilling test (",
"    <a class=\"graphic graphic_figure graphicRef72051 \" href=\"UTD.htm?22/29/22994\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef62166 \" href=\"UTD.htm?7/10/7340\">",
"     table 4",
"    </a>",
"    ). However, vitamin B12 deficiency, pernicious anemia, malabsorption, blind loop syndromes, and ileal disease can be reliably and quickly diagnosed using methods other than the Schilling test. As an example, in two studies, elevated concentrations of MMA and total homocysteine were present in 15 to 33 percent of patients with normal Schilling tests, indicating the superior sensitivity of these two metabolites in diagnosing Cbl deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Difficulties with the radiolabeled reagent used in the Schilling test, as well as certification issues, make this test generally unavailable in many parts of the United States. Accordingly, although the Schilling test has historical importance in understanding abnormalities of vitamin B12 absorption, it is not commonly employed, and has potential usefulness only when more simple tests (eg, anti-IF antibodies) are normal and the diagnosis is in doubt.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Evaluation of test results",
"    </span>",
"    &nbsp;&mdash;&nbsp;If serum folate and Cbl concentrations are &gt;4",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (&gt;9.1",
"    <span class=\"nowrap\">",
"     nanomoles/L)",
"    </span>",
"    and &gt;300",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    (&gt;221",
"    <span class=\"nowrap\">",
"     picomoles/L)",
"    </span>",
"    respectively, deficiencies of the two vitamins are unlikely, and additional testing is not required [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the above two tests are not in the ranges cited above, or if there is difficulty in interpretation of the results, the next step should be evaluation of the metabolites methylmalonate (MMA) and total homocysteine:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If both test results are normal (ie, MMA 70 to 270",
"      <span class=\"nowrap\">",
"       nanomol/L",
"      </span>",
"      and total homocysteine 5 to 14",
"      <span class=\"nowrap\">",
"       micromol/L),",
"      </span>",
"      deficiency of both vitamins is ruled out. As an example, both metabolites were normal in only 0.2 percent of 400 patients with proven Cbl deficiency and 10 percent of 98 patients with folate deficiency; the false negative results in the patients with folate deficiency were largely limited to patients with renal disease [",
"      <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If concentrations of both metabolites are increased, Cbl deficiency is confirmed, with a sensitivity and specificity of 94 and 99 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/3\">",
"       3",
"      </a>",
"      ]. Because of test and patient variability, re-assay is advisable if marginally abnormal results are obtained [",
"      <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/8\">",
"       8",
"      </a>",
"      ]. Concomitant folate deficiency cannot be ruled out when the concentrations of both metabolites are increased. In such cases, serum folate levels are helpful.",
"     </li>",
"     <li>",
"      If MMA is normal and total homocysteine is increased, folate deficiency is likely, with a sensitivity and specificity of 86 and 99 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For the diagnosis of pernicious anemia (PA), initial testing should be done for the presence of antibody to intrinsic factor (IF); a positive test is confirmatory for PA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3619854\">",
"    <span class=\"h1\">",
"     DIAGNOSIS OF VITAMIN B12 AND FOLATE DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of vitamin B12",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    folate deficiency has been suspected, the following testing is recommended. Of importance, once the diagnosis has been made, the cause(s) for the deficiency should also be determined (",
"    <a class=\"graphic graphic_table graphicRef77437 \" href=\"UTD.htm?30/51/31547\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef55010 \" href=\"UTD.htm?26/43/27323\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Overview'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3619967\">",
"    <span class=\"h2\">",
"     Vitamin B12 deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum B12 (Cbl) levels can be interpreted, as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      &gt;300",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      (&gt;221",
"      <span class=\"nowrap\">",
"       pmol/L)",
"      </span>",
"      &mdash; normal result; Cbl deficiency is unlikely (ie, probability of 1 to 5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      200 to 300",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      (148 to 221",
"      <span class=\"nowrap\">",
"       pmol/L)",
"      </span>",
"      &mdash; borderline result; Cbl deficiency possible.",
"     </li>",
"     <li>",
"      &lt;200",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      (&lt;148",
"      <span class=\"nowrap\">",
"       pmol/L)",
"      </span>",
"      &mdash; low; consistent with Cbl deficiency (specificity of 95 to 100 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3620304\">",
"    <span class=\"h3\">",
"     Metabolite testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metabolite testing should be reserved for those patients in whom a high degree of suspicion of Cbl deficiency is present, especially those with borderline serum Cbl levels, in the patient with otherwise unexplained neurologic complaints or unexplained macrocytosis, and when it is important to uncover a treatable cause of dementia. Serum concentrations of homocysteine (HC) as well as serum (and urinary) concentrations of methylmalonic acid (MMA) are elevated in Cbl deficiency; only HC is elevated in folate deficiency. Normal serum levels are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Methylmalonic acid &mdash; 70 to 270",
"      <span class=\"nowrap\">",
"       nanomol/L",
"      </span>",
"     </li>",
"     <li>",
"      Homocysteine &mdash; 5 to 15",
"      <span class=\"nowrap\">",
"       micromol/L",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3620311\">",
"    <span class=\"h3\">",
"     Pernicious anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of anti-intrinsic factor (IF) antibodies is highly confirmatory for the diagnosis of pernicious anemia (PA), with a sensitivity of 50 to 70 percent and a specificity approaching 100 percent. Elevated serum gastrin levels, low pepsinogen I levels, and a low ratio of pepsinogen I to pepsinogen II are highly sensitive for the diagnosis of PA (90 to 92 percent), although these tests lack specificity. Addition of these tests may help to make the diagnosis of PA in those patients who do not have anti-IF antibodies. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Diagnosing pernicious anemia'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3619877\">",
"    <span class=\"h2\">",
"     Folate deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum folate concentration should be obtained as an initial screening test [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/6\">",
"     6",
"    </a>",
"    ]; there is no basis for the routine testing of all samples for both serum folate and red cell folate [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the serum folate concentration is &gt;4",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (9.1",
"      <span class=\"nowrap\">",
"       nanomol/L),",
"      </span>",
"      folate deficiency is effectively ruled out.",
"     </li>",
"     <li>",
"      In the absence of recent anorexia or fasting, a serum concentration &lt;2",
"      <span class=\"nowrap\">",
"       nanog/mL",
"      </span>",
"      (4.5",
"      <span class=\"nowrap\">",
"       nanomoles/L)",
"      </span>",
"      is diagnostic of folate deficiency.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3620318\">",
"    <span class=\"h3\">",
"     Additional testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Red cell folate levels and the more expensive metabolite testing should be reserved for patients with borderline values (folate concentration 2 to 4",
"    <span class=\"nowrap\">",
"     ng/mL),",
"    </span>",
"    in those suspected of having a combined deficiency of both Cbl and folate, and for patients in whom the serum folate level may not be easily interpreted (eg, recent hospital meal or recent anorexia) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/6\">",
"     6",
"    </a>",
"    ]. Serum concentrations of homocysteine (HC) as well as serum and urinary concentrations of methylmalonic acid (MMA) are elevated in Cbl deficiency; only HC is elevated in folate deficiency. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Methylmalonic acid and homocysteine'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Folate deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Folate deficiency is treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    (1 to 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    orally) for one to four months, or until complete hematologic recovery occurs. A dose of 1",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    is usually sufficient, even if malabsorption is present. These doses are considerably in excess of the 200",
"    <span class=\"nowrap\">",
"     micrograms/day",
"    </span>",
"    (0.2",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    recommended for disease prevention (eg, recommended daily allowance in normal adults, alcoholics, the elderly, prevention of neural tube defects). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=see_link&amp;anchor=H3#H3\">",
"     \"Vitamin supplementation in disease prevention\", section on 'Folic acid'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     Folic acid",
"    </a>",
"    can partially reverse some of the hematologic abnormalities of Cbl deficiency, although the neurologic manifestations will progress for reasons that are not entirely clear [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/35\">",
"     35",
"    </a>",
"    ]. Thus, it is important to rule out Cbl deficiency before treating a patient with megaloblastic anemia with folic acid. If initiation of treatment is urgently required, blood samples should be obtained for the appropriate assays (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Laboratory evaluation'",
"    </a>",
"    above), and the patient should be treated with",
"    <strong>",
"     both",
"    </strong>",
"    folic acid and vitamin B12 until the test results are known.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     Folic acid",
"    </a>",
"    can be continued if the underlying condition cannot be eradicated (eg, congenital hemolytic anemia). Repeat testing for Cbl deficiency may be warranted in patients receiving long-term folic acid, especially if hematologic (eg, macrocytic anemia, increasing levels of serum lactate dehydrogenase)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neurologic worsening occur [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Empiric therapy for folate deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical value of measuring serum folate is uncertain. The limitations of this approach were illustrated in a study in which low values were noted in 2.3 percent of almost 3000 folate levels ordered in a group of hospitalized patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/37\">",
"     37",
"    </a>",
"    ]. However, the presence of low serum folate was commented on in only 53 percent of the patients' records and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    was given as treatment in only 24 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/37\">",
"     37",
"    </a>",
"    ]. It was suggested that it would be more cost-efficient to treat all such patients with folic acid rather than to initiate testing for the deficiency.",
"   </p>",
"   <p>",
"    We have no strong objection to this empiric approach, provided that testing for vitamin B12 deficiency is carried out prior to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    &nbsp;(see",
"    <a class=\"local\" href=\"#H16\">",
"     'Folate deficiency'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    However, in view of the possible association of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    treatment with certain malignancies, general administration of folic acid without a specific indication has been considered unwise, particularly at higher doses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=see_link&amp;anchor=H3#H3\">",
"     \"Vitamin supplementation in disease prevention\", section on 'Folic acid'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cobalamin deficiency",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Parenteral cobalamin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pernicious anemia (PA) is typically treated with parenteral (ie, intramuscular or deep subcutaneous) Cbl, in a dose of 1000 micrograms (1000 mcg, 1 mg) every day for one week, followed by 1 mg every week for four weeks and then, if the underlying disorder persists (eg, PA, surgical removal of the terminal ileum), 1 mg every month for the remainder of the patient's life. If the cause of the Cbl deficiency can been eliminated (eg, diet, drugs, reversible malabsorption syndrome(s)), treatment can be stopped when the Cbl deficiency has been fully reversed and the cause eliminated.",
"   </p>",
"   <p>",
"    While doses lower than those noted above have been recommended (ie, 100 micrograms in place of 1,000 micrograms), there are few adverse consequences of this potential \"overtreatment\", as parenteral vitamin B12 is inexpensive, relatively nontoxic, and amounts given in excess of need are excreted harmlessly in the urine. Conversely, use of the lower dose could result in a slower response, which might be critical when severe neurologic disease (eg, subacute combined degeneration) is present and avoidance of irreversible neurologic damage is a concern [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Oral and nasal formulations",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative that appears to be as effective as parenteral therapy, but which requires much greater patient compliance, is high dose oral cobalamin. The rationale for this approach in patients with impaired intrinsic factor function is the presence of a second, lower efficiency transport system for Cbl that does not require intrinsic factor or a functioning terminal ileum. This system consistently produces adequate long-term vitamin B12 replacement at doses of 1000 to 2000",
"    <span class=\"nowrap\">",
"     mcg/day.",
"    </span>",
"    Because of variability in absorption, lower oral doses are not completely effective in some patients with pernicious anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/39\">",
"     39",
"    </a>",
"    ]. Similarly, use of \"timed release\" oral Cbl preparations should be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dose given in this situation (1 to 2",
"    <span class=\"nowrap\">",
"     milligrams/day)",
"    </span>",
"    is more than 200 times higher than the minimum daily requirement for normal subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/41\">",
"     41",
"    </a>",
"    ], and significantly higher than that available in most standard multivitamins and B12 supplements (&le;100",
"    <span class=\"nowrap\">",
"     mcg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the few randomized clinical trials which have been reported, the use of oral cobalamin (1000 to 2000",
"    <span class=\"nowrap\">",
"     mcg/day)",
"    </span>",
"    in newly diagnosed patients was found to be as effective as intramuscular administration in obtaining short-term hematological and neurological responses in vitamin B12-deficient patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/43-45\">",
"     43-45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the possibility of erratic absorption, it is most appropriate to use this route of treatment AFTER the patient's Cbl status has been normalized with parenteral treatment",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    to monitor the response frequently with determinations of serum Cbl and methylmalonate concentrations.",
"   </p>",
"   <p>",
"    Cobalamin can be also be given sublingually [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/46\">",
"     46",
"    </a>",
"    ], or via a nasal spray or gel [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/47\">",
"     47",
"    </a>",
"    ]. Sublingual and nasal routes of treatment have not been adequately studied and the available formulations are expensive [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Cobalamin responsive disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-randomized studies support the existence of at least some patients with normal values for serum Cbl, MMA,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    HC whose hematologic, and especially neurologic, impairments improved following pharmacologic doses of vitamin B12 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition to the possibility that these observations were due to a fortuitous combination of unrelated events or a placebo effect, at least two other explanations for this phenomenon are possible:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Variability in measurement of Cbl, MMA, and HC, yielding falsely normal values in patients who are truly B12 deficient.",
"     </li>",
"     <li>",
"      A direct benefit of pharmacologic doses of cobalamin on altered neurologic function [",
"      <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/48-50\">",
"       48-50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Preventive measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of clinical settings in which patients with marginal or deficient Cbl status may be at increased risk for worsening Cbl deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Vegetarians",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pure vegetarians are at risk of development of Cbl deficiency and require Cbl supplementation, although some may refuse such treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/51\">",
"     51",
"    </a>",
"    ]. Pregnant women who plan exclusive breast-feeding for their infants also need supplementation, as these infants are at much greater risk of Cbl deficiency than their mothers [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33098?source=see_link&amp;anchor=H24346287#H24346287\">",
"     \"Overview of acquired peripheral neuropathies in children\", section on 'Vitamin B12 (cobalamin) deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Gastric surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of malabsorption of food-bound Cbl is increased after gastric surgery (eg, subtotal gastrectomy, bariatric surgery). Preventive supplementation with large doses of oral Cbl, preferably on an empty stomach, is warranted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=see_link&amp;anchor=H11#H11\">",
"     \"Etiology and clinical manifestations of vitamin B12 and folate deficiency\", section on 'Older adult subjects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Nitrous oxide exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/29/11732?source=see_link\">",
"     Nitrous oxide",
"    </a>",
"    (N2O) inactivates cobalamin and its use in anesthesia may precipitate rapid neuropsychiatric deterioration in Cbl-deficient subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/54-57\">",
"     54-57",
"    </a>",
"    ]. Patients contemplating nitrous oxide anesthesia should be checked for Cbl deficiency and treated prior to such exposure.",
"   </p>",
"   <p>",
"    Similarly, inhalant abuse of N2O may cause neuropsychiatric problems, even in Cbl-sufficient subjects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=see_link&amp;anchor=H20#H20\">",
"     \"Disorders affecting the spinal cord\", section on 'Subacute combined degeneration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Response to treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory studies should be monitored after cobalamin therapy to document a hematologic and metabolic response:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevated levels of serum iron, indirect bilirubin, and LDH fall rapidly within the first one to two days following treatment with parenteral vitamin B12; bone marrow erythropoiesis also changes from megaloblastic to normoblastic during this period. In addition, the patient might note an improved feeling of well being, long before there are any changes in the degree of anemia.",
"     </li>",
"     <li>",
"      Hypokalemia during the early response is due to the marked increase in potassium utilization during production of new hematopoietic cells. It may be profound in those who are severely anemic at the time of treatment, but its clinical relevance is uncertain [",
"      <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/58\">",
"       58",
"      </a>",
"      ]. Such patients should be monitored during their initial response, and severe hypokalemia treated with potassium supplementation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5402?source=see_link&amp;anchor=H8#H8\">",
"       \"Causes of hypokalemia\", section on 'Increased blood cell production'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the patient is anemic, there will be a reticulocytosis in three to four days, peaking at one week, followed by a rise in hemoglobin and a fall in red blood cell mean corpuscular volume. The hemoglobin concentration begins to rise within 10 days and usually returns to normal within eight weeks. A delayed response suggests the presence of an additional abnormality or an incorrect diagnosis (eg, iron deficiency, infection, hypothyroidism, malignancy).",
"     </li>",
"     <li>",
"      Hypersegmented neutrophils disappear at 10 to 14 days.",
"     </li>",
"     <li>",
"      Neurologic abnormalities, if present, improve over the ensuing 3 months, with maximum improvement attained at 6 to 12 months. The degree of improvement is inversely related to the extent and duration of disease [",
"      <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/1,6,59\">",
"       1,6,59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Blood transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Cbl deficiency develop anemia slowly, and thus are able to develop compensatory increases in oxygen delivery. Even elderly patients may tolerate severe anemia, often to levels as low as 5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/8,60\">",
"     8,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The decision to transfuse can be a difficult one, particularly in elderly patients at risk for congestive failure due to an already expanded plasma volume from the chronic anemia, the presence of co-morbid disease (eg, coronary artery disease), as well as the association between heart failure and elevated levels of homocysteine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of homocysteine\", section on 'Role in vascular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If anemia is severe, the patient is critically ill, and fluid status is a concern, one unit can be given initially at a very slow rate of infusion, in combination with a diuretic. In extreme circumstances, isovolemic exchange can be performed, in which one unit of the patient's blood (with a low hematocrit) is removed at the same time as a unit of packed cells (with a hematocrit of 60 to 80 percent) is infusing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42214?source=see_link&amp;anchor=H2#H2\">",
"     \"Transfusion reactions caused by chemical and physical agents\", section on 'Transfusional volume overload (TACO)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Monitoring for malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with PA appear to have an increased risk of developing malignancies of the gastrointestinal tract, but the data are not entirely conclusive for sites other than the stomach [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/1,61,62\">",
"     1,61,62",
"    </a>",
"    ]. A meta-analysis of 27 studies from multiple countries reported incidence rates for gastric cancer varying from zero to 1.2 percent per patient-year, with a pooled incidence rate of 0.27 percent per patient-year and an overall gastric cancer relative risk in PA of 6.8 (95% CI 2.6-18.1) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is prudent to periodically monitor stools in these patients for the presence of blood. A single endoscopy should be considered at the time of diagnosis to identify early, treatable lesions (gastric cancer, neuroendocrine tumors, metaplasia or dysplasia) in patients with PA [",
"    <a class=\"abstract\" href=\"UTD.htm?5/0/5130/abstract/8,63\">",
"     8,63",
"    </a>",
"    ], but there are insufficient data to support routine subsequent endoscopic surveillance for these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/52/6983?source=see_link&amp;anchor=H2859243#H2859243\">",
"     \"Screening and prevention of gastric cancer\", section on 'Pernicious anemia and gastric carcinoid tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/15/6387?source=see_link\">",
"       \"Patient information: Vitamin B12 deficiency and folate (folic acid) deficiency (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/57/7057?source=see_link\">",
"       \"Patient information: Pernicious anemia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Suspecting the diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin B12",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    folate deficiency should be suspected in patients with one or more of the following clinical settings. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Overview'",
"    </a>",
"    above.):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The presence of oval macrocytic red cells, with or without anemia",
"     </li>",
"     <li>",
"      The presence of hypersegmented neutrophils",
"     </li>",
"     <li>",
"      Pancytopenia (anemia, thrombocytopenia, neutropenia) of uncertain cause",
"     </li>",
"     <li>",
"      Unexplained neurologic signs and symptoms (eg, dementia, progressive weakness, ataxia, paresthesias)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Suspicion for these diagnoses should be greater in those populations at higher risk for development of these deficiencies, such as older adults, alcoholics, pure vegans, and those with malnutrition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Confirming the diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a first step, serum for determination of both Cbl and folate concentrations should be obtained. If serum folate and Cbl concentrations are &gt;4",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    and &gt;300",
"    <span class=\"nowrap\">",
"     pg/mL,",
"    </span>",
"    respectively, deficiencies of the two vitamins are unlikely, and additional testing is not required. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Laboratory evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If the above two tests are not in the ranges cited above, or if there is difficulty in interpretation of the results, the next step should be evaluation of the serum levels of the metabolites methylmalonate (MMA) and total homocysteine. (See",
"    <a class=\"local\" href=\"#H1276753\">",
"     'Need for metabolite testing'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If both test results are within the normal range (ie, MMA 70 to 270",
"      <span class=\"nowrap\">",
"       nmol/L",
"      </span>",
"      and total homocysteine 5 to 15",
"      <span class=\"nowrap\">",
"       micromol/L),",
"      </span>",
"      deficiency of both vitamins is ruled out.",
"     </li>",
"     <li>",
"      If concentrations of both metabolites are increased, Cbl deficiency is confirmed, with a sensitivity and specificity of 94 and 99 percent, respectively.",
"     </li>",
"     <li>",
"      If MMA is normal and total homocysteine is increased, folate deficiency is likely, with a sensitivity and specificity of 86 and 99 percent, respectively.",
"     </li>",
"     <li>",
"      For the diagnosis of pernicious anemia, initial testing should be done for the presence of antibody to intrinsic factor. A positive test is confirmatory for the diagnosis of PA, with a sensitivity of 50 to 70 percent and a specificity approaching 100 percent. (See",
"      <a class=\"local\" href=\"#H3620311\">",
"       'Pernicious anemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If a diagnosis of Cbl",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    folate deficiency has been established, it is reasonable to determine, if possible, the cause for the deficiency in order to not overlook a potentially treatable underlying condition (eg, sprue, inflammatory bowel disease, pancreatic insufficiency, medication). A listing of the various causes of folate (",
"    <a class=\"graphic graphic_table graphicRef55010 \" href=\"UTD.htm?26/43/27323\">",
"     table 1",
"    </a>",
"    ) and Cbl deficiency (",
"    <a class=\"graphic graphic_table graphicRef77437 \" href=\"UTD.htm?30/51/31547\">",
"     table 2",
"    </a>",
"    ) indicates the avenues which should be explored in this regard. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=see_link\">",
"     \"Etiology and clinical manifestations of vitamin B12 and folate deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Folate deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with documented folate deficiency should be treated with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    . Standard dosing of oral folic acid is 1 to 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    orally for one to four months, or until complete hematologic recovery occurs. The oral route is sufficient even in those with malabsorption.",
"   </p>",
"   <p>",
"    Vitamin B12 deficiency must be ruled out, and treated if present, before giving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    to a patient with megaloblastic anemia, since administration of folic acid may worsen neurologic complications of untreated vitamin B12 deficiency. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Folate deficiency'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Vitamin B12 deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with documented vitamin B12 deficiency should be treated. Treatment can be given via parenteral or oral routes. For patients with permanently decreased ability to absorb dietary vitamin B12 (eg, pernicious anemia, total gastrectomy, surgical removal of the terminal ileum), life-long treatment is necessary. If the cause of the Cbl deficiency can been eliminated (eg, diet, drugs, reversible malabsorption syndrome(s)), treatment can be stopped when the Cbl deficiency has been fully reversed and the cause eliminated. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Cobalamin deficiency'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that patients be treated initially with parenteral B12 (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We consider this particularly important in patients with neurologic complaints, where a goal is to maximize the probability of full neurologic recovery. Although oral B12 appears to be at least as effective as parenteral B12, concerns about patient compliance lead us to prefer the more certain parenteral route. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Parenteral cobalamin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once the patient's Cbl status has been normalized, maintenance therapy can be performed with parenteral or oral B12. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Oral and nasal formulations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/1\">",
"      Pruthi RK, Tefferi A. Pernicious anemia revisited. Mayo Clin Proc 1994; 69:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/2\">",
"      Toh SY, Zarshenas N, Jorgensen J. Prevalence of nutrient deficiencies in bariatric patients. Nutrition 2009; 25:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/3\">",
"      Savage DG, Lindenbaum J, Stabler SP, Allen RH. Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies. Am J Med 1994; 96:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/4\">",
"      Snower DP, Weil SC. Changing etiology of macrocytosis. Zidovudine as a frequent causative factor. Am J Clin Pathol 1993; 99:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/5\">",
"      Green R, Kinsella LJ. Current concepts in the diagnosis of cobalamin deficiency. Neurology 1995; 45:1435.",
"     </a>",
"    </li>",
"    <li>",
"     Antony AC. Megaloblastic anemias. In: Hematology: Basic principles and practice, 4th ed, Hoffman R, Benz EJ, Shattil SJ, et al. (Eds), Churchill Livingstone, New York 2005. p.519.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/7\">",
"      Galloway M, Rushworth L. Red cell or serum folate? Results from the National Pathology Alliance benchmarking review. J Clin Pathol 2003; 56:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/8\">",
"      Carmel R. How I treat cobalamin (vitamin B12) deficiency. Blood 2008; 112:2214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/9\">",
"      Metz J, McGrath K, Bennett M, et al. Biochemical indices of vitamin B12 nutrition in pregnant patients with subnormal serum vitamin B12 levels. Am J Hematol 1995; 48:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/10\">",
"      Solomon LR. Cobalamin-responsive disorders in the ambulatory care setting: unreliability of cobalamin, methylmalonic acid, and homocysteine testing. Blood 2005; 105:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/11\">",
"      Lindenbaum J, Savage DG, Stabler SP, Allen RH. Diagnosis of cobalamin deficiency: II. Relative sensitivities of serum cobalamin, methylmalonic acid, and total homocysteine concentrations. Am J Hematol 1990; 34:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/12\">",
"      Naurath HJ, Joosten E, Riezler R, et al. Effects of vitamin B12, folate, and vitamin B6 supplements in elderly people with normal serum vitamin concentrations. Lancet 1995; 346:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/13\">",
"      Matchar DB, McCrory DC, Millington DS, Feussner JR. Performance of the serum cobalamin assay for diagnosis of cobalamin deficiency. Am J Med Sci 1994; 308:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/14\">",
"      Hamilton MS, Blackmore S, Lee A. Possible cause of false normal B-12 assays. BMJ 2006; 333:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/15\">",
"      Yang DT, Cook RJ. Spurious elevations of vitamin B12 with pernicious anemia. N Engl J Med 2012; 366:1742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/16\">",
"      Carmel R, Agrawal YP. Failures of cobalamin assays in pernicious anemia. N Engl J Med 2012; 367:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/17\">",
"      Stabler SP. Clinical practice. Vitamin B12 deficiency. N Engl J Med 2013; 368:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/18\">",
"      Green R. Screening for vitamin B12 deficiency: caveat emptor. Ann Intern Med 1996; 124:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/19\">",
"      Stabler SP, Allen RH, Savage DG, Lindenbaum J. Clinical spectrum and diagnosis of cobalamin deficiency. Blood 1990; 76:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/20\">",
"      Lindenbaum J, Rosenberg IH, Wilson PW, et al. Prevalence of cobalamin deficiency in the Framingham elderly population. Am J Clin Nutr 1994; 60:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/21\">",
"      van Asselt DZ, de Groot LC, van Staveren WA, et al. Role of cobalamin intake and atrophic gastritis in mild cobalamin deficiency in older Dutch subjects. Am J Clin Nutr 1998; 68:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/22\">",
"      Hvas AM, Ellegaard J, Nex&oslash; E. Increased plasma methylmalonic acid level does not predict clinical manifestations of vitamin B12 deficiency. Arch Intern Med 2001; 161:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/23\">",
"      Allen LH. Vitamin B12 metabolism and status during pregnancy, lactation and infancy. Adv Exp Med Biol 1994; 352:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/24\">",
"      Morkbak AL, Hvas AM, Milman N, Nexo E. Holotranscobalamin remains unchanged during pregnancy. Longitudinal changes of cobalamins and their binding proteins during pregnancy and postpartum. Haematologica 2007; 92:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/25\">",
"      Wheeler S. Assessment and interpretation of micronutrient status during pregnancy. Proc Nutr Soc 2008; 67:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/26\">",
"      Allen RH, Stabler SP, Savage DG, Lindenbaum J. Metabolic abnormalities in cobalamin (vitamin B12) and folate deficiency. FASEB J 1993; 9:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/27\">",
"      Sumner AE, Chin MM, Abrahm JL, et al. Elevated methylmalonic acid and total homocysteine levels show high prevalence of vitamin B12 deficiency after gastric surgery. Ann Intern Med 1996; 124:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/28\">",
"      Norman EJ, Morrison JA. Screening elderly populations for cobalamin (vitamin B12) deficiency using the urinary methylmalonic acid assay by gas chromatography mass spectrometry. Am J Med 1993; 94:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/29\">",
"      Carmel R. Reassessment of the relative prevalences of antibodies to gastric parietal cell and to intrinsic factor in patients with pernicious anaemia: influence of patient age and race. Clin Exp Immunol 1992; 89:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/30\">",
"      Ottesen M, Feldt-Rasmussen UF, Andersen J, et al. [Pernicious anemia. A study of initial forms of the disease and diagnostic significance of determination of the intrinsic factor antibody and parietal cell antibody]. Ugeskr Laeger 1992; 154:3758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/31\">",
"      Carmel R. Pepsinogens and other serum markers in pernicious anemia. Am J Clin Pathol 1988; 90:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/32\">",
"      Alonso N, Granada ML, Salinas I, et al. Serum pepsinogen I: an early marker of pernicious anemia in patients with type 1 diabetes. J Clin Endocrinol Metab 2005; 90:5254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/33\">",
"      Lindgren A, Bagge E, Cederblad A, et al. Schilling and protein-bound cobalamin absorption tests are poor instruments for diagnosing cobalamin malabsorption. J Intern Med 1997; 241:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/34\">",
"      Lindgren A, Swolin B, Nilsson O, et al. Serum methylmalonic acid and total homocysteine in patients with suspected cobalamin deficiency: a clinical study based on gastrointestinal histopathological findings. Am J Hematol 1997; 56:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/35\">",
"      Selhub J, Morris MS, Jacques PF. In vitamin B12 deficiency, higher serum folate is associated with increased total homocysteine and methylmalonic acid concentrations. Proc Natl Acad Sci U S A 2007; 104:19995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/36\">",
"      Dhar M, Bellevue R, Carmel R. Pernicious anemia with neuropsychiatric dysfunction in a patient with sickle cell anemia treated with folate supplementation. N Engl J Med 2003; 348:2204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/37\">",
"      Robinson AR, Mladenovic J. Lack of clinical utility of folate levels in the evaluation of macrocytosis or anemia. Am J Med 2001; 110:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/38\">",
"      Vasconcelos OM, Poehm EH, McCarter RJ, et al. Potential outcome factors in subacute combined degeneration: review of observational studies. J Gen Intern Med 2006; 21:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/39\">",
"      Hathcock JN, Troendle GJ. Oral cobalamin for treatment of pernicious anemia? JAMA 1991; 265:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/40\">",
"      Solomon LR. Oral vitamin B12 therapy: a cautionary note. Blood 2004; 103:2863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/41\">",
"      Eussen SJ, de Groot LC, Clarke R, et al. Oral cyanocobalamin supplementation in older people with vitamin B12 deficiency: a dose-finding trial. Arch Intern Med 2005; 165:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/42\">",
"      Rajan S, Wallace JI, Brodkin KI, et al. Response of elevated methylmalonic acid to three dose levels of oral cobalamin in older adults. J Am Geriatr Soc 2002; 50:1789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/43\">",
"      Kuzminski AM, Del Giacco EJ, Allen RH, et al. Effective treatment of cobalamin deficiency with oral cobalamin. Blood 1998; 92:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/44\">",
"      Bolaman Z, Kadikoylu G, Yukselen V, et al. Oral versus intramuscular cobalamin treatment in megaloblastic anemia: a single-center, prospective, randomized, open-label study. Clin Ther 2003; 25:3124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/45\">",
"      Butler CC, Vidal-Alaball J, Cannings-John R, et al. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency: a systematic review of randomized controlled trials. Fam Pract 2006; 23:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/46\">",
"      Delpre G, Stark P, Niv Y. Sublingual therapy for cobalamin deficiency as an alternative to oral and parenteral cobalamin supplementation. Lancet 1999; 354:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/47\">",
"      Slot WB, Merkus FW, Van Deventer SJ, Tytgat GN. Normalization of plasma vitamin B12 concentration by intranasal hydroxocobalamin in vitamin B12-deficient patients. Gastroenterology 1997; 113:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/48\">",
"      McCaddon A, Regland B, Hudson P, Davies G. Functional vitamin B(12) deficiency and Alzheimer disease. Neurology 2002; 58:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/49\">",
"      Di Rocco A, Bottiglieri T, Werner P, et al. Abnormal cobalamin-dependent transmethylation in AIDS-associated myelopathy. Neurology 2002; 58:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/50\">",
"      Kuwabara S, Nakazawa R, Azuma N, et al. Intravenous methylcobalamin treatment for uremic and diabetic neuropathy in chronic hemodialysis patients. Intern Med 1999; 38:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/51\">",
"      Carmel R, Mallidi PV, Vinarskiy S, et al. Hyperhomocysteinemia and cobalamin deficiency in young Asian Indians in the United States. Am J Hematol 2002; 70:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/52\">",
"      Antony AC. Vegetarianism and vitamin B-12 (cobalamin) deficiency. Am J Clin Nutr 2003; 78:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/53\">",
"      Centers for Disease Control and Prevention (CDC). Neurologic impairment in children associated with maternal dietary deficiency of cobalamin--Georgia, 2001. MMWR Morb Mortal Wkly Rep 2003; 52:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/54\">",
"      Schilling RF. Is nitrous oxide a dangerous anesthetic for vitamin B12-deficient subjects? JAMA 1986; 255:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/55\">",
"      Flippo TS, Holder WD Jr. Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency. Arch Surg 1993; 128:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/56\">",
"      Doran M, Rassam SS, Jones LM, Underhill S. Toxicity after intermittent inhalation of nitrous oxide for analgesia. BMJ 2004; 328:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/57\">",
"      Hadzic A, Glab K, Sanborn KV, Thys DM. Severe neurologic deficit after nitrous oxide anesthesia. Anesthesiology 1995; 83:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/58\">",
"      Carmel R. Treatment of severe pernicious anemia: no association with sudden death. Am J Clin Nutr 1988; 48:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/59\">",
"      Healton EB, Savage DG, Brust JC, et al. Neurologic aspects of cobalamin deficiency. Medicine (Baltimore) 1991; 70:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/60\">",
"      Carmel R, Shulman IA. Blood transfusion in medically treatable chronic anemia. Pernicious anemia as a model for transfusion overuse. Arch Pathol Lab Med 1989; 113:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/61\">",
"      Talley NJ, Chute CG, Larson DE, et al. Risk for colorectal adenocarcinoma in pernicious anemia. A population-based cohort study. Ann Intern Med 1989; 111:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/62\">",
"      Hsing AW, Hansson LE, McLaughlin JK, et al. Pernicious anemia and subsequent cancer. A population-based cohort study. Cancer 1993; 71:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/0/5130/abstract/63\">",
"      Vannella L, Lahner E, Osborn J, Annibale B. Systematic review: gastric cancer incidence in pernicious anaemia. Aliment Pharmacol Ther 2013; 37:375.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7155 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-8C00B56BB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_0_5130=[""].join("\n");
var outline_f5_0_5130=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INITIAL DIAGNOSTIC STRATEGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Classical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      LABORATORY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Overall approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Red blood cell MCV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Folate levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cobalamin levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1276753\">",
"      Need for metabolite testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Methylmalonic acid and homocysteine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Diagnosing pernicious anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Antibodies to IF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Schilling test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Evaluation of test results",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3619854\">",
"      DIAGNOSIS OF VITAMIN B12 AND FOLATE DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3619967\">",
"      Vitamin B12 deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3620304\">",
"      - Metabolite testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3620311\">",
"      - Pernicious anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3619877\">",
"      Folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3620318\">",
"      - Additional testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Empiric therapy for folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cobalamin deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Parenteral cobalamin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Oral and nasal formulations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Cobalamin responsive disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Preventive measures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Vegetarians",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Gastric surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Nitrous oxide exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Response to treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Monitoring for malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Suspecting the diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Confirming the diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Vitamin B12 deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7155\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7155|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/53/14175\" title=\"figure 1\">",
"      Actions of cobalamin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/29/22994\" title=\"figure 2\">",
"      The Schilling test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7155|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/45/9942\" title=\"picture 1\">",
"      Macroovalocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/47/4854\" title=\"picture 2\">",
"      Megaloblastic smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/25/23955\" title=\"picture 3\">",
"      Megaloblastic erythropoiesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7155|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/43/27323\" title=\"table 1\">",
"      Causes of folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/51/31547\" title=\"table 2\">",
"      Causes of B12 deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/47/9980\" title=\"table 3\">",
"      Causes of macrocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/10/7340\" title=\"table 4\">",
"      Schilling test variations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5402?source=related_link\">",
"      Causes of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31205?source=related_link\">",
"      Classification and diagnosis of gastritis and gastropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=related_link\">",
"      Disorders affecting the spinal cord",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=related_link\">",
"      Etiology and clinical manifestations of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=related_link\">",
"      Evaluation of cognitive impairment and dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21767?source=related_link\">",
"      Macrocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/45/35543?source=related_link\">",
"      Mean corpuscular volume",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7914?source=related_link\">",
"      Organic acidemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33098?source=related_link\">",
"      Overview of acquired peripheral neuropathies in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=related_link\">",
"      Overview of homocysteine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/57/7057?source=related_link\">",
"      Patient information: Pernicious anemia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/15/6387?source=related_link\">",
"      Patient information: Vitamin B12 deficiency and folate (folic acid) deficiency (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25751?source=related_link\">",
"      Physiology of gastrin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23782?source=related_link\">",
"      Physiology of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/52/6983?source=related_link\">",
"      Screening and prevention of gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42214?source=related_link\">",
"      Transfusion reactions caused by chemical and physical agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/4/8266?source=related_link\">",
"      Vegetarian diets for children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=related_link\">",
"      Vitamin supplementation in disease prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_0_5131="Signs and symptoms of rejection";
var content_f5_0_5131=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical findings of acute lung transplant rejection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        No symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonproductive cough",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dyspnea on exertion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decline in oximetry (with exercise)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decline in spirometry (&gt;10 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest x-ray: Diffuse opacities or normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leukocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crackles on physical examination",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Clinical findings alone are not sufficient to separate infection from acute rejection.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_0_5131=[""].join("\n");
var outline_f5_0_5131=null;
var title_f5_0_5132="Treatment of Erysipelothrix";
var content_f5_0_5132=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F73058&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F73058&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antibiotic therapy for Erysipelothrix rhusiopathiae infection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type of infection",
"       </td>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adult dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Localized cutaneous infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Preferred",
"       </td>",
"       <td>",
"        Penicillin V",
"       </td>",
"       <td>",
"        500 mg every 6h orally",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Alternatives",
"       </td>",
"       <td>",
"        Ciprofloxacin*",
"       </td>",
"       <td>",
"        250 mg every 12h orally",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clindamycin",
"       </td>",
"       <td>",
"        300 mg every 8h orally",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythromycin&bull;",
"       </td>",
"       <td>",
"        500 mg every 6h orally",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Diffuse cutaneous infection OR systemic infection (bacteremia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Preferred",
"       </td>",
"       <td>",
"        Penicillin G",
"       </td>",
"       <td>",
"        2-4 million units every 4h IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Alternatives",
"       </td>",
"       <td>",
"        Ceftriaxone",
"       </td>",
"       <td>",
"        2 g every 24h IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Imipenem",
"       </td>",
"       <td>",
"        500 mg every 6h IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ciprofloxacin&Delta;",
"       </td>",
"       <td>",
"        400 mg every 12h IV",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The duration of therapy for localized or diffuse cutaneous infection is 7 days. The duration of therapy for systemic infection (bacteremia) is at least 4 weeks; 14 days of intravenous therapy followed by 2 to 4 weeks of oral therapy has also been successful.",
"    <div class=\"footnotes\">",
"     * Other fluoroquinolones may be substituted.",
"     <br>",
"      &bull; Other macrolides may be substituted.",
"      <br>",
"       &Delta; Other IV fluoroquinolones may be substituted.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_0_5132=[""].join("\n");
var outline_f5_0_5132=null;
var title_f5_0_5133="Formula for reverse osmosis";
var content_f5_0_5133=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F57198&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F57198&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Formulae for calculating the performance characteristics of a reverse osmosis unit for hemodialysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 413px; height: 126px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     %: percent.",
"     <br>",
"      * Feed flow rate = Product flow rate + Reject flow rate.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_0_5133=[""].join("\n");
var outline_f5_0_5133=null;
var title_f5_0_5134="TNM stage cutaneous SCC";
var content_f5_0_5134=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F78140&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F78140&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    TNM staging system for cutaneous squamous cell carcinoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Primary tumor (T)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TX",
"       </td>",
"       <td colspan=\"3\">",
"        Primary tumor cannot be assessed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T0",
"       </td>",
"       <td colspan=\"3\">",
"        No evidence of primary tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tis",
"       </td>",
"       <td colspan=\"3\">",
"        Carcinoma in situ",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T1",
"       </td>",
"       <td colspan=\"3\">",
"        Tumor 2 cm or less in greatest dimension with less than two high-risk features (see list of high-risk features below)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        T2",
"       </td>",
"       <td colspan=\"3\">",
"        Tumor greater than 2 cm in greatest dimension",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Tumor any size with two or more high-risk features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T3",
"       </td>",
"       <td colspan=\"3\">",
"        Tumor with invasion of maxilla, mandible, orbit, or temporal bone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T4",
"       </td>",
"       <td colspan=\"3\">",
"        Tumor with invasion of skeleton (axial or appendicular) or perineural invasion of skull base",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        High-risk features for the primary tumor (T) staging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Depth/invasion",
"       </td>",
"       <td colspan=\"3\">",
"        &gt;2 mm thickness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Clark level &ge;IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Perineural invasion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Anatomic location",
"       </td>",
"       <td colspan=\"3\">",
"        Primary site ear",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Primary site hair-bearing lip",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Differentiation",
"       </td>",
"       <td colspan=\"3\">",
"        Poorly differentiated or undifferentiated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Regional lymph nodes (N)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NX",
"       </td>",
"       <td colspan=\"3\">",
"        Regional lymph nodes cannot be assessed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N0",
"       </td>",
"       <td colspan=\"3\">",
"        No regional lymph node metastases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N1",
"       </td>",
"       <td colspan=\"3\">",
"        Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        N2",
"       </td>",
"       <td class=\"sublist_other_start\" colspan=\"3\">",
"        Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension; or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension; or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        N2a",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        N2b",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        N2c",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N3",
"       </td>",
"       <td colspan=\"3\">",
"        Metastasis in a lymph node, more than 6 cm in greatest dimension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Distant metastasis (M)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M0",
"       </td>",
"       <td colspan=\"3\">",
"        No distant metastases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MI",
"       </td>",
"       <td colspan=\"3\">",
"        Distant metastases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Anatomic stage/prognostic groups",
"        <span class=\"small\">",
"         &bull;",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage 0",
"       </td>",
"       <td>",
"        Tis",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage I",
"       </td>",
"       <td>",
"        T1",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage II",
"       </td>",
"       <td>",
"        T2",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Stage III",
"       </td>",
"       <td>",
"        T3",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T1",
"       </td>",
"       <td>",
"        N1",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T2",
"       </td>",
"       <td>",
"        N1",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T3",
"       </td>",
"       <td>",
"        N1",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        Stage IV",
"       </td>",
"       <td>",
"        T1",
"       </td>",
"       <td>",
"        N2",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T2",
"       </td>",
"       <td>",
"        N2",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T3",
"       </td>",
"       <td>",
"        N2",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any T",
"       </td>",
"       <td>",
"        N3",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T4",
"       </td>",
"       <td>",
"        Any N",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any T",
"       </td>",
"       <td>",
"        Any N",
"       </td>",
"       <td>",
"        M1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: cTNM is the clinical classification, pTNM is the pathologic classification.",
"    <div class=\"footnotes\">",
"     * Excludes cSCC of the eyelid.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Patients with primary cSCC or other cutaneous carcinomas with no evidence (clinical, radiologic, or pathologic) of regional or distant metastases are divided into two stages: Stage I for tumors measuring &le;2 cm in size and Stage II for those that are greater than 2 cm in size. In instances where there is clinical concern for extension of tumor into bone and radiologic evaluation has been performed (and is negative), these data may be included to support the Stage I vs. II designation. Tumors that are &le;2 cm in size can be upstaged to Stage II if they contain two or more high-risk features. Stage III patients are those with (1) clinical, histologic, or radiologic evidence of one solitary node measuring &le;3 cm in size or (2) tumor extension into bone: maxilla, mandible, orbit, or temporal bone. Stage IV patients are those with (1) tumor with direct or perineural invasion of skull base or axial skeleton, (2) &ge;2 lymph nodes or (3) single or multiple lymph nodes measuring &gt;3 cm in size or (4) distant metastasis.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_0_5134=[""].join("\n");
var outline_f5_0_5134=null;
var title_f5_0_5135="Variables included in valvular surgery risk scores";
var content_f5_0_5135=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F83133&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F83133&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Variables included in valvular surgery risk scores",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        STS score",
"       </td>",
"       <td class=\"subtitle1\">",
"        EUROSCORE additive/logistic*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ambler score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"4\">",
"        <strong>",
"         Patient characteristics",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Age",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gender",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Height",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Weight",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Body mass index",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ethnicity",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist1_start\" colspan=\"4\">",
"        <strong>",
"         Comorbid conditions",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diabetes",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypertension",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chronic lung/pulmonary disease",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Extracardiac arteriopathy",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Peripheral vascular disease",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neurological dysfunction",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cerebrovascular accident",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serum creatinine",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dialysis-dependent renal failure",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Immunosuppressive therapy",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist1_start\" colspan=\"4\">",
"        <strong>",
"         Cardiac history",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        NYHA classification",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Unstable angina",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Recent myocardial infarction",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Arrhythmias",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Previous cardiac surgery",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Previous CABG",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Previous valvular surgery",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Previous PCI",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Active endocarditis",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Number of diseased coronary vessels",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Type and severity of valvular disease",
"        <br/>",
"        (stenosis/regurgitation, aortic/mitral)",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist1_start\" colspan=\"4\">",
"        <strong>",
"         Haemodynamic state",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Systolic pulmonary pressure &gt;60 mmHg",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ejection fraction",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Critical pre-operative state",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cardiogenic shock",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Resuscitation",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Inotropic agents",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intra-aortic balloon pump",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Procedure",
"        </strong>",
"       </td>",
"       <td class=\"sublist_other_start_centered\">",
"        +",
"       </td>",
"       <td class=\"sublist_other_start_centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other_start_centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Emergency",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Surgery on thoracic aorta",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aortic valve surgery",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mitral valve surgery",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aortic and mitral valve surgery",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tricuspid surgery",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Surgery for congenital heart disease",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rhythmologic surgery",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Concomitant CABG",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Concomitant tricuspid valve surgery",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Post-infarct septal rupture",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     STS: The Society of Thoracic Surgeons; CABG: coronary artery bypass grafting; NYHA: New York Heart Association; PCI: percutaneous coronary intervention.",
"     <br/>",
"     * The same variables are used for the additive and logistic EuroSCORE.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     In the STS score, the type of valvular surgery (valve replacement or repair) is taken into account.",
"    </div>",
"    <div class=\"reference\">",
"     From: Rosenhek R, Lung B, Tornos P, et al. ESC Working Group on Valvular Heart Disease Position Paper: assessing the risk of interventions in patients with valvular heart disease. Eur Heart J 2012; 33:822, by permission of the European Society of Cardiology. Copyright &copy; 2012 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_0_5135=[""].join("\n");
var outline_f5_0_5135=null;
